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Abstract 
Background: Polypharmacy is a recognised patient safety risk, with older adults at 
greater risk due to co-morbidities and reduced clearance of drugs due to ageing. 
However, very little is known about the concurrent use of prescription drugs and 
herbal medicinal products (HMPs) among older adults. There is no common 
understanding of what HMPs are and no UK based studies among older adults 
completed in the last 15 years were identified. 
Aim: To understand the concurrent use of prescription drugs and HMPs among UK 
older adults.  
Research questions: The different phases of the study were guided by the following 
questions.  
Phase 1: Systematic Literature Review 
 What is the prevalence and pattern of concurrent use of prescription drugs 
and herbal medicinal products (HMPs) among older adults? 
 What patient and clinical characteristics are associated with concurrent use of 
prescription drugs and HMPs? 
 What are the range of prescription drugs and HMPs most concurrently used 
by older adults? 
 What safety issues and other factors are associated with concurrent 
prescription drug and HMPs use in older adults? 
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Phase 2: Questionnaire Survey 
 What is the prevalence and patterns of concurrent prescription drugs and 
HMPs use among UK community dwelling older adults? 
 What types of HMPs and prescription drugs are concurrently used? 
 What is the potential herb-drug interactions from the HMPs, and prescription 
drugs reported? 
 What patient and clinical characteristics are associated with concurrent HMPs 
and prescription drugs use? 
Phase 3: In-depth exploration of older adults’ experiences of using HMPs with 
 prescribed medications 
 Why do older adults concurrently use prescription drugs, HMPs and dietary 
supplements (DS)? 
 What is the experience of concurrent users? 
 
Methods: Three phased mixed method sequential explanatory study. Phase1 was a 
systematic literature review to evaluate and summarise available evidence. Phase 2 
estimated the prevalence of concurrent use and identified the pattern and range of 
medicines combined using questionnaire survey among community dwelling older 
adults from two GP surgeries in Essex and London. Phase 3 Interviews with older 
people to gain in-depth understanding of the older peoples’ reasons for concurrently 
using HMPs with prescription medications, their experiences and views.  
Findings: Both the review and survey demonstrated that concurrent prescription 
drugs and HMPs use among older adults is widespread, with potentially serious 
herb-drug interactions from certain combinations. Prevalence among older adults 
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varied widely between 5.3% and 88.3% among previous studies, while this study 
estimated it to be 33.5%. Dietary supplements (DS) are also concurrently used with 
prescribed medicines. The most commonly used HMPs were evening primrose oil, 
valerian, and Nytol Herbal® (a combination of hops, gentian, and passion flower) 
while cod liver oil, glucosamine, multivitamins and vitamin D were the dietary 
supplements most reported. The prescription drugs most commonly combined with 
HMPs are beta blockers, diuretics, antihyperlipidemic agents, anticoagulants, 
analgesics, antihistamines, antidiabetics, antihypertensive drugs, antidepressants, 
non-steroidal anti-inflammatory drugs (NSAIDs) and statins. Although most of the 
survey participants were not exposed to significant harm from concurrently using 
HMPs and DS with prescription medicines, the potential risk of herb-drug and 
supplement-drug interactions cannot be ignored. 
 
The interviews revealed that older adults draw on different rationale and sources of 
information when making the decision to use HMPs or dietary supplements 
concurrently with prescription drugs. Six main themes captured the range of 
experience and underlying reasons for concurrent use. These were: older people’s 
values and beliefs, the decision to use HMPs and DS, sources of information and 
advice, self-management and taking control, disclosure and non-disclosure, 
awareness of potential herb-drug interactions.  
 
Discussion: This study has provided the first estimate of the prevalence of 
concurrent HMPs and prescription drug use among UK older adults and established 
the range of HMPs and dietary supplements that older adults most commonly 
combine with prescribed medicines. It has highlighted potential interactions from 
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certain combinations of prescription drugs, HMPs and dietary supplements which 
healthcare practitioners should routinely ask older adults about. As well as the need 
to systematically identify older people who may be at risk of potential herb-drug 
interactions, the range of reasons for concurrent use provided by this study adds to 
the literature on polypharmacy and interventions to support medicine management 
for older adults living at home with multiple health needs. Evidence from the study 
demonstrates the range of experience that reflects individual and system issues 
about accessing medical care and advice on medication. The findings highlight the 
difficulties that this population face in accessing the advice and support they need. It 
also indicates a need to revisit the responsibilities of clinicians and regulators with 
regards to the regulation and sale of HMPs. Likewise, accurate and key information 
regarding interactions with other products and possible adverse effects should be 
readily available. Future work could test what enables older consumers to make 
informed choices about the safe use of HMPs.  
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Glossary 
Concurrent:  given or used at the same time as another. 
Dietary supplements: a product taken orally that contains one or more ingredients 
(such as vitamins or amino acids) that are intended to supplement one's diet and are 
not considered food. 
Herbal medicinal products: any medicinal product, exclusively containing as active 
ingredients one or more herbal substances, one or more herbal preparations, or a 
combination of the two. 
Herb-drug interaction: Any pharmacological modification caused 
by herbal substances to another prescription medication (diagnostic, therapeutic or 
other action of a drug) in or on the body. An herb might increase or decrease the 
effects of co-administered drugs. 
Older adults:  The age of 60 or 65, roughly equivalent to retirement ages in most 
developed countries and is said to be the beginning of old age. In many parts of the 
developing world, chronological time has little or no importance in the meaning of old 
age. 
Prescription drugs: A prescription drug (also prescription medication or prescription 
medicine) is a pharmaceutical drug that legally requires a medical prescription to be 
dispensed. In contrast, over-the-counter drugs can be obtained without 
a prescription. 
Polypharmacy: Polypharmacy refers to the use of a large number of medications, 
commonly considered to be the use of five or more. Since polypharmacy is a 
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consequence of having several underlying medical conditions, it is much more 
common in elderly patients. 
Patient safety: The simplest definition of patient safety is the prevention of errors 
and adverse effects to patients associated with health care. 
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Chapter 1: Introduction and     
    Outline of Thesis 
1.1 Introduction to the Study 
This thesis reports the findings from a study on the concurrent use of herbal 
medicinal products (HMPs) and prescription drugs among older adults. It examines 
the prevalence and potential interactions, as well as, the reasons why older adults 
concurrently use HMPs with prescribed medicines.  
 
The aim of this research is to explore and better understand the concurrent use of 
prescription drugs and HMPs among UK older adults. The following sets out the 
study’s objectives and research questions and describes how the different study 
phases systematically addressed the questions. It then summarises the content of 
the thesis chapters. 
1.2 Objectives  
a. To collate, evaluate and summarise available evidence on concurrent use of 
prescription drugs and HMPs in older adults (Phase 1: systematic literature 
review).  
b. To identify the different types of HMPs and prescription drugs concurrently used 
by UK older adults.  ( Phases 1 and 2: review, survey ) 
c. To identify patient and clinical characteristics associated with concurrent use. 
(Phases 1,2,& 3: review, survey and in-depth study)  
d. To examine potential major herb-drug interactions from the concurrent HMPs and 
prescription drugs reported (Phase 2: Questionnaire survey). 
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e. To explore any other factors and reasons for concurrent use of prescription drugs 
and HMPs (Phase 3: In depth study). 
1.3 Research Questions 
The different phases of the study were guided by the following questions: 
Phase 1: Systematic Literature Review 
 What is the prevalence and pattern of concurrent use of prescription drugs 
and herbal medicinal products (HMPs) among older adults? 
 What patient and clinical characteristics are associated with concurrent use of 
prescription drugs and HMPs? 
 What are the range of prescription drugs and HMPs most concurrently used 
by older adults? 
 What safety issues and other factors are associated with concurrent 
prescription drug and HMPs use in older adults? 
 
Phase 2: Questionnaire Survey 
 What is the prevalence and patterns of concurrent prescription drugs and 
HMPs use among UK community dwelling older adults? 
 What types of HMPs and prescription drugs are concurrently used? 
 What are the potential herb-drug interactions from the HMPs, and prescription 
drugs reported? 
 What patient and clinical characteristics are associated with concurrent HMPs 
and prescription drugs use? 
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Phase 3: In depth exploration of older adults’ experiences of using HMPs with 
 prescribed medications 
 Why do older adults concurrently use prescription drugs, HMPs and dietary 
supplements (DS)? 
 What is the experience of concurrent users? 
 
1.4 Thesis Outline 
This thesis is formed of eight chapters. Chapter 1 begins with a brief introduction to 
the study; outline of the research aims and objectives and the research questions. 
The chapter concludes with an outline of the chapters that make up the thesis.  
 
Chapter 2 provides a background to the research, with an overview of polypharmacy 
and potential herb-drug interactions within the context of concurrent HMPs and 
prescription drugs use. It discusses the rationale for focusing on older people, recent 
and relevant research and why the concurrent use of HMPs and prescription drugs is 
an important topic to study. 
 
Chapter 3 provides an account of the design and development of the three phases 
sequential mixed method used in the study and how it was applied. It also describes 
the data collection and analysis methods for all three phases. Patient and participant 
involvements and the process of developing, testing, and refining the mixed method 
study is explained. Some of the challenges faced during recruitment are also 
discussed. The data and findings from one phase provided the basis for subsequent 
phases (Mertens, 2014). 
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Chapter 4 sets out evidence from Phase 1; a systematic literature review which 
synthesised and critically appraised available studies to establish what is known on 
concurrent use of prescription drugs and HMPs among older adults. The review also 
explored possible explanations as to why this occurs and identified gaps in 
knowledge. No recent UK study on the topic was found but previous studies from 
other countries acknowledged there are potentials for interactions to occur between 
herbal and conventional medicines. Chapter 4 reports the findings and discussions 
from the literature review.  
 
Findings from the systematic review were used to refine objectives for the phase 2 
study. In this, a cross sectional survey was used to establish the prevalence of 
concurrent prescription medicines, HMPs and DS use among UK community 
dwelling older adults. Chapter 5 reports findings from the survey including 
demographics and the range of medicines that respondents combined. The potential 
interactions from these combinations were also explored and reported with a 
discussion of the findings and how it relates to existing research.  
 
Phase 3 built on findings from the survey to explore the experiences of older people 
using HMPs and prescribed medications. Thirteen in depth qualitative interviews 
were conducted with concurrent users who responded to the phase two survey. 
Chapter 6 reports these interviews and findings about the reasons, motivations and 
experiences of older adults concurrently using prescription drugs with HMPs and/or 
DSs. The main themes from older adult’s narratives in relation to decision making, 
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reasons and motivations for concurrently using HMPs and DS with prescription drugs 
are presented.  
 
Chapter 7 draws together findings from the three phases to answer the study 
objectives. It also provides a discussion of all the findings by considering related 
literature and the study’s contributions to knowledge around concurrent use of 
HMPs, DS and prescription drugs. The chapter ends with how this work has 
enhanced the understanding of the multiple personal, organisational and cultural 
factors that inform decisions about concurrent use of HMPs and prescribed 
medications. 
 
 
Finally, Chapter 8 presents the conclusions of the study, implications of the findings 
for current and future work and recommendations for future research. Particular 
attention is also given to the implications of the findings for clinicians, service 
provision and patient safety. 
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Chapter 2 Background to the Study 
2.1 Introduction to Chapter 
This chapter explores polypharmacy among older adults, the use of HMPs and the 
patient safety issues that can arise. A brief overview of the policies and regulations 
regarding HMPs in Europe and the United Kingdom is also provided. For the 
purpose of this study, the WHO definition of ‘elderly’ as individuals over the age of 65 
years in developed countries, and over 60 years in developing countries (World 
Health Organisation, 1984) have been adopted. Therefore, in this research, all 
participants were aged 65 years or older. 
 
2.2 Polypharmacy and Older Adults 
The world population is ageing and according to the World Health Organisation 
(WHO), by 2050 the population of people aged ≥60 years will double and around 400 
million people will be ≥80 years (World Health Organisation, 2012).  Around 18.2% of 
the UK population are aged over 65 years, by 2068 a quarter of UK residents will be 
aged 65 years or over (Office for National Statistics, 2018). 
 
Before addressing the issue of concurrent use of HMPs with prescribed medications 
among this population, it is important to acknowledge two issues; polypharmacy, 
drug reactions and interactions and the impact this has on individual’s health and 
health care organisations.   
 
Older adults, especially those with multiple chronic conditions (Nyborg, Straand, & 
Brekke, 2012) and those with serious conditions such as cancer rely on medicines to 
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manage their conditions. Consequently, multiple drugs are used resulting in 
polypharmacy (Maggiore, Gross, & Hurria, 2010). There are inconsistencies in the 
definition of polypharmacy but it is often described as the use of multiple medications 
to treat health problems (Junius-Walker, Theile, & Hummers-Pradier, 2007). 
Polypharmacy is often clinically indicated and is beneficial in conditions such as 
diabetes and hypertension and among patients with multimorbidity. However, 
multiple use of medicines has been associated with drug-drug interactions, adverse 
drug events, hospitalisation and increased length of stay, as well as mortality 
(Guthrie, Makubate, Hernandez-Santiago, & Dreischulte, 2015; Maher, Hanlon, & 
Hajjar, 2014).  
 
Polypharmacy is a recognised patient safety risk and older adults are a high risk 
group (Leiss et al., 2015). The chances of medication-related problems are higher in 
older people because of existing co-morbidities, metabolic changes and reduced 
clearance of pharmacologically active compounds (Mangoni & Jackson, 2004; 
Salmond, 2002; Vacas Rodilla et al., 2009). Moreover, the likelihood of an adverse 
drug event increases with the number of medications  (Eichhorn, Greten, & Efferth, 
2011; Heuberger, 2012). About 20% of people aged over 70 years take five or more 
prescribed medications (Kaufman, Kelly, Rosenberg, Anderson, & Mitchell, 2002; 
Rollason & Vogt, 2003). This is further complicated when older people use over-the-
counter medicines, as well as DS; a situation that is prevalent among older adults 
(Qato, Wilder, Schumm, Gillet, & Alexander, 2016). Although herbal medicines and 
dietary supplements are generally not included in standard definitions of 
polypharmacy, it is known that they could increase the risk for drug interactions 
(Qato et al., 2016). 
8 
 
 
In addition to the harm to the individual, adverse drug reactions are major clinical 
and economic burden on healthcare systems, with increased hospitalisation and 
prolonged hospital stays raising costs (Sultana, Cutroneo, & Trifirò, 2013). About 
1,105.8 million prescriptions were dispensed in England pharmacies in 2017(HSCIC, 
2018). NHS spending on medicines in England was estimated at a total of £17.4 
billion in 2016/17, increased from £13 billion in 2010/11. This is an average growth of 
about 5% per year and substantially a faster rate of increase than the total NHS 
budget over the same period (Ewbank, Omojomolo, Sullivan, & McKenna, 2018). 
Prescription medicines dispensed for older people  accounted for 52.6% of the net 
cost for exempted categories (HSCIC, 2018), this is more than half of the total 
prescription cost and a big pressure on the healthcare budget. 
 
2.3 Herbal Medicinal Products (HMPs), Policies and Regulations 
Herbal medicinal products are medicinal products where the active ingredients 
consists exclusively of herbal substances or herbal preparations (Commission of the 
European Communities, 2003). Herbal medicinal products are covered by Directive 
2001/83/EC on the Community code relating to medicinal products for human use 
"Directive on human medicinal products" (Commission of the European 
Communities, 2003). The World Health Organisation  (WHO) has defined herbal 
medicines as finished labelled medicinal products that contain an active ingredient, 
aerial, or underground parts of the plant or other plant material or combination 
(World Health Organisation, 1991). 
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Herbal medicines include herbal supplements, herbs, herbal preparations and 
finished herbal products. The terms herbal product, herbal medicinal product and 
natural product are often used interchangeably but they are different. Herbal 
products could be food, medicine or cosmetic. In herbal medicinal products, the 
active ingredient consists exclusively of herbal substances or herbal preparations 
(e.g. parts of plant) or pharmaceutical preparations (e.g. essential oil, 
extracts)(Gupta, 2015). While natural products are medicinal products where the 
active ingredient is of natural origin and consists of an animal part, a bacterial 
culture, a mineral or a salt (Gupta, 2015). This distinction is important because the 
active ingredients differ and so does the manner in which they react when consumed 
with food and conventional medicines.  
 
The Dietary Supplement Health and Education Act of 1994 classified herbal products 
as dietary supplements.  A dietary supplement is defined as a non-food, non-drug 
product taken by mouth and containing at least one identified dietary ingredient such 
as a vitamin, mineral, herb or botanical, amino acid, enzyme, or metabolite (Office of 
Dietary Supplements, 1994). Herbal supplement is a type of dietary supplement 
made from plants.  
 
Herbal medicine is one form of complementary and alternative medicine (CAM). 
Complementary and alternative medicine refers to any medical systems, practices, 
treatments or therapies that do not currently fall into accepted mainstream or 
conventional medicine (National Center for Complementary and Alternative 
Medicines (NCCAM), 2019). In addition to herbal medicine, CAM includes diverse 
therapies such as acupuncture, Ayurveda, homoeopathy, hypnotherapy, 
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naturopathy, osteopathy, reflexology, Reiki, traditional Chinese medicine (TCM) and 
yoga. Some of which do include herbal medicines as part of their treatment regimens 
e.g. Chinese medicine. 
 
Many drugs are derived from plants, with up to 25% of conventional medicines  
directly or indirectly from medicinal plants (Robinson & Zhang, 2011). In some 
cultures, medicinal plants have been the main source of healthcare for thousands of 
years and continue to be (Halberstein, 2005). Populations in middle and low income 
countries continue to rely on herbal medicines as primary source of health care. 
Although, this is at a much lower number than the 75-80% reported in earlier 
literatures (Bodeker & Ong, 2005; Robinson & Zhang, 2011). In these countries, it is 
mainly the patients who cannot afford conventional drugs that rely on herbal 
medicines. In contrast however, higher social class patients are the top users in 
developed countries (Eichhorn et al., 2011).  
 
Global consumption of herbal medicines is considerable although correct estimates 
are difficult to arrive at because it is uncoordinated and with variable regulations. 
Inconsistencies in what is and what is not herbal medicine also makes it extremely 
difficult to provide precise economic valuations (Robinson & Zhang, 2011). It is 
estimated however, that the herbal industry is worth about US$100 billion worldwide, 
with trade in medicinal plants, herbal raw materials, and herbal drugs at annual 
growth rate of about 11% between 2017 and 2022 (Zion Market Research, 2017). 
The herbal market varies from region to region, with Europe accounting  for the 
largest share of the market (Chapman 2012).  
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Historically, there have been efforts to regulate the production and use of HMPs. The 
Alma Ata declaration of 1978 by the WHO recognised the role of traditional, 
complementary and alternative medicine (CAM) in the healthcare of developing and 
developed nations. This was informed by a renewed focus on  primary health care 
(WHO, 1978), highlighting the need to address those aspects of public health that 
were outside conventional and western health care. The declaration called for the 
inclusion of proven traditional remedies in national drug policies and regulatory 
measures (World Health Organisation, 1978) and strengthen the role of primary 
healthcare in access to medicines. The WHO also developed key documents (World 
Health Organisation, 2000, 2003, 2007; World Health Organisation & Zhang, 2004) 
to strengthen regulatory capacity and assist national authorities, scientific 
organisations and manufacturers in the monitoring of herbal medicines. These 
documents provide basic criteria for evaluating the safety, quality and efficacy of 
traditional medicines to assist regulatory authorities in dossier assessments for 
herbal products (Ajazuddin, 2012). Policies and frameworks of South Africa (Ngcobo, 
Nkala, Moodley, & Gqaleni, 2011), Australia and many others (Calixto, 2000) have 
all evolved from these documents. Nevertheless, the regulation of herbal medicines 
depends largely on the ethnological and historical background of each country.    
 
As the demands for herbal products grew, regulations continue to present challenges 
to many countries including the UK. Consumer access to herbal medicines is not 
prescription controlled and whether or not access and use is included in medicines 
regulation vary widely from country to country (Girard & Vohra, 2011). The UK has a 
historical tradition of herbal medicine (Culpeper, 1653/1995), with remedies sold 
alongside other products in pharmacies as OTC products (Nissen, 2010), this is also 
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widespread and well established in some other European countries like Spain and 
Italy (Pieroni, Pardo-de-Santayana, Firenzuoli, & Quave, 2013; Williamson & Chan, 
2015). One of the many reasons for the continued demand for herbal therapy in 
these developed countries is that it is perceived that the use of home remedies and 
over-the-counter drugs is consistent with consumer choice; taking control in 
maintaining ones health and wellbeing  (Ekor, 2014). It is reasonable to predict that 
the herbal medicines market will continue to expand exponentially, representing a 
substantial proportion of the global drug market, especially as the number of older 
people living with multiple conditions that affect their quality of life in different ways  
grow (Barnett et al., 2012; Zion Market Research, 2017). 
 
In the UK, the Medicines and Healthcare products Regulatory Agency (MHRA) 
regulates medicinal products for human use in accordance with the European 
Community’s medicinal product directive (Directive 201/83/EC) and the UK law. For 
regulatory and legal reasons, many herbal products are considered food 
supplements even though most of them are medicines (Williamson, 2003). For 
example, Gingko (Gingko biloba) is sold as a food supplement in the UK and 
Netherlands, as registered OTC medicine in Germany and France but available in 
Ireland as prescription only (Gulati & Berry Ottaway, 2006). Due to these diverse 
classifications, HMPs are subject to multiple or concurrent levels of certification 
resulting in further complications in how they are regulated and who is responsible 
for their oversight (Coppens et al., 2007). Consequently, HMPs are manufactured, 
licensed, dispensed and sold differently all over the world. Moreover, HMPs and DS 
are easily sourced cheaply online. The availability of these products on the internet 
with little or no regulations emphasises the challenges of dealing with different 
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legislative frameworks between countries and information on quality and safety 
(World Health Organisation, 2015). Inadequate labelling, exaggerated reports of 
efficacy and minimal safety warnings (Owens, Baergen, & Puckett, 2014) are the 
main concerns about these products bought online. Around 83% of UK older adults 
in the 65 to 74 age group use the internet (Office for National Statistics, 2019), with 
up to 30% using the internet to look for health-related information (Age UK, 2018), 
including HMPs and DS.  
 
Since April 2011, all HMPs sold in the UK market must have a Traditional Herbal 
Registration (THR) or a marketing authorisation (previously known as a product 
licence). Currently, there is no requirement under the THR scheme to provide 
scientific prove that a product works, but registration is restricted to HMPs requiring 
no medical personnel for administration or monitoring and oral medicines for external 
use or inhalation (Medicines and Healthcare products Regulatory Agency, 2012). 
 
2.4 Older Adults and Herbal Medicinal Products  
Globally, the use of herbal medicines continue to grow particularly among older 
adults (Arcury et al., 2007; Canter & Ernst, 2004; Loya, Gonzalez-Stuart, & Rivera, 
2009; Yoon, Horne, & Adams, 2004). In the last decade, about a quarter of UK 
adults (MHRA & Ipsos MORI, 2009) and up to 35% of adults in the United States 
frequently use herbal products (Rashrash, Schommer, & Brown, 2017). Some of the 
reasons cited for the use of herbal medicines include dissatisfaction with 
effectiveness of conventional drugs, poor therapeutic outcomes (Astin, 1998; Chan, 
2003) and the perception that herbal medicines are safe (Delgoda et al., 2004; 
Delgoda, Younger, Barrett, Braithwaite, & Davis, 2010). Moreover, cultural and 
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personal beliefs, and in some cases better experiences with herbal medicine 
practitioners compared to conventional healthcare professionals may explain 
preferences for herbal medicines (Ernst & White, 2000).  
 
Compared to other forms of CAM, herbal therapy is the most popular across different 
ethnic and age groups (González-Stuart, 2011; Posadzki, Watson, Alotaibi, & Ernst, 
2013). Herbal medicines are used to maintain health, treat chronic illnesses (Albert 
et al., 2009; Marinac et al., 2007), for cardiovascular problems (Elmer, Lafferty, 
Tyree, & Lind, 2007; Farina, Austin, & Lieberman, 2014; Izzo, Di Carlo, Borrelli, & 
Ernst, 2005; Tachjian, Maria, & Jahangir, 2010) and pain management (Artus, Croft, 
& Lewis, 2007; Wilkinson & Jelinek, 2009). Likewise, they are also used for the 
management of anxiety (Parslow & Jorm, 2004) and depression (Hsu et al., 2009; 
Parslow & Jorm, 2004). 
 
The use of herbs and HMPs by older adults may not be disclosed to health care 
professionals (Barnes, Mills, Abbot, Willoughby, & Ernst, 1998; Walji et al., 2011). 
Only 55% of those who concurrently used herbal medicines with prescriptions 
reported that their doctors knew about their co-use, 73% of these co-users 
voluntarily informed their doctors (Delgoda et al., 2010). Considering that almost one 
in four adults co-use prescription medications with HMPs (Gardiner, Graham, 
Legedza, Eisenberg, & Phillips, 2006; Loya et al., 2009), the potential risk for 
adverse reactions may be under-estimated or not considered. 
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2.5 Rationale for the study 
Although there is some awareness that older adults concurrently use prescription 
drugs and HMPs (Arcury, Bell, et al., 2006; Dergal et al., 2002; Elmer et al., 2007; 
Gonzalez-Stuart, 2011; Loya et al., 2009; Qato et al., 2008; Yoon & Schaffer, 2006), 
very little has been done to find out what is happening and why. The majority of 
studies that have explored the concurrent use of prescribed medications with HMPs 
among older adults were conducted in the United States (Dergal et al., 2002; Elmer 
et al., 2007; Nahin et al., 2009; Qato et al., 2016).  Only one study on this issue 
among this age group within the context of the NHS has been reported from the UK 
(Canter & Ernst, 2004).  
 
There is evidence that some HMPs are clinically effective for particular conditions 
and patient groups (Izzo, Hoon-Kim, Radhakrishnan, & Williamson, 2016). However, 
there is potential for adverse drug reactions (ADRs) to occur between conventional 
drugs and HMPs, some of which may have serious consequences (Fugh-Berman, 
2000; Izzo & Ernst, 2001; Williamson, 2001; Williamson, Driver, & Baxter, 2013). For 
example, Ginkgo (Ginkgo biloba) when combined with anticoagulants could interfere 
with platelet functions (Fugh-Berman, 2000). Although many reported interactions 
between herbal products such as Echinacea or valerian and conventional medicines 
are of minor risks, with limited clinical significance. However, HMPs such as St. 
John’s wort may cause serious and life-threatening interactions with certain 
antidepressants (Izzo, 2012; Izzo et al., 2016; Williamson, 2003).  
 
Considering that the half-life of most drugs is 72 hours, polypharmacy combined with 
the use of HMPs raises the risk of interactions significantly. Interactions could occur 
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during the absorption, distribution, metabolism and excretion of drugs (Holford, 
2009). For this reason, it is important that healthcare professionals consider  
potential interactions between herbal medicines and prescribed drugs, especially 
drugs with a narrow therapeutic index (Izzo, 2012). Most drug-drug interactions are 
due to concurrent use of drugs, many of which are well-known and preventable. For 
example, Warfarin and acetaminophen could increase bleeding or increase the 
international normalised ratio (INR); it is recommended that this is managed by using 
the lowest possible acetaminophen dosage and monitoring the INR (Hughes, Patel, 
& Saxena, 2011; Lopes, Horowitz, Garcia, Crowther, & Hylek, 2011). Nevertheless, 
the interactions between most HMPs and prescription drugs remain unknown.  
 
The quality and safety of herbal medicines has been subjected to more scrutiny in 
the last decade (Ekor, 2014), with research on specific health conditions such as 
cancer (Molassiotis & Xu, 2004) and irritable bowel syndrome (Bahrami, Hamedi, 
Salari, & Noras, 2016).  Nevertheless, the incidence of herbal interactions is still 
unknown and there is no reliable up-to-date evidence on which to assess the scale 
of the problem or predict possible clinical outcomes. Of the few studies that have 
researched concurrent use of HMPs and prescription drugs in the UK (Alsanad, 
Howard, & Williamson, 2016; McLay et al., 2017; Steyn et al., 2018; Williamson et 
al., 2013), only one was conducted with older adults as participants (Canter & Ernst, 
2004). Although these studies share a common methodological approach i.e. cross-
sectional surveys, participants had conditions e.g. cancer and diabetics or were of all 
ages and not just older people. For the only study among older adults (Canter & 
Ernst, 2004), there was an implicit assumption that all older people are similar, and 
their identification and inclusion may have relied on self-selection. 
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The risks from concurrent use of HMPs and prescription drugs among older adults 
has been investigated (Bush et al., 2007; Elmer et al., 2007; González-Stuart, 2011; 
Kaufman et al., 2002; Nahin et al., 2009; Qato et al., 2008; Zyoud et al., 2014). Many 
herb-drug interactions were identified, with a risk of interaction reported in 5.8% of 
herbal products concurrently used with conventional medicines(Elmer et al., 2007). 
However, very little research has been done to investigate the incidence and severity 
of these herb-drug interactions and if certain patient groups are more susceptible 
than others  (Williamson et al., 2013).  
 
Although older people are the main users of the NHS, old age is not synonymous 
with ill health; the markers for being frail or vulnerable are not the same. Adverse 
drug reactions increase the risk of hospitalisation and can prolong hospital stay thus 
raising costs and putting pressure on the NHS. The prevalence of nearly all major 
chronic and long-term conditions increase significantly with age (Age UK, 2015). The 
majority of people aged 75 and over have one or more health conditions (Melzer et 
al., 2015). While having a health condition may not necessarily impact on daily life, 
having more chronic conditions could have limitations on daily living and the 
likelihood for health and social care needs. The rise in demand for health and care 
services is driven by the increasing complexity of health needs. As people age, they 
acquire multiple long-term conditions and disabilities or become frail (Mortimer & 
Green, 2015). Frailty affects around 10% of people aged 65 and over, rising to 25-
50% of those aged 85 and over (Collard, Boter, Schoevers, & Oude Voshaar, 2012). 
Frailty is a distinctive health state relating to the ageing process whereby multiple 
body systems gradually lose their in-built reserves (Clegg, Young, Iliffe, Rikkert, & 
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Rockwood, 2013). Older people living with frailty are at risk of adverse health events 
such as a fall or infection, with dramatic changes in physical and mental wellbeing 
even after minor incidents (Mortimer & Green, 2015). Individuals’ experience of ill 
health as they age is also affected by their socio-economic status and access to 
formal and informal networks of support (Centre for Ageing Better, 2017). These 
variables are of clinical and public health relevance, and key to understanding if 
there are certain groups of older people who are more or less likely to use HMPs 
concurrently with prescribed medications and why. 
 
2.6 Significance of the study 
Failure to review and manage concurrent use of prescription drugs and herbal 
medicines in older adults is a patient safety risk. Excessive and inappropriate 
medicine use is a common problem among older adults (O'Mahony & Gallagher, 
2008; Pérez-Jover et al., 2018) and concurrent use with HMPs further complicates 
the issue. It is important to have a better understanding of the way older adults co-
use medications, if there are specific health conditions where HMPs are used 
alongside prescribed medication and how they are used. For example, if they are 
used for the relief of symptoms as part of ongoing health management regimen or 
used intermittently. There is considerable heterogeneity within the older population 
(Looman et al., 2018). Therefore, it is unclear how people with more or less 
functional ability, those who come from particular cultural backgrounds or have 
different levels of health literacy and knowledge (Jill Roberts, 2015) engage with the 
use of HMPs and when.  
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From the perspective of the health service and practitioners, knowing why older 
adults concurrently use HMPs and DS with prescribed medications has the potential 
to reduce adverse drug events and uncover symptoms not previously disclosed in 
clinical encounters. This awareness and improved understanding will equip health 
care professionals to identify older adults at risks of potential herb-drug interactions, 
the reasons for medication non-adherence and how best to discuss treatments and 
target interventions. 
 
This study updates and builds on evidence from the UK on this issue. Previous 
related study (Canter & Ernst, 2004) was published 15 years ago and investigated 
only prevalence but not the reasons and factors associated with concurrent use of 
prescription drugs and HMPs. By focusing on community dwelling older adults, this 
study considers the breadth of use of HMPs and explored in-depth, the reasons and 
factors associated with concurrent use through individual qualitative interviews. 
Importantly, this study provides some answers to why older adults concurrently use 
their prescriptions drugs alongside HMPs; an area that is still under-researched.   
 
2.7 Chapter Summary  
Chapter 2 sets the scene for the study presenting a case for the research in the 
context of polypharmacy and herb-drug interactions and establishing the rationale for 
a better understanding of concurrent HMPs and prescription drug use among older 
adults.  A discussion of challenges with the regulation of HMPs and DS due to 
differences in national policies is also presented. 
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Chapter 3 now reports on the three phases mixed method research design selected 
as suitable to meet the aims of this research. The strength and limitations of this 
research design, as well as details of the individual phases are discussed. 
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Chapter 3: Methods 
3.1 Introduction to Chapter 
This chapter outlines the research design, data collection and analytic methods 
employed to investigate the concurrent use of prescription medicines and herbal 
medicinal products (HMPs) among UK older adults. The rationales for adopting a 
mixed method sequential explanatory design to address the research questions are 
articulated. The advantages and challenges of the approaches adopted are also 
discussed. Ethical considerations and the involvement of public and participants 
throughout the study are considered. In addition, the chapter provides detailed 
accounts of how validity and reliability were ensured throughout the study and how 
data from the three phases were analysed and drawn together. The chapter 
concludes with a critical reflection of the chosen method and approaches.  
 
3.2 Research Paradigm: Pragmatism 
All research has a foundation.  Whether explicit or not, this foundation is found in the 
‘worldview’ or theoretical framework adopted by the researcher (Creswell & Clark, 
2011). The overarching aim of this study was to explore the concurrent use of 
prescription medicines and HMPs among older adults in the UK. As the researcher in 
pursuit of the ‘realities’ for this social issue, I bring along my beliefs and assumptions 
about herbal medicines. In addition, my previous knowledge about concurrent use 
and the safe use of medicines, all of which may have influenced my approach to this 
research. It is important that I understand and acknowledge this at the outset. 
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The assumption underlying the research questions are; that the use of herbal 
medicinal products (HMPs) is common among older adults. Herbal medicinal 
products are frequently bought over the counter, consumed concurrently with 
prescription drugs and not disclosed to health care professionals. An important 
patient safety concern for the concurrent use of herbal and prescription medicines is 
potential herb-drug interactions. 
 
Older adults are a growing percentage of the UK population (Office for National 
Statistics, 2013) and the risk for adverse drug reactions (ADRs) increases with age 
(Davies et al., 2009). The chances of medication-related problems are higher among 
older people because of co-morbidities, metabolic changes and reduced clearance 
of pharmacologically active compounds (Mangoni & Jackson, 2004; Salmond, 2002; 
Vacas Rodilla et al., 2009). Also, the number of medications increases the risk of an 
ADR (Eichhorn et al., 2011; Heuberger, 2012). Considering that up to 20% of over 
70s take five or more prescribed medications (Kaufman et al., 2002; Rollason & 
Vogt, 2003), the clinical and economic implications of ADRs on healthcare systems 
are huge (Sultana et al., 2013). 
 
Despite these concerns, little is known about concurrent use of prescriptions and 
HMPs by older adults and possible interactions. Therefore, the focus of this study is 
patient safety. And this is threaded all through the different stages of the research.  
 
This study is grounded in pragmatism, a claim on knowledge based on the 
assumption that collecting different types of data provides better understanding of a 
research problem (Creswell, 2013). Pragmatism is a philosophical theory seen as a 
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bridge between the conflicting inductive-subjective-contextual approach (qualitative) 
and the deductive-objective-generalising approach (quantitative) (Morgan, 2007). 
According to Tashakkori and Teddllie (2003), pragmatism debunks concepts such as 
‘truth and reality’ and rather focusses on ‘what works’ as the truth regarding the 
research question under investigation. Proponents of pragmatism view it as a 
philosophy of common sense with purposeful inquiry as its focal point (Shields, 
1998). 
 
The research questions have informed the choice of methods and approaches. A 
mixed method approach that draws on quantitative and qualitative approaches and 
data ensures that the study questions can test what is effective (systematic review), 
establish how many people use HMPs with prescribed medication (systematic review 
and survey) and explore the reasons that have informed these choices (survey and 
interviews).  
 
3.3 Research Design: A mixed method sequential explanatory 
 study 
 
There is no consensus about what mixed methods design should or should not 
include or the kind of research questions that it is most suited to as an approach 
(Creswell & Clark, 2011; Morse & Niehaus, 2009; Tashakkori & Teddlie, 2003). 
However, there is a general understanding that combined methods can provide 
different perspectives and richer insights that challenge or enlighten a particular 
world view of what the problem or issues are (Creswell & Clark, 2007; Johnson, 
Onwuegbuzie, & Turner, 2007; Tashakkori & Teddlie, 2003). 
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For mixed method designs, both quantitative and qualitative data are collected and 
analysed using suitable approaches and techniques, both data sets are then 
synthesised at the point of interpretation(Creswell & Clark, 2011; Creswell, Plano 
Clark, Gutmann, & Hanson, 2003).  
 
Quantitative and qualitative methods can complement each other (Greene, Caracelli, 
& Graham, 1989; Plano Clark & Creswell, 2011; Tashakkori & Teddlie, 1998). It 
builds an account based on the data to answer the research question. In this study, 
using mixed method design where each stage established what was known and 
each stage informed the next. The systematic review tested possible explanations as 
to why older people use HMPs concurrently with prescribed medications and then 
explored in depth key issues of interest in a survey with a small group of concurrent 
users (interviews). This contrasts with multiple methods studies which involves the  
simultaneous collection of either multiple qualitative or quantitative data to maximise 
understanding of how  research questions are understood and answered  within one 
study (Morse, 2003). For example, a study on prescribing that includes secondary 
data analysis of prescribing practice, and in-depth exploration of how supplementary 
prescribing has worked from the perspective of patients, pharmacists, and nurses 
provides multiple perspectives on the same issue (Bissell et al., 2008). 
 
However, combining methods that are usually associated with a paradigm requires 
that the researcher is explicit about how data are synthesised and interpreted. There 
are a number of ways in which qualitative and quantitative methods can be 
combined within mixed methods design (Greene et al., 1989). A typology by Green 
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et al provides an overview of different types of mixed method approaches and their 
supporting rationale. Table 3.1 provides a summary. 
 
Table 3.1: Purposes of mixing methods in a research study and appropriate mixed 
  method design 
 
Purpose Description Mixed method design 
 
Triangulation Using two or more methods to measure 
the same phenomenon, such that 
convergence or corroboration gives 
weight to the interpretation or make it 
more reliable. 
 
Convergent parallel  
Complementarity  Using results of one research method 
to clarify, elaborate or illustrate results 
of another method, to achieve a more 
comprehensive understanding of the 
phenomenon 
 
Sequential Exploratory 
Sequential Explanatory 
Development  
 
Results from one method help to 
develop, to inform or refine the second 
method  
Sequential Exploratory 
 
Expansion   
 
 
Seeking to analyse and to explore 
different facets of a phenomenon, to 
get a richer and more detailed 
understanding e.g. Explaining 
quantitative results with qualitative data 
Sequential Explanatory  
Initiation  Discovering paradoxes or seeking 
contradictions which lead to the 
reframing of research questions. 
Different methods are used to assess 
various dimensions of the phenomena 
of interest to arrive at new insights and 
understanding 
 
Concurrent nested 
 
Concurrent 
transformative 
 
To address the different objectives of this study, a mixed method approach using a 
sequential design was chosen, the decision to use qualitative and quantitative 
methods was planned before the start of data collection. This contrasts with 
emergent mixed method design where the decision to use a second approach arises 
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due to issues during the conduct of the research for example, unexpected findings or 
gaps in understanding (Morse & Niehaus, 2009).   
 
The mixed method design was adaptable to reflect the research experience. For 
example, an interview was used to inform the survey design when it became 
apparent that people were unwilling to participate in focus groups. Therefore, using a 
mixed method approach provided flexibility and maximised the opportunities to 
provide a comprehensive approach when addressing the research question within 
the resources available (Onwuegbuzie & Leech, 2006). The different sources of 
evidence also had the potential to achieve a more nuanced account of the issue 
under study. The sequential mixed method study was organised in three phases (Fig 
3.1), with data from each phase answering the research questions and providing 
basis for further refinement of the questions for the next phase (Mertens, 2014).  
 
Findings from the systematic review informed development of the survey, its focus, 
structure and content. The survey established prevalence of concurrent use; the 
range of medicines combined and identified a sample of concurrent users. The 
interviews with a sub- sample of concurrent users explored experiences, reasons for 
concurrent use, understanding of risks and therapeutic benefits of taking HMPs 
concurrently with prescribed medication for linked or different conditions. The design 
did not assume a hierarchy of evidence but used the findings from one phase to 
inform the next, with the different methods linked in their common focus on this 
issue. 
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Figure 3.1: Sequential mixed method design (Adapted from Cameron (2009) 
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3.4 Strengths and Limitations of Mixed Method Design 
The strength of mixed methods design is that it supports the use of a range of data 
collection tools, to study the problem of interest from a range of perspectives (Lewin, 
Glenton, & Oxman, 2009). It enables the researcher to test different explanations of 
why what is observed has occurred. Using both qualitative and quantitative data 
allows for a fuller understanding of the research problem (complementarity). Mixed 
methods often combine approaches to serve the dual purpose of gaining overview of 
issues from a larger sample, as well as gaining in-depth understanding through 
detailed study of a smaller sample (Bazeley, 2004). For example, Fox et al.,(2013) 
used semi-structured interviews to ascertain the views of oncology professionals and 
CAM practitioners regarding the role of CAM in patients with cancer. In Phase 2, a 
survey of women with breast cancer determined the rate and type of CAM, reasons 
for use, and perceptions regarding the utility of CAM.  Lastly, individual interviews 
with a sub-set of the survey sample elucidated in greater detail the reasons for CAM 
use and patients' experience of CAM.  
 
However, using mixed methods approach is not without limitations. A common 
criticism is that full integration of findings from the multiple approaches is difficult, 
and there is tendency to privilege one source of evidence or set of theoretical 
assumptions (Bazeley, 2004). Greater resources and time are also often required for 
data collection, analysis and interpretation than might be the case for single method 
studies.  
 
To summarise, the rationale for the study was that concurrent use of prescription 
drugs with HMPs is a patient safety issue. The sequential mixed method design 
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involving quantitative and qualitative data provided an in-depth understanding of the 
issues in ways that would capture both the scale of the problem, patient perspectives 
of the benefits and risks of using HMPs alongside prescribed medication and the 
implications for patient safety (Plano Clark & Creswell, 2011). The combination of 
quantitative and qualitative methods was both complementary and developmental 
(O'Cathain, Murphy, & Nicholl, 2007).  
 
3.5 Ethical Considerations and Approvals 
Permission to conduct the study was sought from the University of Hertfordshire, the 
NHS Research Ethics Committee (REC) and Research & Development (R&D) office 
for the two study sites. Application forms and study proposal were submitted to the 
University of Hertfordshire Ethics Committee for Studies Involving the Use of Human 
Participants for ethical scrutiny and approval (EC1). The study was examined, 
approved and granted research indemnity by the University of Hertfordshire Ethics 
Committee. Reference no: HSK/PG/NHS/00336 (Appendix A). 
 
Since the study involved NHS participants, an online application was made to the 
REC on the Integrated Research Application System (IRAS). The study had a 
proportionate review because patient records were not accessed, and the research 
did not involve sensitive issues. Permission to contact and interview interested 
participants in the next phase of the research was sought as part of this application. 
The study was granted a full REC approval, Reference no: 15/LO/1870 (Appendix 
B).  
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Permission was also required from the local R&D office to conduct the study at 
identified general practices. This process took 7 months, from May to December 
2015. The delay was in identifying the responsible R&D offices. Due to the 
reorganisation of primary care in England in 2012, R&D offices were either merged 
or non-existent. This further complicated research management and governance 
(RM&G) within primary care, making it harder to navigate the application process.  
 
Protecting participant’s rights to confidentiality and anonymity are some of the ethical 
principles of research upheld throughout the conduct of this study. Key obligations 
included privacy, minimising distress, intrusion, and protecting participants from 
harm if possible adverse interactions from concurrent use of HMPs were identified 
based on their responses. 
 
3.5.1  Ethical considerations for conducting research with    
  older adults  
 
Research involving older adults can present challenges resulting from the 
physiological and psychological factors such as decline in physical and cognitive 
functions associated with ageing (Quinn, 2010). Nonetheless, age and vulnerability 
should not be used as reasons for exclusion in research (Diener et al., 2013). 
Therefore, special measures should be taken in designing research involving older 
adults, to support their inclusion and participation. 
 
In this study, some of the ethical issues were treating personal data confidentially 
and storing them securely. To maintain privacy and anonymity for the survey, 
individual questionnaires were coded using letters and digits written on the front 
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page. To protect participant’s personal information, section 5 of the questionnaire 
where those interested in being interviewed provided names and addresses were 
detached from the questionnaire after the participant’s ID was copied unto it 
(Appendix C). All questionnaires were stored securely in a locked cabinet. Access to 
the research data was restricted to me, and my two supervisors. In accordance with 
the ethics approval obtained for the study, digital records are destroyed after 
transcription and data will be stored for five years and then destroyed. 
 
Study Information was written in plain language and the choice to participate or pull 
out of the study without providing any reason to do so was explained. It was also 
made clear on the participant information sheet (PIS) (Appendix D) that their GPs will 
be contacted, if potentially dangerous herb-drug interaction was suspected from the 
information they provide. 
 
While every effort was made to ensure that enough participants were recruited for 
this study, there was a risk that participants would feel pressurised to take part in the 
study. To minimise the likelihood of this occurring, it was explained in the PIS, that 
those who do not wish to participate could send uncompleted questionnaire back in 
the reply-paid envelopes.  
 
The principles outlined by the UK Framework for Health and Social Care Research 
(Health Research Authority, 2017) for the conduct of human research such as right 
to privacy, respect and autonomy, benefit and risks were adhered to throughout the 
study. Interviews were always conducted in the place of the participants’ choice and 
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attention was paid to privacy and their right to withdraw at any point. All data was 
anonymised so individuals would not be recognised.  
 
3.6 Patient and Public Involvement (PPI)  
Patient and public involvement (PPI) is a process whereby patients, service users 
and members of the public are actively involved in the planning, prioritisation, 
commissioning, conduct and communication of research (INVOLVE, 2012), as 
opposed to just being the ‘researched’. Patient and public involvement is a statutory 
part of the UK policy framework for health and social care research (Health 
Research Authority, 2017), and a key requirement by major funding bodies 
(Staniszewska & Denegri, 2013). The responsibilities and expectations of research 
funders with regards to public engagement is also well described in the Concordat 
for Engaging the Public with Research (Research Councils UK (RCUK), 2010). The 
aims of PPI are to improve dialogue and trust between researchers and the public, 
and to enhance the quality and impact of research for the benefit of the society and 
economy. In this study, PPI was particularly important to ensure that the research 
design and researcher approach would be acceptable to participants and the needs 
for the research (how the questions were framed) were credible to older people. 
 
The transparency and accountability inherent in the PPI process, helps to create 
trust between researchers and the public. Involving PPI at all stages of the research 
activity leads to a higher quality research. This is due to the unique perspectives that 
patients and member of the public bring to the process (Brett et al., 2014; Brett et al., 
2010; Staley, 2009). When there is a lack of shared understanding on the moral and 
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methodological purpose of PPI between researchers and the public, this has been 
reported as a major barrier to effective PPI (Wilson et al., 2015).  
 
Throughout this study, I ensured that PPI representatives were part of the research 
process. Community dwelling older adults in Broxbourne, Hoddesdon and Cheshunt, 
members of a public involvement and research group (PIRg), were involved in 
providing advice and helping to improve the study.  They highlighted the confusion 
around what is and what is not an HMP as an issue to address.  At the planning 
stages, in addition to formal conversations with PPI representatives, there were 
discussions with older family members, colleagues and friends who helped to clarify 
key questions and challenged my assumptions.  
 
The PIRg members made suggestions on the survey protocol, reviewed early 
versions of the PIS, the questionnaire and interview guide. They suggested sending 
an invitation to participate in the study personally addressed to prospective 
participants, along with the PIS and questionnaires. This is because older adults 
were more likely to agree to participate in the study, if they get a letter in their name 
and not a general invitation. The PIRg group also suggested including examples of 
HMPs on the PIS and questionnaire, so that participants know the types of 
medicines that are of interest to the study. Also, they suggested reducing the length 
of the PIS, helped to reframe survey questions and write the instructions in plain 
language.    
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3.7 Overview of Study Methods 
3.7.1  Phase 1- Systematic Review  
Systematic reviews are summaries of the best available evidence addressing sharply 
defined questions (Sackett, Rosenberg, Gray, Haynes, & Richardson, 1996). To limit 
bias and random error, pre-planned strategies are used during literature search. 
Critical appraisal and synthesis of relevant data is also important, with clear 
documentation of the process (Chalmers, Altman, & Gotzsche, 1995; Cook, Sackett, 
& Spitzer, 1995) . 
 
Systematic reviews differ from other types of literature reviews such as scoping and 
narrative reviews as they are designed to answer specific, often narrow questions in 
depth (Richardson, Wilson, Nishikawa, & Hayward, 1995). Questions for systematic 
reviews are often formulated according to four variables; patient, problem or 
population (P), intervention (I), comparison, control or comparator (C ) and outcome 
(O) (Guyatt, Rennie, Meade, & Cook, 2002). In addition, the sources of and the 
searches for evidence in systematic reviews are comprehensive and explicit, for 
narrative review this is often not specified (Cook, Mulrow, & Haynes, 1997). Rigorous 
critical appraisal is also a key stage in the conduct of systematic reviews.  
 
Systematic reviews are considered important tools for policy makers because they 
are scientifically rigorous and informs decision making based on the totality of 
evidence rather than a single study (Sheldon, 2005). 
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The systematic review addressed the following questions: 
a. What is the prevalence and pattern of concurrent use of prescription drugs 
and herbal medicinal products (HMPs) among older adults? 
b. What patient and clinical characteristics are associated with concurrent use of 
prescription drugs and HMPs? 
c. What are the range of prescription drugs and HMPs most concurrently used 
by older adults?  
d. What safety issues and other factors are associated with concurrent 
prescription drug and HMPs use in older adults? 
 
a. Data Sources 
The Medline, PsychInfo, Embase, CINAHL, AMED, Web of Science and Cochrane 
electronic databases were searched systematically from inception until May 2017, for 
studies reporting concurrent use of prescription medicines with HMPs among older 
adults (≥65 years) (Appendix E). Also, lateral searching via related citation (PubMed) 
and reference lists of identified studies. Two reviewers independently screened 
studies, extracted data and appraised methodological quality using the Joanna 
Briggs Institute (JBI) checklists for appraising studies reporting prevalence data 
(Munn, Moola, Lisy, Riitano, & Tufanaru, 2015) and for case reports (The Joanna 
Briggs Institute, 2016). Qualitative and quantitative studies from all settings were 
included. Non empirical papers, experiments and animal studies were excluded. 
Primary outcomes were prevalence and patterns of concurrent use, number and 
types of prescription and HMPs, and adverse reactions reported. Secondary 
outcomes included disclosure of HMP use to health care professionals and cost of 
HMPs. A narrative synthesis of included studies was done to summarise the 
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evidence. More detailed account of the systematic review method is provided in 
Chapter 4. 
 
The systematic review identified what was known and not known about concurrent 
use of prescription drugs and HMPs among older adults, and other issues that 
needed further exploration. These findings informed the next stages of the study.  
 
3.7.2  Phase 2- Quantitative Study (Cross-sectional Survey) 
Cross-sectional studies such as surveys are used to establish prevalence or 
incidence of particular conditions, and to collect information on attitudes and 
behaviour about a population of interest (Lavrakas, 2008; Sapsford, 2006).They are 
particularly useful in providing a snapshot of a population, at a given time (Olsen, 
Christensen, Murray, & Ekbom, 2010). Cross-sectional, cohort and case control 
studies are referred to as observational studies, because no intervention is required 
and the investigator simply observes (Mann, 2003). Moreover, there is no need to 
allocate participants into different groups, data are collected only once and multiple 
outcomes can be studied (Mann, 2003). 
 
Surveys have several advantages. They are flexible and a cost-effective way of 
gathering information from widely dispersed participants (Gillham, 2008). In fact, the 
majority of studies investigating medication use among older adults have used cross-
sectional surveys (Canter & Ernst, 2004; Kaufman et al., 2002; Peklar, Henman, 
Kos, Richardson, & Kenny, 2014; Qato et al., 2008; Turkmenoglu, Kutsal, Dolgun, 
Diker, & Baydar, 2016). Questionnaires are the commonly used tool in surveys and 
data can be collected with standardised measures (Bulmer, 2004).  
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Previous research suggests that sensitive behaviours are reported more in self-
completed questionnaires than in face- to -face interviews (Beebe, McRae, Harrison, 
Davern, & Quinlan, 2005; Bowling, 2005; Tipping et al., 2010; Tourangeau & Smith, 
1996). Therefore, for a descriptive study such as this one, which seeks to describe 
reality (Creswell, 2013), a cross-sectional survey, using self-completed questionnaire 
was chosen. A major strength of this approach is that it allowed for populations of 
older adults from different backgrounds and social groups, representative of those 
who may take HMPs with prescribed medications to be surveyed, expanding on the 
findings from the systematic review.  
 
The self-completed questionnaire survey was designed to address the following 
objectives:  
 Establish the prevalence of concurrent prescription drugs and HMPs use among 
UK community dwelling older adults. 
 Identify the pattern of concurrent use and the range of medicines combined.  
 Examine potential herb-drug interactions from such combinations.  
 
a. Exploratory and Pilot Work (March – November 2015) 
I attended five coffee mornings with residents of retirement settlement schemes at 
Cheshunt, Broxbourne and Hoddesdon between March and June 2015 to discuss 
my research and solicit participation in focus groups. Only 8 of the 45 older adults 
(38 residents and 7 staffs) at the coffee mornings had any experience of using HMPs 
(two in the past and six currently using HMPs). An interesting finding from these 
meetings was that older adults were unwilling to talk about their herbal medicine use 
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in a group but were happy to speak to me one-to-one. Therefore, initial plans to 
develop the questionnaire out of findings from focus groups was abandoned and 
replaced with individual interviews and findings from the systematic review.  
 
The questionnaire and participant information sheet (PIS) were tested in a pilot of 15 
older adults identified from records of the two GP practices (n= 10), family and 
friends (n= 5). The purpose of the pilot was to find out if the questions were 
understood and if they elicit responses that related to the research objectives. 
 
Responses from the pilot work prompted some minor amendments to the PIS and 
the questionnaire. The PIS was changed to make it clear that the survey can be 
completed, even if participants do not currently use HMPs. And because it was 
evident from the systematic review that no consistent term exists for HMPs, different 
terms are used in different countries and HMPs mean different things to different 
people (Agbabiaka, Wider, Watson, & Goodman, 2017). It was therefore important to 
rephrase section three of the questionnaire, and to include some examples of 
common HMPs to show participants the possible breadth of responses. 
 
Also, changes were required to ensure that detailed responses regarding 
prescription medicines were captured, especially from participants who may use 
many prescribed medicines. Question 2.1 was amended to include an option of 
attaching a copy of the repeat prescription sheet they got from their GP. 
Furthermore, two questions with duplicated information on participant’s level of 
educational were re-phrased and merged into one, thus reducing the length of the 
questionnaire. Initially, Question 1.1 asked participants to write their age. However, 
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to make the question less personal, so that respondents were more willing to provide 
a response, it was amended so they could select which age group they belong. 
Question 3.2 was also expanded to seek information on the appearance of HMPs 
and how often it was taken. 
 
b. Setting and Participants 
The study was limited to a sample from a purposive sampling frame of older adults 
aged 65years or more and on at least one prescription medication registered at two 
general practices. 
i. Practice A (NZ): a small practice in an Essex village of Epping Forest with 
predominantly white population. About 19.5% of the population was aged 65 
years or older. 
ii. Practice B (SG): a large urban practice in North London with a sizeable 
British, Black, Asian and minority ethnic (BAME) population. The percentage of 
older people living within the catchment area was 9% and there are small 
pockets of social deprivation. 
  
It is assumed that people from BAME groups use more HMPs than people who are 
white (Gardiner et al., 2013). There is however very little research on concurrent use 
with prescription drugs among these groups. The systematic literature review 
(Agbabiaka et al., 2017) found only one study that assessed concurrent use between 
different ethnic groups (Elmer et al., 2007). Therefore, including Practice B (SG), 
which has a sizeable BAME population in the sampling frame will provide some 
information on BAME population.  
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Table 3.2 compared the demographic profile of older adults in England with the two 
local authorities for the GP practices where older adults were recruited for this study.  
 
Table 3.2: Demographic profile of study sites A and B  
% (Year) England Epping 
Forest 
Haringey 
Population aged 65+ (2016) 
 
17.9 19.5 9.3 
Life expectancy at 65+ (male) 
2013-15 
18.7 19.2 19.2 
Life expectancy at 65+ 
(female) 2013-15 
21.1 21.2 22.4 
Index of multiple deprivation 
IMD (2015) 
21.8 15.3 31.0 
Deaths in usual place of 
residence among people aged 
65 years and over (2016) 
47.2 41.4 33.4 
Population from Black and 
Minority Ethnic (BME) groups 
(2011) 
14.6 9.5 39.5 
 
Source: Public Health England (2016)  
 
The two general practises randomly selected from their records 400 patients (200 
each) who met the following inclusion criteria: 
 65 years and older 
 using at least one prescription medication 
 able to consent 
Patients were excluded from the sample based on the following criteria: 
 terminally ill  
 have dementia or  
 assessed as lacking capacity to consent. 
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c. Sample size 
To ensure that the proposed number of participants to be recruited for the study is 
enough to meet the research objectives, such that resulting estimates of means or 
proportions can be reported with a satisfactory degree of accuracy, a sample size 
calculation was necessary. Sample size is a function of three factors - significance 
level, power and magnitude of the difference (effect size) (Devane, Begley, & Clarke, 
2004; McCrum-Gardner, 2010). Two main approaches are adopted in calculating 
sample size; one is based on the precision of the estimates i.e. the sampling error 
deemed acceptable. The other approach is based on the power of a study, this is the 
ability to detect a significant change in the true magnitude of the effect anticipated 
(Barlett, Kotrlik, & Higgins, 2001). For example, a hypothesis test is conducted, and 
power calculation is done to ensure that the sample is large enough for the test to 
have enough power. 
 
For this study, the focus was on estimating prevalence of concurrent use in the 
population of older adults and not the statistically significant change of an 
intervention. The primary outcome measure was the proportion of older adults who 
take HMPs alongside prescription medicines. Therefore, the sample size calculation 
was based on the following: 
 Previous research that up to 50% of older adults use HMPs (Farina et al., 
2014; Schnabel, Binting, Witt, & Teut, 2014; Yoon et al., 2004)  
 achieving a confidence interval (CI) of 95%  
 with ± 7.5% accuracy 
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So, using normal distribution to approximate the binomial distribution gave the 
sample size required as 171 respondents (the worst-case scenario of the actual 
proportion being 50%).  
 
In addition, to conduct t tests for differences in normally distributed variables 
between the two groups (i.e. those concurrently using HMPs and prescription drugs 
and those who do not), a power calculation showed that a sample of 128 (64 in each 
group) would be sufficient (and hence the above 171 would be sufficient). This was 
based on having 80% power, a medium standardised effect size of 0.5 for each of 
the dependent variables, and a significance level of 5% for a two-tailed test. For 
differences in proportions between the two groups, the above sample size of 171 
would be sufficient to be detecting differences of about 21 percentage points 
between the groups (assuming the sample to be equally split between the groups 
and again using 80% power, two sided tests and the 5% level of significance). 
Although this is a relatively large difference in percentage points, the sample sizes 
required for any substantially smaller difference were infeasible (e.g. 776 responses 
required to detect a difference of 10 percentage points). These calculations have 
been carried out using G*Power version 3.1.9.2. 
 
d.  Response rate 
Low response rates are common with mailed questionnaires (Blair, Czaja, & Blair, 
2013; Edwards et al., 2009; McColl et al., 2001) and studies are often abandoned or 
the statistical power reduced due to poor recruitment (Bryman, 2012; Mangione, 
1995). Expected response rates for surveys reported in the literature ranged from 
20%-60% (Fincham, 2008). Therefore, oversampling by up to 40-50% is necessary 
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and often recommended for mailed surveys (Fink, 2003; Salkind, 2012). Although 
oversampling adds to the cost of research, it accounts for lost mails or non-
response.   
 
So, using the most conservative response rate of 50% obtained in similar previous 
studies (Ly, Percy, & Dhanani, 2002), it was necessary to invite more than double 
the required number of participants (McCrum-Gardner, 2010) hence,  a total of 400 
older adults were invited to participate in this survey.  
 
e. Questionnaire Design 
Self- completion questionnaires are like structured interviews but with the obvious 
difference that the interviewer asks questions and record responses in the latter. 
Although face-to-face is considered a gold standard for surveys (De Leeuw & 
Dillman, 2008; Groves et al., 2011), self-completion questionnaires are cheaper and 
more convenient with regards to travel time and costs (Bryman, 2012).  
 
The questionnaire consisted of 18 questions divided into five sections to cover 
demographics, prescription use, HMPs use, side effects and benefits. Closed ended 
questions were used where possible responses could be predicted in advance (e.g. 
demographics) and respondents could choose a category from a selection provided. 
Using closed-ended questions means that the responses were easily coded, and the 
statistical analyses were done in a more structured and meaningful manner. 
Moreover, answers from different respondents or groups of respondents could be 
compared (Bulmer, 2004).  
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On the other hand, open ended questions were more appropriate for obtaining 
information on the different prescription drugs and HMPs the participants used. 
Although more time consuming to administer and more difficult to analyse than 
closed questions, open questions are more suited for questions where responses 
are unknown or too numerous to pre-code (Bryman, 2012; Kelley, Clark, Brown, & 
Sitzia, 2003). Other considerations include, avoiding complex questions by ensuring 
that all questions were simply worded. The PIS explained what the research was 
about, the aims of the study, why and how they were selected, and the time required 
for completing questionnaire and the interviews.   
 
 
Participants were asked to provide the names of medications, what they are used for 
and how often. They also had to provide any information on benefits, side effects 
and reactions experienced from taking the HMPs they have reported. Those who 
indicated use of HMPs were asked to provide contact details, if happy to participate 
in the next phase of the study. The questionnaire took an average of twenty to thirty 
minutes to complete. 
 
e. Main study (January to April 2016) 
A total of four hundred questionnaires were sent out to older adults from Practices A 
and B (two hundred from each practice). Eligible participants were sent a study pack 
by post containing:  
 Letter of invitation  
 Participant Information Sheet (PIS) 
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 Questionnaire (Appendix C) and reply-paid envelope addressed to the 
research team 
 Request for permission to be contacted for an interview, if they meet the 
criteria for the next phase of the study. 
 
Each of the 400 questionnaires and pre-paid return envelope were coded with study 
ID for the GP site (i.e. SG 001-200 and NZ001 – 200). Participants were asked to 
return completed questionnaire to me at the University address (i.e. Centre for 
Research in Primary and Community Care (CRIPACC), in the pre-paid envelope 
provided. Completing and returning the questionnaire implied consent to participate 
in the study. This was further explained in the PIS that were sent with the 
questionnaire. My contact details and that of the University Secretary and Registrar 
were provided on the PIS, if participants had any queries or concerns about the 
research.  
 
An administrator received responses in the post, recorded codes from the envelopes 
on a spreadsheet and stored the envelopes safely in a locked cabinet. I contacted 
the administrator weekly to ascertain how many responses were received. And those 
who did not return the questionnaire after two weeks were sent a reminder letter, 
asking them to please complete and return the questionnaire (Figure 3.2). If no 
response had been received after two weeks, another copy of the questionnaire was 
sent to participants along with the PIS. Participants were not followed up again after 
this third contact. 
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Figure 3.2 Survey Flowchart  
 Week 2 
Completed and returned 
questionnaires = 51 
 
Eligible concurrent users, agreed 
to be interviewed and contacted = 
20 
Non eligible respondents sent 
appreciation letters = 8 
 
Semi structured interviews = 13 
Week 3 
Reminder letter sent to non – 
responders = 349 
Week 6 
Non-responders sent questionnaire, 
PIS and reply-paid envelope again = 
317 
 
Total number of questionnaires 
returned = 155 
Incomplete questionnaires 
excluded from analysis n = 8 
General practice A and B identified from Patient list: 
 Males and females,  65 years and older 
 on 1≥ prescription drug 
 able to consent 
 
Identified patients were posted: 
 Invitation to participate in the study 
 Participant Information  Sheets 
 Questionnaire with reply-paid envelope 
 
n= 400 
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3.7.3 Phase 3- Qualitative Study (Semi-structured Interviews) 
The survey provided an overview of the HMPs used by older adults concurrently with 
prescribed medications and the possible interactions from such combinations 
(Agbabiaka, Spencer, Khanom, & Goodman, 2018). However, it did not provide an 
in-depth understanding of the reasons why older adults concurrently use medications 
neither did it examine their views and experiences.  
 
Interview is the most frequently employed method in qualitative research. The 
strength lies in gaining information on the perspectives, understanding and meanings 
constructed by others regarding events and experiences (Patton, 1990). Interviews 
can be unstructured, semi-structured or structured. Semi structured interview are 
series of open-ended questions based on the topic under investigation (Bryman, 
2012). An open and more relaxed approach to interviewing is achieved with the 
semi-structured approach because it is focused, yet less directive and less 
intimidating than structured interviews (Louise Barriball & While, 1994; Tashakkori & 
Teddlie, 2003). It also allows the participant to identify what is important to them 
about the topic being discussed. 
 
 
The dynamics between interviewer and interviewee in semi-structured interviews 
provide opportunities to change the words but not the meaning of the questions to  
suit different participants when conducting the interview (Holloway & Galvin, 2016). 
For example, herbal medicinal product does not mean the same thing to every 
participant. Therefore, examples of herbal medicines, or the words ‘herbal medicine’, 
‘herbs’ or ‘herbals’ were used at different occasions based on the participant’s 
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understanding. More importantly, the interviews allowed for interrogation of new 
ideas or explanations as they emerge, while at the same time exploring and 
clarifying inconsistencies in the participant’s account (Barriball & While, 1994; 
Hutchinson & Wilson, 1992). 
 
A disadvantage of interviews is that it can be time-consuming and expensive to 
conduct. Also, the volume of data generated from interviews are more difficult and 
time-consuming to analyse or generalise (Moore, 2000; Potter & Hepburn, 2005). 
The quality of the interview depends heavily on the skills and how the personal 
biases of the interviewer are addressed.  
 
In this study, the priority was adopting approaches that best answer the research 
aims and objectives, considering that collecting diverse types of data is key to better 
understanding a research problem (Plano Clark & Creswell, 2011). The exploratory 
nature of the semi-structured interviews provided additional depth to the issue of 
concurrent prescription and HMP use, and explained further the quantitative data 
collected from the survey providing detailed exploration of the problem (Creswell & 
Clark, 2011).  
a. Participant- Researcher Relationships  
Previous works have recognised the complex dynamics between researcher and the 
interviewee. According to Robertson (2011), the communication is different from that 
of a health interview survey and therefore a change in perspective is important.  
While some authors perceived the power dynamics as fluid (Tang, 2002), dialogic 
(Russell, 2000) or egalitarian (Beale, Cole, Hillege, McMaster, & Nagy, 2004), other 
authors have questioned the asymmetries of power in interviews and considered the 
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interviewer as having control over what is said, how it is said and disseminated 
(Briggs, 2003; Kvale, 2006; Scheurich, 1995). However, as Reed (2000) pointed out, 
the hierarchy between participants and the researcher during interviews is fluid; 
moving from the researcher being dominant at particular times and respondents 
being dominant at others. For example, there were times during the interviews where 
I was perceived to be a ‘Doctor’, while at other times I was the ‘researcher’ or the 
‘herbal medicine expert’ and asked for advice on herbal medicines. At other points it 
was the older person who was the expert controlling what information they would or 
would not disclose. This reinforces “the contextual location of knowledge and the 
production of knowledge through dialogue which makes room for a plurality of voice 
(Reed, 2000). 
 
As argued by feminist scholars, possessing similar characteristics such as race, 
ethnicity, gender and socio economic status with participants may potentially benefit 
research relationships (Tang, 2002) but impacts on the power relationships (Bhopal, 
2001; Finch, 1984; Hesse-Biber, 2007; Oakley, 1998). This can result in difficulties 
with gaining access, establishing trust and rapport, and developing non-hierarchical 
relationships (Riessman, 1987; Zubair, Martin, & Victor, 2012). Therefore, 
understanding that these multiple factors shape the quality and content of the 
information generated, is important to interpreting the research (Manderson, Bennett, 
& Andajani-Sutjahjo, 2006).  
 
The two sites for this study were Practice A (NZ), a large agricultural village, 
predominantly White and middle class, but representing a range of socioeconomic 
status. Practice B (SG) is urban, deprived and multicultural inner- city area. 
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Participants on both sites were retired older adults receiving pensions, some living 
on council estates, retirement schemes or in large semi-rural properties. In contrast, I 
am Black, middle class, educated, middle aged, Muslim and hijab (Muslim head 
cover) wearing woman. Although I was dressed casually for the interviews, my style 
of dress and outlook was very different from many of the participants. This may have 
affected the way I was viewed by participants and subsequently the flow of the 
interviews. 
 
It is probable that the interactions, rapport and disclosure between me and 
interviewees were determined predominantly by gender and ethnicity (McNay, 2003) 
rather than differences in age. This is because the interviews with female 
participants were longer, richer and more revealing, compared to those with the men. 
However, the notion that women’s account of experiences, illnesses, and social 
worlds are expansive than those of men (Finch, 1984; Finlay, 2002), might explain 
this. Although this does not suggest that men place no emphasis on health or 
interaction with others.  
 
It is not possible to know if different information would have come from the interviews 
if a white researcher was conducting them. Although the PPI input and the pilot 
interviews did not suggest this was a significant issue. Either way, this does not 
render such accounts invalid, but emphasises the complexity and the significance of 
social interactions in collecting and interpreting research data (Manderson et al., 
2006). 
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b. Validity and Reliability  
A common criticism of qualitative research relates to the issues of validity and 
reliability. While credibility in quantitative research depends on construction of the 
instrument in qualitative research, “the researcher is the instrument” (Patton, 1990). 
Therefore, the credibility of a qualitative research depends on the ability and effort of 
the researcher to ensure credible and trustworthy findings by minimising biases.   
There are varied opinions regarding the suitability of extending rigour, validity and 
reliability as employed in quantitative research to qualitative research (Koch, 2006; 
Morse, Barrett, Mayan, Olson, & Spiers, 2002; Sandelowski, 1986). Considering that 
qualitative research methods does not lend itself to statistical or empirical 
calculations of validity, different ways to enhance the truthfulness or validity of 
qualitative findings must be employed (Golafshani, 2003). Terms such as credibility, 
trustworthiness, truth, value, applicability, consistency and confirmability are often 
used when referring to criteria for evaluating the merit of qualitative research 
(Golafshani, 2003). Although some authors believe that irrespective of the research 
tradition, validity and reliability have the same meaning, therefore nothing is gained 
by changing labels (Long & Johnson, 2000). 
 
i. Credibility and trustworthiness: Bias in qualitative research may occur in many 
ways. Firstly, the researcher’s personal beliefs, pre-existing views on the topic, 
professional or cultural views can influence data collection, analysis and 
interpretation of findings either intentionally or otherwise (Brink, 1993; Patton, 1990). 
My personal biography as a Black, Muslim, middle class woman, inevitably shapes 
my perception and outlook of issues. Also, the influence of my African background 
and culture, where herbal medicines are commonly used to treat diseases, maintain 
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health and well-being cannot be overstressed. In addition, my training and 
experience in patient safety is also to be considered.  All these are likely to influence 
my views and subsequently my interpretation of the findings. However, a first step 
towards reducing the risk of bias is an awareness of the possible ways that bias may 
be introduced throughout the research process (Brink, 1993). I have maintained 
reflexivity and thorough analyses of findings throughout the research process, some 
of which are outlined in a reflection on the strength and limitations of chosen 
methodology and methods in section 7.6 and 7.7. The research methods and data 
analyses were also regularly shared with and checked by my supervisors, to discuss 
and compare interpretations. 
 
Another source of bias relates to participants behaving differently, portraying 
themselves in the best possible way to the researcher, withholding or distorting 
information (Goffman, 2006). To minimise this bias, a friendly and open rapport was 
developed with participants, through non-judgement of their narratives and 
interrupting them as little as possible. Also, the responses provided in questionnaires 
were verified during interviews and any discrepancies were noted.  
 
Other forms of biases which threatens the credibility and trustworthiness of research 
are procedural, sampling and systemic bias (Coggon, Barker, & Rose, 2009). Asking 
leading questions or closed questions restrict participant’s response, discouraging 
open accounts of their views and experiences. To minimise procedural bias, an 
interview guide was developed and used to shape the interviews, and efforts were 
made to use open-ended questions and allow participants tell their ‘story’. 
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Sampling and systematic biases were minimised through purposive sampling, and a 
consistent approach to coding interviews. Also, all methods and findings have been 
reported transparently throughout this thesis. 
 
ii. Dependability: In quantitative research, reliability and validity depends on the 
potential for subsequent research to reconstruct data collection and analysis to yield 
the same result. This is a problem for qualitative research; therefore, the alternative 
employed is dependability. Dependability is similar to accountability, and it is judged 
by clear explanation and presentation of the methods; with precise and thorough 
description of data analysis and strategies, to enable fellow researchers form valid 
judgement (Brink, 1993; Lincoln & Guba, 1985; Sandelowski, 1986). 
   
The protocol for this study demonstrates a clear trend of the study and the 
rationales, with initial assumptions declared right from the onset (Lincoln & Guba, 
1985). The systematic literature review (Chapter 4) highlighted existing gaps in the 
literature, from which decisions on the research questions, study objectives and 
research design were made. Also, dependability was strengthened by reporting the 
challenges encountered during the study and the decisions taken to overcome them. 
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iii. Transferability: this refers to the extent that the study findings can be transferred 
to another setting or group (Polit & Beck, 2004). Although no study is universally 
transferable, irrespective of the methods used. In qualitative research, transferability 
is synonymous with external validity or generalisability in quantitative research. This 
also relates to providing the reader with evidence that findings are applicable to other 
contexts. 
 
To facilitate transferability, it was valuable to give a clear and distinct description of 
culture and context, selection and characteristics of participants, data collection and 
process of analysis (Graneheim & Lundman, 2004; Lincoln & Guba, 1985), all of 
which have been provided in this chapter. Where appropriate, the findings have been 
presented together with verbatim quotations from participants in Chapter 6 (semi-
structured interviews). This information will enable others to determine the extent of 
transferability of the findings to another context (Fain, 2017). 
 
c. Objectives 
Semi-structured interviews were conducted to: 
a. Further explain and interpret results obtained in the quantitative phase, using 
selected participants who can best provide these details. 
b. Gain a better understanding of why older adults combine HMPs with 
prescription medications, their views and experiences. 
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d. Pilot Study (November 2015) 
The survey data informed how participants were identified for the semi-structured 
interviews as it ensured that those recruited were willing to participate and were 
taking HMPs concurrently with prescribed medications typical of this population. The 
main objective of the interviews was to provide a better understanding of why older 
adults combine HMPs with prescription medications. The findings from the 
systematic review and the survey informed areas that were explored in these 
qualitative interviews. For example, people use HMPs for different reasons and at 
different times, and this relates to how they believe they work, the length of time that 
they have used HMPs and whether they think the prescribed medication is 
complementary to the HMPs or vice versa. A focus of the interviews was to 
understand if participants are aware of possible interactions from combining HMPs 
with prescription medicines, and if they discussed using HMPs with healthcare 
professionals. 
 
An interview guide with prompts (Appendix F) was developed to focus the 
conversation, but at the same time allow the flexibility to probe emerging issues and 
lines of thought identified from the survey and from earlier interviews (Corbetta, 
2003). The content of the interview guide was informed directly from the survey and 
covered themes relating to concurrent use, attitude to HMPs, awareness of potential 
herb-drug interactions and disclosure to health practitioners. It asked participants 
about the different types of HMPs they used, their reasons and experience of 
combining them with prescription drugs.   
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The guide was tested on one older participant in a pilot interview in order to check if 
the questions were clear and likely to elicit responses specific to the concurrent use 
of HMPs and prescribed medications. It was also a practise exercise to develop my 
interviewing skills and gain some confidence.  
 
The pilot interview lasted for 32 minutes. The questions were understood, and I was 
able to gather the information required. However, I interrupted the participant many 
times, sometimes completing the participant’s sentences. The pilot helped me to 
address this and to consider structuring the interview so as to allow the older person 
to talk, but to also include points of clarification as part of the interview process.  
 
i. Sampling 
Sampling was purposeful so as to include ‘information-rich cases’ to be studied in- 
depth (Patton, 1990). Initially, a total of 32 interviews were planned for this phase 
(i.e. at least two participants from the five age groups, single users and multiple 
users) in order to capture age and gender differences, ethnicity, as well as multiple 
uses (Table 3.3). However, only 20 of the 49 respondents who reported using HMPs 
in the survey wanted to be interviewed and provided contact details on the 
questionnaire.   
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Table 3.3: Selection of participants for semi-structured interviews 
 
Group Sub-groups Age group (years) and number of 
participants 
65-74 75 - 84 85 - 94 ≥95 
Gender Male 2 2 2 2 
Female 2 2 2 2 
Number of 
HMPs 
Using 1HMP 2 2 2 2 
Using more than 
1 HMP 
2 2 2 2 
Total  8 8 8 8 
 
 
 
ii. Recruitment  
Participant information sheets (Appendix D) and consent forms (Appendix G) were 
posted to the 20 participants. Participants were contacted a few days later to arrange 
interview date and venue over the phone. Interviews were only confirmed, if 
participant understood the PIS and were still happy to proceed with interview.  
 
iii. Data Collection  
All participants were over 65 years old and had a range of physical and mental 
capabilities. When preparing for the interviews, care was taken to ensure there was 
sufficient time to introduce the study and for discussion afterwards (Wenger, 2002). 
Before each interview, the choice to participate or not and to stop interview at any 
time without providing any reason for doing so was explained to participants. Their 
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consent was also sought to inform them and their GP, if potentially dangerous herb-
drug interaction was suspected from the information they have provided. 
 
Twelve interviews were held with thirteen participants (one interview with a couple) 
between April and August 2016. The focus of the interviews were participant’s’ 
reasons, views and experiences of concurrently using HMPs with prescribed 
medications. Participants were given the opportunity to have the interview in their 
homes, as it was important to have the conversations in a setting most relaxing for 
participant. 
 
3.8 Data Analyses 
Analysis involves the persistent interrogation of data in a critical, reflexive and 
iterative fashion that cycles between data and overarching frameworks (O'Leary, 
2017). For mixed methods research, this includes data preparation, exploration, 
analysis, representation and validation (Creswell & Clark, 2011). Since a sequential 
explanatory design was used in this study, data was collected, analysed sequentially 
and integrated in the final stage (Creswell & Clark, 2011). See Figure 3.3 
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Figure 3.3 Sequential explanatory data analysis  
 
3.8.1 Quantitative Data Analysis  
Quantitative data analysis was done during and immediately after the survey. Data 
were recorded and analysed using SPSS version 23.0. Anonymised data were 
double-checked and discrepancies corrected. Descriptive statistics were calculated 
to summarise the sample. Names and number of HMPs and prescription drugs 
reported by participants were entered on a spreadsheet and the 10 most commonly 
reported prescription and HMPs identified.   
 
Statistical significance was measured at p ≤0.05 level. Statistical significance is a 
measure that assesses actual probability that the results are more than coincidental 
Stage 1 
QUAN data 
analysis 
Stage 2 
Identify QUAN results 
 to use  
Stage 3 
Apply selected QUAN 
results to QUAL phase 
QUAN data 
analysis  
Options 
a. prevalence 
b. demographics of 
concurrent users/non-
concurrent users 
c. most reported 
prescription drugs 
d. most reported HMPs 
e. non-herbal DS 
f. potential interactions 
a. select cases 
b. explain results 
c. compare concurrent 
users with non-
concurrent users 
d. explore reasons for 
concurrent use 
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(O'Leary, 2017). However, statistical significance does not necessarily mean that the 
results have clinical or social significance. The observations recorded were number 
and names of prescription medications, HMPs and DS per participants.  
 
a. Descriptive data 
Prevalence was calculated as the number of those reporting concurrent HMPs and 
prescription medications intake over the total number of study subjects. Proportions 
were calculated to describe the frequency of use in prescription drug classes and 
HMP categories. Data were summarised as mean ± standard deviation (S.D.) for 
continuous variables (e.g. age, number of herbal medicines used), and as frequency 
and percentages for categorical variables (e.g. sex of respondents, educational 
qualification, living arrangements and ethnicity). 
 
b. Demographic Analyses  
Using the chi-square test for independence, comparisons were undertaken to see 
whether concurrent use was affected by demographic factors such as gender, 
ethnicity, educational qualifications and living arrangements.  
 
To conduct analysis for educational level and see if educational level was associated 
with concurrent use of HMPs, it was necessary to split data into two i.e. those with 
further education and with no further education. The further education group 
consisted of participants with some education or training after secondary school. 
While those without further education were those with no education or training 
beyond secondary school.  
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Considering that only 21 responses were received from non-white participants, 
compared to 126 responses from white participants, it was not possible to test for 
differences between individual ethnic groups. There were three responses from 
participants of multiple or mixed background (i.e. white and black Caribbean, white 
and black African and other multiple ethnic background), 15 from Black or Black 
British, two from other ethnic groups and only one of Asian or British Asian 
background.  
 
On account of the small sizes in each of the ethnic groups, Fisher’s exact test of 
independence was more appropriate to determine whether the proportion of one 
variable was different depending on the value of another variable. Statistical advice 
and support were provided by my second supervisor Dr Neil Spencer, a statistician 
and head of the Statistical Services & Consultancy Unit, University of Hertfordshire.  
 
 
3.8.2 Assessing potential interactions between prescription  
 drugs, herbal medicinal products and dietary supplements 
 
Participants were categorised as concurrent user if they reported current use or have 
used HMPs or DS in the last 12 months. Potential interactions between prescription 
drugs, HMPs and DS were assessed only among concurrent users. All medicines 
reported by participants were listed in a spreadsheet. Combinations of HMPs, DS 
and prescription medicines were assessed using an online interaction database, 
Stockley’s Herbal Medicines Interactions (available on Medicines Complete at 
https://www.medicinescomplete.com/mc/shmi/current/). Stockley’s Herbal Medicines 
Interactions is a comprehensive evidence database and the digital version of the 
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textbook (Williamson et al., 2013). Information regarding potential interactions 
between herbal medicines (including nutritional supplements and some food) and 
conventional medicines are expertly assessed with practical advice provided. This 
database was selected because it is comprehensive, rigorous and a critical 
evaluation of available evidence provided in easy-to- read format and regularly 
updated. 
 
The Stockley’s database rates herbal medicine interactions using three different 
categories i.e. action, severity and evidence.  
a. Action 
This describes whether an action needs to be taken to address the interaction or not. 
And this could be one of the following five actions: 
 No action: for drug pairs where no interaction occurs, therefore no action is 
required. 
 Informative: for drug pairs where probability of interaction is low, and close 
follow up or monitoring is not required but more information is given in case 
there is a problem. 
 Monitor: for interactions where biochemical or therapeutic drug monitoring is 
recommended since further action may be required based on the outcome. 
 Adjust: for drug pairs where the interaction can be accommodated but 
recommended that either one of the drugs is changed, or the dose altered. 
 Avoid: for contraindicated drug pairs, where the drug combination is best 
avoided. 
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b. Severity: This describes the severity of the interaction and the likely effect on 
 a patient if interaction is unmanaged.  Severity ranges from ‘severe’ to 
 ‘nothing expected’.   
c. Evidence: This describes the weight of available evidence (both clinical and 
 experimental) regarding the interaction. Much of the available data on 
 interactions with herbal medicines comes from animal and in vitro studies. 
 Even though these data do not always extrapolate to clinical situations, it 
 provides some idea of the likelihood and potential severity of interactions. This 
 category ranges from ‘extensive’ to ‘theoretical weak’.  
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Based on these three categories (i.e. action, severity and available evidence), one of 
five symbols are used to describe the combination. And this ranges from ‘life 
threatening outcome’, ‘significant hazard’, ‘potentially hazardous outcome’, ‘doubt 
about outcome of use’ and ‘no interaction’. The combinations are represented by the 
following symbols:  
 
  
 
    
 
   
 
 
    
 
 
    
 
 
 
 
 
 
Doubt about outcome of use: where there is doubt 
about outcome of concurrent use, but necessary to 
give patients advice/guidance about possible side 
effects and/or consider monitoring.  
Potentially hazardous outcomes: interactions may 
have potential hazardous outcome, but data is poor or 
sparse. Therefore, it is difficult to draw conclusions 
regarding interaction.   
Life- threatening outcome: interaction is life 
threatening, concurrent use is best avoided. 
Significant hazard: concurrent use may result in 
significant hazard, dosage adjustment or close 
monitoring required. 
No interaction: no interaction occurs, or interactions 
are of no clinical significance.  
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In the Stockley’s database: 
 For each concurrent user, all the medications reported were entered in the 
search box as word or words separated by spaces, in "double quotes". 
 Predictive text provided suggestions of drug names or herbal medicines, 
therefore helping with misspelt entries. 
 Terms recognised as drug names or drug groups are checked by the 
database for specific interactions between any of the two terms entered. 
 The default search is ‘interactions’ tab. When no result is displayed (i.e. no 
available information on interactions between the drugs entered), the ‘Full 
Text’ tab provides general information on the herbal medicine. 
 One name is consistently used for each herbal medicine throughout the 
monograph, and across the database. However, a synonyms field is available 
to aid users who know the plant by different names to match the correct one. 
 
Participants were categorised as having a potential for interaction if using an HMP or 
DS in combination with prescription drug for which there is documentation of an 
interaction in Stockley’s Herbal Medicines Interactions. All recorded potential 
interactions were independently validated by a second reviewer (a colleague and 
qualified pharmacist) also using the Stockley’s database. Any disagreements were 
resolved through discussions with the second reviewer. 
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3.8.3  Qualitative Data Analysis  
a. Transcription and data management 
All thirteen interviews were audio recorded and transcribed verbatim, three by me 
and the remaining ten by a professional transcriber. All personal details were 
removed from the transcript in line with the rules of anonymity and confidentiality.  All 
transcripts were saved on a secured NHS computer, with password protection only 
accessible to me.  
 
Anonymised transcripts were imported into the computer-based programme Nvivo11 
(QSR International) to organise the data and support analysis. Transcripts were read 
repeatedly to get immersed in the data, read line by line, and then word by word to 
derive codes. The process of re-reading, familiarisation and categorisation was to 
map the scope of the content and the range of responses. This was a descriptive 
process, a systematic sorting of the data. 
 
The process of identifying and coding statements was to develop categories that 
were as close as possible to the individual participant accounts. The analysis 
followed the way that the interviews had been structured i.e. questions that 
addressed the gaps from the systematic review and the survey. Narratives to the 
questions were analysed one after the other.   
 
b. Framework analysis 
The primary method used for analysing qualitative data in this study was framework 
analysis, drawing on the approach by Ritchie and Spencer (2002). Framework 
analysis belongs to the broad family of thematic or content analytic methods, 
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characterised by identifying differences and similarities within data, seeking 
relationships and then drawing conclusions on the themes or patterns (Braun & 
Clarke, 2006; Gale, Heath, Cameron, Rashid, & Redwood, 2013). 
 
The choice of framework analysis lies in its clarity and flexibility (Srivastava & 
Thomson, 2009). The method is open to change, addition and amendment 
throughout the analytic process. Analysis can be done during data collection or after 
all data has been collected. Following the clear steps to analysis generates highly 
structured outputs of summarised data (Gale et al., 2013). Although analysis is 
based on and largely driven by  original accounts from participants (Ritchie & 
Spencer, 2002), thus making it quite similar to grounded theory. However, it differs in 
the sense that, it is better suited to research that has specific questions, a pre-
designed sample and a priori issues that need to be dealt with. In this case, older 
adults’ reasons and experiences of concurrently using HMPs with prescription drugs. 
Framework analysis involves systematic processes of sifting, charting and sorting 
transcript material according to key issues and themes. It allows analysis of cases 
(i.e. individual interviews) within the whole content, thus conferring accuracy and 
intricacies to the interpretation (Ritchie & Spencer, 2002). Theories may be 
generated through framework analysis, but the main task is to describe and interpret 
what is happening in a setting (Ritchie & Spencer, 2002). 
 
Framework analysis involves a five-step process; familiarisation, identifying a 
thematic framework, indexing, charting and finally mapping and interpretation 
(Ritchie & Spencer, 2002). Although more recently expanded to seven stages (Gale 
et al., 2013), the main steps are still covered in the five steps by the pioneers.  
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i. Familiarisation 
The process of familiarisation is already explained (Ritchie & Spencer, 2002; 
Srivastava & Thomson, 2009). All the 13 transcripts and the field notes written during 
the interviews were read repeatedly to get familiar with details of each transcript and 
understand the context in which things were said. Reading a few times allowed for a 
full picture and for connections to be made between different aspects of participants’ 
accounts. To organise the data, each interview was entered in NVivo Pro Version 11 
(QSR International, UK) and initially treated as a unit of analysis.  
 
ii. Developing the analytic framework  
This was done by identifying recurrent and important themes based around key 
areas of interest in the interview (Appendix H). Labels (or nodes as called in NVivo) 
were generated for codes inductively from the data using words and phrases that 
captured key thoughts and/or concepts. Highlighting and coding was undertaken in 
each transcript with attention to identifying the reasons, views and experiences of 
concurrent use. As a summary for each of the individual codes, analytic memos were 
written to capture what comes to mind about the data and early interpretations (Gale 
et al., 2013). For example, what were HMPs used for and why, the values and 
beliefs about HMPs, experiences and benefits of using HMPs, knowledge or 
experiences of herb-drug interactions. This was piloted on 2 transcripts and what 
was clear from the data was that participants were exhibiting or adopting different 
behaviours to concurrently use HMPs and DS with prescription drug but not 
abandoning their prescription drugs. Initially, it was not clear where to code data 
regarding how participants did not ditch their prescriptions but continue to use them 
with HMPs and DS. So, this draft framework was refined to fit with emerging data. 
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Highlighted sections of the transcripts were split into smaller segments or themes, 
thus establishing the first set of themes from the data (Alhojailan, 2012). Quotes from 
relevant transcripts were used to illustrate the memos and participants different from 
the themes emerging from the majority were noted. Using this approach allowed for 
similarities and differences between the different narratives to be identified. It also 
showed any links and connections between the categories (Leech & Onwuegbuzie, 
2011). For example, participants’ reasons for concurrently using HMPs with 
prescription drugs were often prompted by a specific focus on dissatisfaction with the 
healthcare system or alleviating pains and avoiding the side effects associated with 
conventional medicines.  
 
There were regular discussions on codes and initial thoughts on the analysis with my 
principal supervisor. This process helped to enhance rigour and reliability in the 
coding (Bryman, 2012; Gale et al., 2013; Miles, Huberman, & Saldana, 1984).  The 
codes were grouped into categories and the study questions were reviewed to 
identify information that relates to similar concepts. All data that related to each 
interview question were organised together and presented in that order. The key 
issues, concepts and themes formed the basis of the analytic framework (Table 6.2). 
 
iii. Indexing  
The 59 codes were then organised into framework categories. This framework was 
then systematically applied to individual transcript. This process of charting and 
indexing was done in NVIVO by working through individual transcript, highlighting a 
chunk of text, deciding which category or categories (or node as it is known in 
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(NIVIVO) from the framework to assign it to and dropping it into the relevant 
category. 
 
iv. Charting or summarising data in the analytical framework 
At this stage, the data was summarised and organised into manageable format to 
facilitate analysis in the next stage. Using the auto summarise function in NIVO 
made this relatively easy, as it automatically populates relevant cells in the 
framework with indexed data for each category. With the data presented in this 
format, it was possible to do within-cases and between-cases analyses, by reading 
across for the former and downwards for the latter. I worked through each framework 
category and summarised all the data indexed to that category for each participant.   
 
v. Mapping and interpretation  
By mapping and summarising the data as described above, I was able to identify 
cross cutting links and patterns of responses. I was also able to develop concepts 
and themes around the concurrent use of HMPs, DS with prescription drugs which 
could be seen to resonate with some of the existing wider literature on self – 
management.  For example, a dominant cross cutting theme identified from the 
interviews was maintaining health. Within that are concerns with managing pain and 
not wanting to bother their GPs, not getting appointments or enough time with the 
GP to explain their conditions. This was also linked to a perception that these issues 
were minor complains and the importance of being left to ‘deal with it’ themselves.  
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c. Analytic Framework 
A descriptive and interpretative analytic approach as described by (Elliott & Timulak, 
2005) was undertaken with each transcript. A set of 59 preliminary codes (or nodes 
as  they are known in NVivo) were developed from the data, informed by the 
interview prompts (Appendix F) and emergent issues relating to participant’s beliefs 
and values, cultural or family history of using herbal medicines, sources of 
information, experiences of using HMPs and the benefits derived. Subsequently, 
numerous codes were grouped together to form categories. This was an iterative 
process where making sense of the data was facilitated by previous understanding 
of the herbal medicine use literature. For example, codes for specific ailments such 
as joints related pain and where participants described HMP use as being for minor 
health related problems were grouped together as a category - used for less serious 
conditions. Codes were frequently compared to each other until all interview data 
were mapped and captured. The interpretation of the categories and the 
development of themes were derived from the identification of recurring issues and 
explanations in the data of how HMPs and DS were used, and these were further 
discussed with the supervisory team. 
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3.9 Data Integration  
This study began with an emphasis on patient safety and an assumption that there 
were right and wrong uses of HMPs. The survey and interviews not only addressed 
this, but they also provided the opportunity for alternative explanations and insights 
as to how medication is used and understood. The key assumption was that people 
take their prescribed medications and that there is a risk if they are taking HMPs 
concurrently. It is also possible that they are not taking the prescribed medications at 
all, which raises a different set of questions for non-adherence. 
 
The data generated in phases 1, 2 and 3 were analysed and interpreted separately 
to address the research questions but combined at the point of interpretation (Moran-
Ellis et al., 2006). Data synthesis in this study was a logical accumulation and 
corroboration of findings from the different phases, therefore more of an aggregation 
than integration. The data was merged in a side-by- side process as outlined by 
Creswell and Plano Clark (Creswell & Clark, 2011) and compared to the self- 
management theory. This side-by-side comparison allows for the presentation of 
results that can be drawn upon to describe the study findings. A further synthesis of 
data was conducted to generate a smaller number of overarching themes 
representing key reasons why older adults concurrently use HMPs and prescription 
medicines. 
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3.10 Chapter summary 
This chapter has justified the methods applied to this study which explores the 
concurrent use of prescription drugs and HMPs among older adults. Evidence shows 
no recent UK study exists on the topic and there is limited research exploring the 
reasons for concurrent use and the experiences of concurrent users. To meet the 
aims of this research, a mixed method sequential explanatory design was 
considered most suitable to answer the research questions. Self-completed 
questionnaire survey was employed to gather information on concurrent use among 
UK community dwelling older adults. Using a purely quantitative approach would not 
provide adequate understanding of the reasons why older adults combine their 
prescriptions medicines with HMPs or their experience of doing so. Therefore, semi-
structured interviews were used to explore reasons, views and experiences of older 
adults concurrently using prescriptions with herbal medicines. Results from the 
survey identified participants for the in-depth interviews and informed areas to further 
explore. 
 
The Chapter also provided details of the systematic review, the cross-sectional study 
design and the semi-structured interviews. This included information on ethical 
issues, setting, access and data collection, questionnaire design, sample size and 
statistical analysis. Details of the thematic analysis processes have been provided 
including how themes were developed from the initial stages using the computer 
software package NVivo. The next chapter presents the findings from Phase 1 of the 
study i.e. a systematic literature review to critically assess available evidence on the 
concurrent use of prescriptions drugs and HMPs among older adults. 
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Chapter 4: Concurrent use of 
Prescription Drugs and Herbal 
Medicinal Products in Older Adults: A 
Systematic Review 
 
A paper based on the work presented in this chapter has been published as: 
Agbabiaka, T. B., Wider, B., Watson, L. K., & Goodman, C. (2017). Concurrent use 
of prescription drugs and herbal medicinal products in older adults: a systematic 
review. Drugs & Aging, 34(12), 891-905. 
4.1 Introduction to Chapter  
This chapter will present the findings from a systematic review which evaluated the 
prevalence, patterns, potential interactions and factors associated with the 
concurrent use of prescription drugs and HMPs among older adults. The Chapter 
provides the methods for the review including criteria for literature searches, 
selection of studies, data extraction and synthesis. The findings were summarised as 
a narrative account addressing each of the review questions. A detailed discussion 
of the limitations of included studies and implications of the findings were also 
provided. 
4.2 Background 
The world population is ageing and according to the World Health Organisation 
(WHO), the population of people aged ≥60 years will double and around 400 million 
people will be ≥80 years by 2050  (World Health Organisation, 2012). By 2040, 
nearly one in four people (24.2%) in the UK will be aged 65 years or older (Office for 
National Statistics, 2015). Pharmacotherapy is facilitating an ageing population 
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(Cherubini, Corsonello, & Lattanzio, 2012) and older people rely on complex 
polypharmacy in managing chronic health conditions (Nyborg et al., 2012).  
 
Older adults are the biggest consumers of prescriptions and over-the-counter (OTC) 
medicines (National Council on Patient Information and Education, 2010; Qato et al., 
2008; Qato et al., 2016). Self- medication (Jerez-Roig et al., 2014; Vacas Rodilla et 
al., 2009), consumption of non-prescription medicines, particularly herbal and other 
DS is also widespread among older adults (Bruno & Ellis, 2005; de Souza Silva et 
al., 2014; Gonzalez-Stuart, 2011; Izzo & Ernst, 2001; Izzo & Ernst, 2009; Marinac et 
al., 2007; Raji, Kuo, Al Snih, Sharaf, & Loera, 2005).  
 
In 2014, prescriptions dispensed for those aged over 60 years in the UK accounted 
for about 51% of the total net cost for all prescriptions (Health and Social Care 
Information Centre, 2015). Also, up to a quarter of UK adults use HMPs (Lynch & 
Berry, 2007; MHRA & Ipsos MORI, 2009; Qato et al., 2016), mostly bought over the 
counter, by self-prescription and generally not disclosed to healthcare practitioners 
(Lynch & Berry, 2007; MHRA & Ipsos MORI, 2009; Qato et al., 2016). Adverse drug 
reactions (ADRs) could occur due to interactions between conventional drugs and 
HMPs, some of which may have serious consequences (Fugh-Berman, 2000; Izzo & 
Ernst, 2001; Williamson, 2001; Williamson et al., 2013). For example, St. John's wort 
(Hypericum perforatum) taken with serotonin-reuptake inhibitors increases the risk of 
serotonin syndrome in older adults (Fugh-Berman, 2000).  
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Currently, there are many studies on the use of herbal medicines and DS by older 
people (Bruno & Ellis, 2005; de Souza Silva et al., 2014; Gonzalez-Stuart, 2011; Izzo 
& Ernst, 2001; Izzo & Ernst, 2009; Marinac et al., 2007; Raji et al., 2005). However, 
less is known about the potentially more troubling practice of concurrently using 
herbal medicines with prescription drugs.  
 
The aim of this systematic review was therefore to evaluate the literature on 
concurrent use of prescription drugs and HMPs among older adults to identify the 
prevalence, patterns, potential interactions and other factors associated. The 
systematic review was registered on PROSPERO (registration number: 
CRD42014009091) (Agbabiaka, Wider, Goodman, & Watson, 2014).  
 
4.3   Review questions 
The review will seek to answer the following questions: 
a. What is the prevalence and pattern of concurrent use of prescription drugs 
and herbal medicinal products (HMPs) among older adults? 
b. What patient and clinical characteristics are associated with the concurrent 
use of prescription drugs and HMPs? 
c. What are the range of prescription drugs and HMPs most concurrently used 
by older adults? 
d. What safety issues and other factors are associated with concurrent 
prescription drug and HMPs use in older adults? 
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The review was conducted according to the principles of systematic review (The 
Cochrane Collaboration, 2011) and reported following the Preferred Reporting Items 
for Systematic Reviews and Meta-Analyses (PRISMA) guidelines (Shamseer et al., 
2015).  The methods are fully described in this chapter  and in a previously published 
review protocol (Agbabiaka, Wider, Watson, & Goodman, 2016). 
 
4.4 Eligibility criteria 
a. Types of studies 
All cross-sectional studies, case reports and case series reporting prevalence, 
patterns and interactions from concurrent HMPs or herbal DS used with prescription 
medicines were considered. PhD theses, editorials, commentaries, in-vitro 
experiments and animal studies were excluded.  
b. Types of participants 
The WHO defined ‘elderly’ as individuals over the age of 65 years in developed 
countries, and over 60 years in developing countries. For the purpose of this review, 
the minimum age of 65 years was adopted since most studies identified from 
literature searches were conducted in developed countries. Therefore, studies with 
participants aged 65 years or older, studies with mean participant age ≥65years or 
studies from which data for participants aged ≥65 years could be extracted were 
included in this review. 
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c. Types of interventions 
The review included studies where any type of HMPs was used concurrently with 
prescribed medicines. Herbal medicinal products are medicinal products where the 
active ingredients consists exclusively of herbal substances or herbal preparations 
(Commission of the European Communities, 2003). Excluded were studies 
assessing herbal medicine as part of a therapeutic system or system of medicine 
such as traditional Chinese medicine, Ayurveda, Kampo, Siddha, Unani. 
Homeopathic herbal remedies were also excluded. Studies assessing concurrent 
use of vitamins, minerals and non-herbal DS or combination products containing 
herbal and non-herbal substances with prescription medicines were also excluded 
from the review. 
d. Primary and secondary outcomes  
The primary outcomes of interest include prevalence and pattern of concurrent use, 
names and number of concurrently used medicines, adverse reactions or potential 
herb-drug interactions reported.  
Secondary outcomes of interests were disclosure of HMPs use to healthcare 
professionals, satisfaction with HMPs and cost of HMPs, where reported. 
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4.4.1 Identification and selection of relevant studies 
a. Databases 
The following databases were searched from inception until November 2015: 
Cumulative Index to Nursing and Allied Health Literature (CINAHL) via EBSCO, 
Cochrane Library, Excerpta Medica database (EMBASE) via OVID, MEDLINE via 
OVID, the Allied and Complementary Medicine Database (AMED) via EBSCO, 
PsycINFO via OVID and Web of Science.  
 
The search was updated in May 2017 to include new relevant studies before the 
review was submitted for publication. To keep up to date with the evidence on this 
topic, a third search was conducted in February 2019.  
 
b. Search terms 
Medical subject headings (MeSH) and text words related to ‘herbal medicine’, 
‘prescription drugs’ and ‘aged’. The scientific names, common names of herbs most 
documented for concurrent use were applied to ensure a broad search strategy. See 
Appendix E for full search strategy.  
 
No restrictions were placed on language of publication. Reference lists of all 
identified studies were checked for relevant studies not identified by the electronic 
searches. Lateral searches were also conducted using the related citation function in 
PubMed and cited by function in Google scholar to capture all relevant articles.  
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c. Study selection  
All references retrieved from all the databases were downloaded into Endnote files 
and merged. Duplicate studies were recorded before discarding. Two reviewers, I 
(TA) and a colleague (BW) individually scanned all titles and abstracts for potential 
relevance. Any article for which there was uncertainty about relevance was retained 
and the full text assessed. Using a pre-designed eligibility checklist, two reviewers 
(TA and BW) independently assessed full text articles against the eligibility criteria 
and recorded an eligibility code. Studies that did not meet inclusion criteria were 
excluded and the reasons recorded. Disagreements on eligibility were resolved 
through discussions between the two reviewers (TA and BW), the third reviewer and 
my principal supervisor (CG) was consulted if no consensus was reached. Full texts 
of all articles which met the eligibility criteria were obtained and downloaded into 
Endnote. 
d. Data extraction  
A data extraction form was designed for the review, piloted and amended to ensure 
that all the required information can be extracted. Data from individual studies were 
extracted by the first reviewer (TA) using this form and validated by the second 
reviewer (BW). Key information extracted included: 
 Publication details: Authors, year of publication, country in which study was 
conducted.  
 Study design: study type, recruitment and data collection method.  
 Participants: demographic and socio-economic characteristics, sampling and 
sample size, previous medical diagnosis etc. 
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 Primary outcomes: prevalence of concurrent use, name and number of HMPs 
and prescription drugs, pattern of use, number and types of adverse 
reactions or potential interactions. 
 Secondary outcomes: Disclosure, satisfaction or dissatisfaction and cost 
expended on HMPs.  
 Study limitations: response bias, selection bias, representativeness of sample 
etc. 
e. Quality assessment of included studies 
The Joanna Briggs Institute (JBI) checklists for appraising studies reporting 
prevalence data (Munn et al., 2015) and for case reports (The Joanna Briggs 
Institute, 2016) were used to screen selected studies prior to inclusion in the review. 
Two reviewers (TA & BW) independently assessed each of the included studies 
against the criteria on the JBI checklist to minimise bias and establish 
methodological validity. The JBI checklist for prevalence studies was the preferred 
assessment tool because it can be used across different study designs reporting 
prevalence. The checklist also addresses issues of internal and external validity 
critical to prevalence data. Disagreements between reviewers were resolved through 
discussion.   
f. Data synthesis 
The Evidence for Policy and Practice Information and Co-ordinating Centre (EPPI-
Centre) three stage approach to mixed method research to synthesise data 
(Kavanagh, 2011) was used. A first synthesis was done to address prevalence, 
pattern of use and patient characteristics associated with concurrent use of HMPs 
and prescription medicines. The second synthesis focused on the safety issues and 
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other factors associated with concurrent use i.e. disclosure, satisfaction and 
cost/resources. Finally, using thematic synthesis, key themes and commonalities 
were identified.  
 
4.5 Results 
The literature searches identified 20,837 titles and abstracts. Initial screening of titles 
and abstracts identified 2,199 potentially relevant articles. A total of 2,106 articles 
were excluded for not satisfying all inclusion criteria. Full texts of the remaining 93 
articles were obtained to assess for eligibility. At the end of the eligibility process, 71 
articles were excluded for the following reasons: type of intervention (e.g. non-herbal 
combinations, non-oral) = 9; age = 24; study type = 19; no concomitant use = 19. 
Twenty-two studies met the inclusion criteria and were included in this systematic 
review (Figure 4.1). 
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Figure 4.1: Flow chart of study selection process 
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4.5.1  Characteristics of included studies 
All but one of the studies included in the review were published in English language, 
one study published in Spanish (Batanero-Hernán, Guinea-López, García-Jiménez, 
& Rodríguez-Chamorro, 2017). Thirteen studies were conducted in the USA (Blalock 
et al., 2009; Kaufman et al., 2002; Lantz, Buchalter, & Giambanco, 1999; Loya et al., 
2009; Ly et al., 2002; Nahin et al., 2009; Parkman, 2001; Peng, Glassman, Trilli, 
Hayes-Hunter, & Good, 2004; Qato et al., 2008; Shane-McWhorter & Geil, 2002; 
Yoon & Horne, 2001; Yoon & Schaffer, 2006), two in Canada (Dergal et al., 2002; 
Singh & Levine, 2007). Two studies conducted in the UK (Canter & Ernst, 2004; Izzo 
& Ernst, 2009). Only one study each was conducted in Ireland (Peklar et al., 2014), 
Norway (Djuv, Nilsen, & Steinsbekk, 2013),Turkey (Turkmenoglu et al., 2016), Spain 
(Batanero-Hernán et al., 2017) and Jamaica (Delgoda et al., 2010).  
 
The majority of studies (n=16) were described as cross- sectional (Batanero-Hernán 
et al., 2017; Blalock et al., 2009; Canter & Ernst, 2004; Delgoda et al., 2010; Dergal 
et al., 2002; Djuv et al., 2013; Kaufman et al., 2002; Loya et al., 2009; Ly et al., 2002; 
Nahin et al., 2009; Peklar et al., 2014; Peng et al., 2004; Qato et al., 2008; Singh & 
Levine, 2007; Turkmenoglu et al., 2016; Yoon & Horne, 2001). Eight of them 
identified concurrent use of prescriptions with other medications using semi-
structured interviews (Batanero-Hernán et al., 2017; Delgoda et al., 2010; Kaufman 
et al., 2002; Loya et al., 2009; Singh & Levine, 2007; Turkmenoglu et al., 2016; Yoon 
& Horne, 2001); others interviewed older people, and then checked and recorded 
their medications (Dergal et al., 2002; Elmer et al., 2007; Kaufman et al., 2002; 
Nahin et al., 2009; Peklar et al., 2014; Qato et al., 2008). Self-completed 
questionnaires were adopted in five studies (Canter & Ernst, 2004; Djuv et al., 2013; 
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Ly et al., 2002; Nahin et al., 2009; Peng et al., 2004) with participants self-reporting 
all the medicines they were taking on the questionnaire. Three studies (Elmer et al., 
2007; Izzo & Ernst, 2009; Yoon & Schaffer, 2006) were secondary analyses of data 
from previous research and three were case reports (Lantz et al., 1999; Parkman, 
2001; Shane-McWhorter & Geil, 2002) of possible interactions between herbal, 
dietary supplements and prescription medicines.  
 
Only four studies have been published in the last five years (Batanero-Hernán et al., 
2017; Djuv et al., 2013; Peklar et al., 2014; Turkmenoglu et al., 2016). Seventeen 
studies were published between 2000 and 2010, and one case report in 1999 (Lantz 
et al., 1999). 
 
The twenty-two studies included in this review had a total of 18,399 participants aged 
65 years or over. The average age of participants ranged from 63 to 78 years; 
number of participants ranged from one (case report) to 5,052. Only in ten studies 
was the focus on those aged 65 years or older, the other studies were conducted 
among the general population aged ≥18 years, but data for participants aged ≥65 
could be extracted.  
 
Participants were predominantly females in 12 studies, varying between 51% 
(Kaufman et al., 2002) and 100% (Yoon, 2001; Yoon & Schaffer, 2006). Male 
participants were the majority in five studies (Izzo & Ernst, 2009; Ly et al., 2002; 
Nahin et al., 2009; Parkman, 2001; Peng et al., 2004). The number of males and 
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females in the different age categories were not specified in four studies (Blalock et 
al., 2009; Delgoda et al., 2010; Djuv et al., 2013; Singh & Levine, 2007). One study 
each was conducted among older adults in hospital (Turkmenoglu et al., 2016) and 
nursing homes (Batanero-Hernán et al., 2017). The remaining studies  were 
conducted among general populations (i.e. community-dwelling older adults) (Blalock 
et al., 2009; Canter & Ernst, 2004; Delgoda et al., 2010; Djuv et al., 2013; Izzo & 
Ernst, 2009; Kaufman et al., 2002; Lantz et al., 1999; Loya et al., 2009; Ly et al., 
2002; Peklar et al., 2014; Qato et al., 2008; Shane-McWhorter & Geil, 2002; Singh & 
Levine, 2007; Yoon, 2001; Yoon & Schaffer, 2006), outpatients of memory clinics 
(Dergal et al., 2002; Nahin et al., 2009), emergency department (Parkman, 2001) 
and veteran centre (Peng et al., 2004). 
 
By looking at the definition where provided and the herbal medications reported, it 
was ensured that only studies which evaluated HMPs were included. However, no 
consistent term exists for HMPs and different terms are used in different countries. 
For example in Canada, HMPs are referred to as natural health products (NHPs), i.e. 
“Substances or combination of substances consisting of molecules and elements 
found in nature and homeopathic preparations sold in dosage forms for the purpose 
of maintaining or improving health, and treating or preventing diseases/conditions’, 
and includes herbal medicines, vitamins and minerals” (Health Canada, 2003; Page 
2). Both Canadian studies included in this review (Dergal et al., 2002; Singh & 
Levine, 2007) used the term ‘natural health products’. Only one study from the US 
(Blalock et al., 2009) used ‘herbs/natural products’ but excluded vitamins and 
minerals. 
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Elmer (Elmer et al., 2007) used the term CAM products, defined as “products such 
as herbal (botanical) products or non-botanical DS (e.g. glucosamine) excluding 
vitamins and minerals”. Five studies (Kaufman et al., 2002; Lantz et al., 1999; Nahin 
et al., 2009; Peklar et al., 2014; Peng et al., 2004) used the definition of DS 
according to Directive 2002/46/EC of the European Parliament and of the Council, 
2002 (Commission of the European Communities, 2003) i.e. “potentially any product 
intended for ingestion as a supplement to regular diet, including vitamins or minerals 
(at any dose level), herbal products, and nutraceuticals”. Twelve studies (Canter & 
Ernst, 2004; Delgoda et al., 2010; Djuv et al., 2013; Izzo & Ernst, 2009; Loya et al., 
2009; Ly et al., 2002; Parkman, 2001; Qato et al., 2008; Shane-McWhorter & Geil, 
2002; Turkmenoglu et al., 2016; Yoon, 2001; Yoon & Schaffer, 2006) provided no 
definition or an explanation of HMP. All potentially eligible studies were therefore 
individually screened to ensure they met this inclusion criterion independent of the 
definition used.  
 
Table 4.1 is a summary of included studies, providing information on study setting, 
sample characteristics, prevalence of concurrent use, most reported prescription 
medicines and HMPs, as well as interactions or potential interactions reported from 
such combinations.  
 Table 4.1: Summary characteristics of included studies (n= 22)  
 
Study, 
Country 
 
Study 
Design/ 
Data 
Collection 
Method 
 
Sample 
size, Age  
 
Definition or 
description of 
HMP 
 
Prevalence 
of 
concurrent 
use (%) 
Most reported 
HMPs  
Most reported 
prescription 
medicinesa  
Number of 
potential herb-
drug 
interactions; 
details 
Batanero-
Hernán et 
al. 
(Batanero
-Hernán 
et al., 
2017) 
Spain 
Cross-
sectional 
survey/ 
semi-
structured 
interview 
384, ≥65y 
M = 129 
F = 255 
mean age 
or range 
NS 
NS 88.3 Chamomile, 
anise, lime 
blossom tea, 
squaw mint or 
mosquito plant, 
red tea, 
valerian, 
plantago, 
Senna, alder 
buckthorn, 
balm mint 
 
Paracetamol, 
omeprazole, 
benzodiazepines, 
lactulose, antacids, 
statins, NSAIDs 
Ventolin, antipsychotics, 
Alzheimer drugs 
 
22; potential risk 
of 
hemorrhage 
from valerian 
with drugs 
metabolised by 
CYP3A4; 
plantago 
interferes with 
the absorption 
of statin, 
acenocoumarol, 
digoxin, 
paracetamol 
and metformin, 
Senna with 
digoxin 
 Study, 
Country 
 
Study 
Design/ 
Data 
Collection 
Method 
 
Sample 
size, Age  
 
Definition or 
description of 
HMP 
 
Prevalence 
of 
concurrent 
use (%) 
Most reported 
HMPs  
Most reported 
prescription 
medicinesa  
Number of 
potential herb-
drug 
interactions; 
details 
Blalock. 
(Blalock 
et al., 
2009) 
USA 
Population-
based 
epidemiolog
ical study/ 
face-to-face 
interviews 
 
1423, 
≥65y 
mean age 
63y  
 
Herbs/natural 
products, 
excluding 
vitamins and 
minerals 
19.9 
 
 
 
 
Garlic, Aloe 
vera, Ginkgo 
biloba, 
Echinacea, 
ginseng, St 
John's wort, 
ginger, saw 
palmetto 
Metoprolol, atenolol 
atorvastatin, simvastatin 
conjugated oestrogens 
omeprazole, 
lansoprazole 
hydrochlorothiazide, 
lisinopril, enalapril 
 
168; inhibition of 
cytochrome 
P450 3A4 
substrates (e.g. 
atorvastatin, 
simvastatin) by 
garlic, Ginkgo 
biloba, 
Echinacea, St 
John's wort 
 
Canter 
and Ernst, 
(Canter & 
Ernst, 
2004) 
UK 
Cross-
sectional/ 
self-
completed 
questionnai
re 
271, ≥50y 
137, ≥65y 
F = 84 
M = 53 
mean age 
or range 
NS 
 
NS  
 
NS 
 
Garlic, Ginkgo 
biloba, 
Echinacea, 
evening 
primrose oil, St 
John’s wort, 
ginseng, Aloe 
barbadensis, 
devils’ claw, 
cranberry, saw 
palmetto 
Aspirin, 
Bendroflumethiazide, β-
Adrenoceptor 
antagonist, HMG-CoA 
reductase inhibitors, 
ACE inhibitor, 
levothyroxine sodium, 
calcium channel 
antagonist, proton-pump 
inhibitor 
Not possible to 
extract data for 
≥ 65y  
 Study, 
Country 
 
Study 
Design/ 
Data 
Collection 
Method 
 
Sample 
size, Age  
 
Definition or 
description of 
HMP 
 
Prevalence 
of 
concurrent 
use (%) 
Most reported 
HMPs  
Most reported 
prescription 
medicinesa  
Number of 
potential herb-
drug 
interactions; 
details 
Delgoda 
et 
al.(Delgod
a et al., 
2010) 
Jamaica 
 
Cross-
sectional 
survey/ 
semi-
structured 
interview 
365 
32, ≥70y 
mean age 
or range 
NS 
NS NS Different types 
of mints 
cerasee, garlic 
and ginger  
Atenolol, metformin, 
Ventolin, nifedipine, 
enalapril, Glucophage, 
hydrochlorothiazide, 
ranitidine, Voltaren, 
Natrilix 
NS 
Dergal et 
al.(Dergal 
et al., 
2002) 
Canada 
Cross-
sectional 
survey/ 
semi-
structured 
interview 
 
195, ≥65y  
M = 84  
F = 111 
mean age 
73y 
Natural health 
products  
17 Ginkgo biloba, 
garlic and 
Echinacea 
Aspirin, trazodone, 
amlodipine, lorazepam 
n = 11 in 9 
patients 
increased risk of 
bleeding (8), 
increased risk of 
coma, 
enhanced 
sedative effects 
of 
benzodiapines, 
and blood 
pressure 
medication 
 
 Study, 
Country 
 
Study 
Design/ 
Data 
Collection 
Method 
 
Sample 
size, Age  
 
Definition or 
description of 
HMP 
 
Prevalence 
of 
concurrent 
use (%) 
Most reported 
HMPs  
Most reported 
prescription 
medicinesa  
Number of 
potential herb-
drug 
interactions; 
details 
Djuv et 
al.(Djuv et 
al., 2013) 
Norway 
 
Cross-
sectional, 
survey/ self-
completed 
questionnai
re 
 
381, ≥18y 
32, ≥70y  
mean age 
54.5y  
NS 40 Bilberry, green 
tea, Aloe vera, 
Echinacea, 
garlic, ginger, 
Ginkgo biloba, 
cranberry 
Antihypertensive and 
diuretics, 
antihyperlipidemic 
agents, anticoagulants, 
analgesics, 
antihistamines, 
antidiabetics, 
antidepressants 
Not possible to 
extract data for 
≥ 65y  
 
 
 
Elmer et 
al.(Elmer 
et al., 
2007) 
USA 
Secondary 
data 
analysis / 
Population 
based 
analysis 
from a 
cohort 
study 
5,052, 
≥65y  
M = 2,009  
F = 3,043; 
mean age 
75y 
CAM products  9.5 Garlic, Ginkgo 
biloba, 
ginseng, 
alfalfa, saw 
palmetto, 
Echinacea, 
Aloe vera, St. 
John’s wort, 
bilberry 
 
NSAID, warfarin, 
antihypertensive, 
statins, omeprazole, 
nifedipine, furosemide, 
oral hypoglycaemics 
 
n = 294; 
elevated drug 
effect, 
decreased drug 
effect, risk of 
bleeding, affects 
blood 
coagulation  
 Study, 
Country 
 
Study 
Design/ 
Data 
Collection 
Method 
 
Sample 
size, Age  
 
Definition or 
description of 
HMP 
 
Prevalence 
of 
concurrent 
use (%) 
Most reported 
HMPs  
Most reported 
prescription 
medicinesa  
Number of 
potential herb-
drug 
interactions; 
details 
Izzo and 
Ernst 
(Izzo & 
Ernst, 
2009) 
UK 
 
Secondary 
data 
analysis / 
systematic 
review 
90, ≥65y 
M = 51 
F = 39 
mean age 
68y 
NS NS St. John’s 
wort, ginseng, 
garlic, Ginkgo 
biloba and 
kava 
Warfarin, sertraline, 
aspirin, caffeine, 
chlorzoxazone, 
debrisoquine, 
midazolam 
n = 47; 
decreased INR, 
Abnormal 
bleeding, fatal 
intracerebral 
haemorrhage, 
Nausea, 
anxiety, 
restlessness, 
irritability 
Kaufman 
(Kaufman 
et al., 
2002) 
USA 
Cross-
sectional, 
survey / 
telephone 
interview 
2590, 
≥18y 494, 
≥65y  
M = 243 
F = 251 
mean age 
or range 
NS 
DS 16 Ginseng, 
Ginkgo biloba, 
garlic, St. 
John’s wort, 
Echinacea, 
saw palmetto 
Acetaminophen, 
ibuprofen, aspirin, 
conjugated oestrogens, 
lisinopril, atenolol, 
levothyroxine sodium, 
hydrochlorothiazide, 
furosemide, 
atorvastatin, calcium 
 
Not assessed 
Lantz et 
al.(Lantz 
et al., 
1999) 
Case 
reports 
 
5, ≥65y 
F = 2 
M = 3  
mean age 
77.4y 
 
DS  NS St. John’s wort Sertraline, calcium 
carbonate, conjugated 
oestrogens aspirin, 
multivitamin, 
cyproheptadine, 
nefazodone 
n = 5; central 
serotonergic 
syndrome 
 
 Study, 
Country 
 
Study 
Design/ 
Data 
Collection 
Method 
 
Sample 
size, Age  
 
Definition or 
description of 
HMP 
 
Prevalence 
of 
concurrent 
use (%) 
Most reported 
HMPs  
Most reported 
prescription 
medicinesa  
Number of 
potential herb-
drug 
interactions; 
details 
Loya et 
al.(Loya 
et al., 
2009) 
Cross-
sectional 
survey/ 
semi-
structured 
interviews 
 
130, ≥65y 
M = 30 
F = 100  
mean age 
71.4y 
NS 34.6 Chamomile 
tea, garlic, 
flaxseed, 
artemisia tea 
(wormwood), 
Ginkgo biloba 
 
 
Aspirin, metformin, 
paracetamol, 
atorvastatin, 
levothyroxine sodium, 
hydrochlorothiazide, 
alendronic acid, 
metoprolol, Lisinopril, 
losartan 
 
n = 220; the 
majority  
had potential to 
result in 
alterations in 
either blood 
glucose or blood 
pressure 
Ly et 
al.(Ly et 
al., 2002) 
USA 
 
Cross-
sectional 
survey/ self-
completed 
questionnai
re 
123, ≥65y 
M = 98 
F = 25 
mean age 
78y 
NS 22.8 Garlic, Ginkgo 
biloba, saw 
palmetto, 
Echinacea, 
ginseng 
Antihypertensives, 
antidiabetic drugs, 
aspirin or another 
NSAID, corticosteroids 
n = 5; Four 
involved Ginkgo 
biloba and 
aspirin, one 
involved garlic 
and warfarin. All 
can increase the 
risk of bleeding. 
Nahin et 
al.(Nahin 
et al., 
2009) 
USA 
Cross-
sectional 
survey/ self-
completed 
questionnai
re 
3,072, 
≥75y  
M = 1,653    
F = 1,419 
mean age 
or range 
NS 
DS  83 Garlic, Ginkgo 
biloba, saw 
palmetto, 
Echinacea, 
Aspirin, statin, beta-
blocker, ACE-inhibitors, 
NSAIDs, thyroid agents, 
oestrogen, 
cyclooxygenase-2 
inhibitor, thiazide 
diuretics, vasodilators 
NS 
 Study, 
Country 
 
Study 
Design/ 
Data 
Collection 
Method 
 
Sample 
size, Age  
 
Definition or 
description of 
HMP 
 
Prevalence 
of 
concurrent 
use (%) 
Most reported 
HMPs  
Most reported 
prescription 
medicinesa  
Number of 
potential herb-
drug 
interactions; 
details 
Parkman, 
(Parkman, 
2001) 
USA 
 
Case report M =1, 68y NS  Ginseng, 
Ginkgo biloba, 
valerian 
Coumadin (Warfarin) n = 3; 
nosebleeds, 
bruises on shins 
and forearms, 
and serious 
headache 
Peklar et 
al.(Peklar 
et al., 
2014) 
Ireland 
 
Cross-
sectional 
survey/  
face-to-
face-
interviews 
8081, 
≥50y 
 
3,446, 
≥65y 
M = 3,706    
F = 4,375 
mean age 
63.8y 
DS 
 
14 Evening 
primrose oil, 
garlic, ginseng  
Bisphosphonates, 
antineoplastic drugs, 
other analgesics, 
antiarrhythmic, opioid 
analgesics 
n = 5; increased 
risk of bleeding 
from evening 
primrose, garlic 
and ginseng 
combined with 
antithrombotic 
Peng et 
al.(Peng 
et al., 
2004) 
USA 
 
 
 
Cross-
sectional 
survey/self-
completed 
questionnai
re 
458 
260, ≥65y 
M = 244    
F = 16 
 
mean age 
or range 
NS 
DS 38 Garlic, Ginkgo 
biloba, saw 
palmetto, 
ginseng, St. 
John’s wort, 
DHEA 
supplements 
(soy, wild 
yam), 
Echinacea, 
Ibuprofen, 
fluoroquinolone, 
Levofloxacin, warfarin, 
Hydrochlorothiazide, 
Digoxin, fosinopril 
sodium, lisinopril, 
paroxetine 
n = 48; 
increased risk of 
bleeding due to 
lowered platelet 
aggregation, 
effectiveness of 
diuretic lowered, 
lowered 
anticoagulant 
effect, increased 
serotonin levels 
 Study, 
Country 
 
Study 
Design/ 
Data 
Collection 
Method 
 
Sample 
size, Age  
 
Definition or 
description of 
HMP 
 
Prevalence 
of 
concurrent 
use (%) 
Most reported 
HMPs  
Most reported 
prescription 
medicinesa  
Number of 
potential herb-
drug 
interactions; 
details 
Qato et 
al.(Qato 
et al., 
2008) 
USA 
 
Cross-
sectional 
survey/ 
interviews 
 
2976, 
≥57y 
 
1960, 
≥65y 
M = 920 
F = 1040;  
mean age 
or range 
NS 
NS 52 Saw palmetto, 
flax, garlic, 
Ginkgo biloba 
Aspirin, 
hydrochlorothiazide 
atorvastatin, 
levothyroxine, lisinopril, 
metoprolol, simvastatin, 
atenolol, amlodipine, 
metformin 
n = 12; 
increased risk of 
bleeding 
 
Shane-
McWorter 
and Geli 
(Shane-
McWhorte
r & Geil, 
2002) 
USA 
Case 
reports 
2, ≥52y 
 
M = 1,72y 
NS  St. John’s 
wort, Asian 
ginseng 
 
 
Metformin, nateglinide, 
rosiglitazone, losartan, 
warfarin, digoxin, 
atorvastatin, paroxetine, 
acetaminophen 
n = 3; reduced 
blood 
pressure–
lowering effect, 
decreased INR, 
decreased 
Digoxin effect 
 Study, 
Country 
 
Study 
Design/ 
Data 
Collection 
Method 
 
Sample 
size, Age  
 
Definition or 
description of 
HMP 
 
Prevalence 
of 
concurrent 
use (%) 
Most reported 
HMPs  
Most reported 
prescription 
medicinesa  
Number of 
potential herb-
drug 
interactions; 
details 
Singh and 
Levine 
(Singh & 
Levine, 
2007) 
Canada 
Cross-
sectional 
survey/telep
hone 
interviews 
11, 424, 
≥18y 
mean age 
or range 
NS 
Natural health 
product 
5.3 Echinacea, 
garlic, evening 
primrose oil, 
Ginkgo biloba, 
ginseng, flax 
seed oil, St 
John’s wort, 
apple cider 
vinegar 
ASA, statin, NSAIDs, 
calcium channel 
blockers 
n = 124; 
increased 
bleeding risk, 
increased blood 
pressure 
reduction, 
reduced drug 
level, reduced 
glucose control 
Turkmeno
glu et 
al.(Turkm
enoglu et 
al., 2016) 
Turkey 
Cross-
sectional 
survey / 
semi-
structured 
interview 
1418, 
≥65y 
M = 462 
F = 956 
mean age 
or range 
NS 
NS 63.3 Lime, nettle, 
sage, mint, 
thyme, 
flaxseed, 
linseed, 
Senna, green 
tea, rosehip, 
chamomile 
 
Cardiovascular, 
digestive and 
metabolism drugs, 
musculoskeletal, 
nervous system drugs, 
haematopoietic, 
systemic hormonal 
drugs, respiratory 
system drugs 
Not assessed 
Yoon and 
Horne 
(Yoon & 
Horne, 
2001) 
USA 
Cross-
sectional 
survey / 
semi-
structured 
interview 
F = 86, 
≥65y 
 
mean age 
74.9y 
NS 45.3 
 
 
Ginkgo biloba 
or 
combinations, 
garlic and 
cloves 
Multivitamin, calcium, 
Vitamin E, Vitamin C, 
aspirin 
Not assessed 
 Study, 
Country 
 
Study 
Design/ 
Data 
Collection 
Method 
 
Sample 
size, Age  
 
Definition or 
description of 
HMP 
 
Prevalence 
of 
concurrent 
use (%) 
Most reported 
HMPs  
Most reported 
prescription 
medicinesa  
Number of 
potential herb-
drug 
interactions; 
details 
Yoon and 
Shaffer 
(Yoon & 
Schaffer, 
2006) 
USA 
 
Secondary 
analysis of 
data                 
F = 58, 
≥65y 
mean age 
75.6y 
NS NS Garlic, Ginkgo 
biloba, 
ginseng, St. 
John’s wort 
Ibuprofen, ASA, 
nabumetone, oestrogen, 
progesterone, 
amlodipine, fentanyl, 
albuterol, warfarin, 
ticlopidine 
n = 43; 
increased risk of 
GI bleeding, 
metabolism of 
calcium 
inhibited, 
antidiabetic 
activity, 
decreased 
contraceptive or 
hormone 
replacement 
efficacy 
 
 
a 10 most commonly reported; ASA: acetylsalicylic acid; NSAIDs: Non-steroidal anti-inflammatory drugs; ACE: Angiotensin-
converting enzyme; HMG-CoA: 3-hydroxy-3-methyl-glutaryl-coenzyme A; CAM: complementary and alternative medicine; 
INR: international normalised ratio; GI: gastro-intestinal; M: Male; F: Female; NS: not stated; HMP: herbal medicinal product 
; DHEA: dehydroepiandrosterone; CYP: cytochrome P450
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4.5.2  Risk of bias in included studies 
Considering the paucity of research in this area, a cut off score of 4 was accepted for 
each JBI checklist, to ensure there were enough studies to review while maintaining 
the strength of methodological quality. Typically, research in this area is not 
randomised. Therefore, a score of 7 and above indicated high quality, while 4 to 6 is 
moderate quality.  All twenty-two studies were of enough quality and were included 
in the review.  
 
4.5.3  Prevalence of concurrent prescription drugs and HMPs 
 among older adults 
 
Fifteen studies reported prevalence of concurrent use, while no such information was  
provided in four articles (Canter & Ernst, 2004; Delgoda et al., 2010; Izzo & Ernst, 
2009; Yoon & Schaffer, 2006), and three were case reports where prevalence 
cannot be calculated (Lantz et al., 1999; Parkman, 2001; Shane-McWhorter & Geil, 
2002). Prevalence of concurrent use varied widely between 5.3% (Singh & Levine, 
2007) and 88.3% (Nahin et al., 2009). 
 
Table 4.1 shows that the most concurrently combined prescription medicines and 
HMPs from the included studies. The common groups of prescription medicines 
concurrently combined with HMPs were antihypertensive drugs, beta blockers, 
diuretics, antihyperlipidemic agents, anticoagulants, analgesics, antihistamines, 
antidiabetics, antidepressants and statins.  
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The most commonly used HMPs as reported in the included studies were: Ginkgo 
(Ginkgo biloba), garlic (Allium sativum), Ginseng (Panax ginseng), St John’s wort 
(Hypericum perforatum), Echinacea (Echinacea purpurea), Saw palmetto (Serenoa 
repens), evening primrose oil (Oenothera biennis) and ginger (Zingiber officinale).  
 
In some studies, non-herbal dietary or nutritional supplements (Canter & Ernst, 2004; 
Ly et al., 2002; Nahin et al., 2009; Peklar et al., 2014; Shane-McWhorter & Geil, 
2002; Singh & Levine, 2007), vitamins and minerals (Kaufman et al., 2002; Nahin et 
al., 2009; Peklar et al., 2014; Peng et al., 2004) and over-the-counter (OTC) 
conventional medicines (Delgoda et al., 2010; Dergal et al., 2002; Elmer et al., 2007; 
Loya et al., 2009) were also concurrently used by participants in addition to 
prescription drugs and HMPs. In one study (Nahin et al., 2009), 82.5% of participants 
on prescription medicines also used at least one non-herbal DS, and 54.5% used 
three or more. 
 
4.5.4  Potential interactions and safety issues  
Potential interactions from reported combinations of prescription drugs and HMPs 
were evaluated using different methods. Some studies used a combination of two or 
more of the following methods: review of possible interactions from previously 
published clinical data, case reports and textbooks (Djuv et al., 2013; Elmer et al., 
2007; Izzo & Ernst, 2009; Ly et al., 2002; Nahin et al., 2009; Singh & Levine, 2007). 
Others used  comprehensive online databases such as Micromedex 
(https://www.micromedexsolutions.com), Natural Medicines 
(https://naturalmedicines.therapeuticresearch.com/, formerly Natural Standard), 
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Stockley’s Drug Interactions 
(http://www.pharmpress.com/product/MC_STOCK/stockleys-drug-interactions) (Loya 
et al., 2009; Nahin et al., 2009; Peklar et al., 2014; Peng et al., 2004; Qato et al., 
2008; Yoon & Schaffer, 2006).  
 
Due to how data were presented in two studies (Canter & Ernst, 2004; Djuv et al., 
2013), it was not possible to extract potential interactions for participants aged ≥65 
years. No evaluation of potential interactions was done in five studies (Delgoda et 
al., 2010; Kaufman et al., 2002; Nahin et al., 2009; Turkmenoglu et al., 2016; Yoon & 
Horne, 2001). A total of 1,010 individual interactions or potential interactions were 
reported in 15 studies.  
 
Potential risks of bleeding due to use of Ginkgo biloba, garlic or ginseng with aspirin 
and warfarin were the most reported (Batanero-Hernán et al., 2017; Dergal et al., 
2002; Elmer et al., 2007; Ly et al., 2002; Parkman, 2001; Peklar et al., 2014; Peng et 
al., 2004; Qato et al., 2008; Shane-McWhorter & Geil, 2002; Yoon & Schaffer, 2006) 
or other antithrombotic drugs (Peklar et al., 2014). Other interactions reported 
included risk of decreased international normalised ratio (INR) (Izzo & Ernst, 2009; 
Shane-McWhorter & Geil, 2002), alterations in either blood glucose or blood 
pressure (Loya et al., 2009), nausea and dizziness (Lantz et al., 1999), anxiety (Izzo 
& Ernst, 2009), headaches (Lantz et al., 1999; Parkman, 2001), restlessness and 
irritability (Izzo & Ernst, 2009). An important and risky mode of herb-drug interaction 
is the inhibition of cytochrome P450 3A4 substrates (e.g. atorvastatin, simvastatin, 
amlodipine, verapamil) by garlic, Ginkgo biloba, Echinacea and St John's wort 
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(Blalock et al., 2009). For example, St John’s wort could reduce the blood pressure 
lowering effect of losartan or decrease the effects of digoxin (Shane-McWhorter & 
Geil, 2002). 
 
Interactions were rated by the authors as ‘major or high risk’, ‘moderate’ or ‘minor’. 
The majority of potential interactions reported in included studies were minor, of 
unknown clinical significance or uncertain risk for an adverse interaction (Elmer et 
al., 2007; Izzo & Ernst, 2009). These interactions were cited in the literature only 
based on theoretical evidence (Singh & Levine, 2007).  
 
Potential major herb-drug interactions reported were between non-steroidal anti-
inflammatory drugs (NSAIDs) and Ginkgo biloba, resulting in increased risk of gastro 
intestinal bleeds due to decreased platelet aggregation (Yoon & Schaffer, 2006). 
Other major interactions occurred between drug and non-herbal supplement (Peklar 
et al., 2014) or involved the use of non-prescription drugs (Qato et al., 2008). 
 
4.5.5  Concurrent use and associated factors 
Many studies included in this review did not assess concurrent use with 
demographic or clinical variables. For the eleven studies that assessed demographic 
or clinical factors (Blalock et al., 2009; Canter & Ernst, 2004; Delgoda et al., 2010; 
Djuv et al., 2013; Elmer et al., 2007; Kaufman et al., 2002; Peklar et al., 2014; Qato 
et al., 2008; Singh & Levine, 2007; Turkmenoglu et al., 2016; Yoon & Horne, 2001), 
the following can be summarised: 
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a.  Ethnicity 
Only one study assessed the differences in concurrent use between different ethnic 
groups. African-Americans used significantly more garlic (p =.003), although no 
significant difference was observed in the use of ginseng or Ginkgo biloba between 
African- Americans and white participants(Elmer et al., 2007). 
 
b.  Gender and Age 
An important difference in gender in relation to medication use was observed in 
seven studies (Blalock et al., 2009; Canter & Ernst, 2004; Djuv et al., 2013; Kaufman 
et al., 2002; Peklar et al., 2014; Qato et al., 2008; Singh & Levine, 2007). Women 
used more herbal supplements than men (Canter & Ernst, 2004; Qato et al., 2008). 
A significantly higher prevalence of use of 5 or more prescription medications among 
women aged 57 through 64 years was reported in two studies (Kaufman et al., 2002; 
Qato et al., 2008). Consequently, more women than men concurrently use HMPs 
with prescription medicines (Blalock et al., 2009; Djuv et al., 2013; Peklar et al., 
2014; Qato et al., 2008). Qato et al. (Qato et al., 2008) found up to 60% of women in 
the oldest age groups used prescription medications in combination with herbal DS. 
Increased odds for a co-user to be female (34% vs 18%, p= 0.001) and older  (more 
than one in every three  older than 50 years) was also confirmed by Djuv et al (Djuv 
et al., 2013).  
 
Two studies (Peklar et al., 2014; Yoon & Horne, 2001) found no association between 
age and concurrent use. Singh and Levine (Singh & Levine, 2007) reported that 
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older users combining prescriptions with natural health products and females were 
more likely to have potential interactions than males combining prescriptions with 
NHPs (63% vs 48%).   
 
c.  Disease state or clinical condition 
Five studies (Delgoda et al., 2010; Djuv et al., 2013; Peklar et al., 2014; Singh & 
Levine, 2007; Turkmenoglu et al., 2016) compared concurrent use with disease state 
or clinical conditions. Herbal product use was slightly higher among participants who 
suffered ongoing health problems (31.1%) than healthy older adults (24.9%), 
although the difference was not significant. Consequently, herbal product use was 
significantly higher among participants who reported continuous drug use compared 
to those who did not use any drugs (Turkmenoglu et al., 2016).  
 
Increased levels of co-use was associated with use of analgesics or a dermatological 
drug (Djuv et al., 2013). Chronic diseases were associated with an increased 
likelihood of concurrent prescription and supplement use (Peklar et al., 2014). High 
blood pressure and diabetes were also strongly associated with potential interaction 
(Singh & Levine, 2007). However, Delgoda et al. (Delgoda et al., 2010) found no 
significant association between concurrent herb-drug use and participant’s disease. 
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d.  Education and household income 
Only four studies (Delgoda et al., 2010; Peklar et al., 2014; Singh & Levine, 2007; 
Turkmenoglu et al., 2016) assessed educational level or household income of 
participants with concurrent use. Concurrent herb-drug use was greater amongst 
individuals who had education no higher than secondary level (Delgoda et al., 2010; 
Peklar et al., 2014). Higher education was associated with a lower probability of 
potential interaction (Singh & Levine, 2007). Therefore, compared to post-secondary 
graduates, participants with less than a high school education were 70% more likely 
to exhibit at least one potential interaction (Singh & Levine, 2007).  
 
The prevalence of concurrent herb-drug use was also greater amongst individuals 
from households with lower household income or with no form of health insurance 
(Delgoda et al., 2010).  Having private medical insurance was associated with an 
increased likelihood of using HMPs (Peklar et al., 2014). However, Turkmenoglu et 
al (Turkmenoglu et al., 2016) found no significant associations between HMP use 
and income. 
e. Disclosure of HMPs use to healthcare professionals  
Only six studies asked participants if use of HMPs was disclosed to their doctors or 
other healthcare professionals (Delgoda et al., 2010; Djuv et al., 2013; Ly et al., 
2002; Peng et al., 2004; Turkmenoglu et al., 2016; Yoon & Horne, 2001). No distinct  
trend was observed among the six studies and disclosure varied widely between 
12% (Turkmenoglu et al., 2016) and 78% (Peng et al., 2004). A study of 1,418 older 
adults (Turkmenoglu et al., 2016) reported that 42.2% (n= 180)  of concurrent users 
believed herbal products were not harmful and so did not need to discuss these with 
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their healthcare providers. Although 51 participants (12%) always reported herbal 
use to their physician, 40% (n= 169) would only disclose herbal product use to 
healthcare providers if asked and 2.8% (n=12) only if they had a problem. In another 
study (Peng et al., 2004), 78% of participants reported HMP use, although 58 of the 
99 concurrent users said they were not asked by healthcare practitioners.  About 
64% of co-users (n= 18) of HMPs and prescription drugs disclosed use in one study 
(Ly et al., 2002). Almost 80% of users of HMPs did not disclose use in another study 
(Djuv et al., 2013).  
 
f. Expenditure on HMPs and satisfaction 
Only two studies (Ly et al., 2002; Peng et al., 2004) considered the cost or resources 
spent on HMPs by older adults. Both studies were conducted in the USA in 2002 and 
2004 respectively. Most concurrent users (64% and 83%) spent $25 or less on 
HMPs monthly.  About 15% spent between $25 and $50 monthly (Peng et al., 2004) 
, only 3 out of 28 (11%) (Ly et al., 2002) and 1 of 99 (1%) (Peng et al., 2004) 
concurrent users spent more than $100 per month on HMPs. 
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4.6 Discussion  
This systematic review included a total of 22 studies that investigated concurrent use 
of prescription medicines with HMPs. Most studies were conducted in the USA and 
only four of the studies were conducted in the last 5 years. It can be concluded from 
the results presented that the prevalence of concurrent prescription and herbal 
medicinal products (HMPs) use among older adults is substantial. The most 
commonly combined prescription drugs by older adults are antihypertensive drugs, 
beta blockers, diuretics, antihyperlipidemic agents, anticoagulants, analgesics, 
antihistamines, antidiabetics, antidepressants and statins.  The HMPs most 
commonly combined include Ginkgo biloba, garlic, ginseng, St John’s wort, 
Echinacea, saw palmetto, evening primrose and ginger. There are demographic and 
clinical factors associated with concurrent prescription and HMP use. Women, 
individuals in the oldest age groups, with chronic conditions, less than a high school 
education and on low income are more likely to be concurrent users. The most 
common potential interaction was the risk of bleeding from combinations of Ginkgo 
biloba, garlic or ginseng with aspirin and warfarin, all of which are frequently used by 
older adults.  
 
The included studies varied greatly in terms of participants, products and outcome 
measures. Generic terms such as ‘elderly’ or ‘older persons’ are commonly used 
(Singh & Bajorek, 2014) but there is no concrete definition of these terms, While 
ageing is an inevitable process measured by chronological age, its impact varies 
across populations (Levine, 2013). Therefore, different definitions and chronological 
age are adopted in clinical studies. While some authors regarded ‘older adults’ or 
‘elderly’ as those aged 65 years and older, others used the cut-off point of 60 years 
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or even 75 years. This affected how participant were grouped and the synthesis of 
data. Furthermore, many studies looked at adult populations including “older adults” 
or “elderly” but did not or only partially reported results separately for this age group. 
In the latter case, only results that were clearly reported for adults aged 65 and older 
were included in our analysis. We therefore had to exclude several potentially 
relevant articles due to either a lack of definition or separate reporting. 
 
The heterogeneity in definitions adopted for HMPs and the inconsistencies on what 
is included as HMPs demonstrates the lack of precision around what may or may not 
be herbal medicinal products. While a study (Elmer et al., 2007) adopted the term 
complementary and alternative medicine excluding vitamins and minerals other 
studies adopted the terms natural health product and DS including both vitamins and 
minerals. Moreover, many did not differentiate between HMPs and DS, rather 
included all types of medications including vitamins, minerals, herbal and non-herbal 
dietary supplements. Only studies of HMPs that were explicitly named in the results 
section are included. This variation did not allow for comparisons across studies to 
be conducted. It also blurred what might be nutritional interventions to improve 
overall health and those that are used explicitly for medicinal purposes to address 
specific medical conditions. 
 
The prevalence of concurrent prescriptions and HMPs use among adults aged 65 
years and older ranged from 5.3 to 88.3%. Several factors might explain the 
discrepancies in prevalence of concurrent use reported in studies included in this 
review.  Firstly, the variation in the range of prevalence reflected the different 
definitions, types of HMPs assessed and participants. Secondly, many of the studies 
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relied on patient recall of the prescription and herbal medicines they use, possibly 
resulting in recall bias. In some studies (Dergal et al., 2002; Elmer et al., 2007; 
Kaufman et al., 2002; Nahin et al., 2009; Peklar et al., 2014; Qato et al., 2008), 
participants took bottles and containers of medicines they were taking along to 
interviews for documentation by the research teams.  
 
One of the outliers, an analysis of the 2000-2001 Canadian National Population 
Health Survey reported only 5.3% concurrent use of NHPs with prescription 
medications(Singh & Levine, 2007). This difference in prevalence may be explained 
by underreporting or recall bias due to how data were collected. Participants were 
asked of medications and NHPs used in the previous 24 hours. This is unusual 
compared to other surveys on this topic where current and previous use of two 
weeks (Nahin et al., 2009) and up to 12 months was requested (Blalock et al., 2009; 
Canter & Ernst, 2004; Ly et al., 2002). Therefore, the data may have revealed only a 
percentage of respondents exposed to a NHP during a limited time period. In 
addition, herbs and other NHPs are widely used in a variety of foods, beverages, and 
multivitamin supplements but because these were not specifically asked in the 
survey, it is possible that their use was not reported. Therefore, the true prevalence 
of concurrent prescription-NHP interaction in the study population may be higher 
than reported.  
 
The other outlier is a Spanish study which reported prevalence of concurrent use of 
88.3%. The study assessed both commercially prepared HMPs and home remedies 
concurrently used with prescription medicines among community dwelling older 
adults and those resident in care homes. All medicinal plants including teas and 
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spices widely consumed in Spain were included in the analysis. This may have 
contributed to the high prevalence recorded in this study.   
 
Three (Nahin et al., 2009; Qato et al., 2008; Yoon & Horne, 2001) of the five studies 
(Batanero-Hernán et al., 2017; Nahin et al., 2009; Qato et al., 2008; Turkmenoglu et 
al., 2016; Yoon & Horne, 2001) with highest prevalence rates were conducted in the 
USA, ranging between 45.3% and 83%. The high prevalence rates could be due to 
the health care system or the sociocultural characteristics of the location where 
research was conducted.  For the American studies, patients potentially used HMPs 
and non-prescription drugs for prevention or self-treatment (Yoon & Horne, 2001) as 
alternatives to expensive medical consultations and prescription drugs. Secondly, 
only one (Nahin et al., 2009) of the five studies provided a definition or what is 
regarded as a HMP. Considering the inconsistencies in what HMPs includes, it is 
possible that other non-herbal dietary products were considered. 
 
Demographic characteristics as well as health status have been associated with use 
of herbal medicines and natural products. Sex, age, ethnicity and health status may 
result in greater use of herbs and natural products (Blalock et al., 2009). Although 
only 50% of the studies included in this review compared demographic 
characteristics and health status with concurrent use, the results confirms earlier 
findings (Raji et al., 2005) that the use of herbal medicines varies widely between 
countries and ethnic groups. For example, the two Canadian studies (Dergal et al., 
2002; Singh & Levine, 2007) reported lower rates compared to studies from the 
United States. In addition, the rate of combining prescription medications and DS 
was higher among women than men across all age groups (Kaufman et al., 2002; 
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Qato et al., 2008). This trends were also reported in earlier studies (Gardiner et al., 
2006; Radimer et al., 2004).  
 
The differences observed in the sexes of older adult concurrent users may be 
explained by the higher prevalence of chronic conditions among women compared to 
men (Tsang et al., 2008). Concurrent use was greater amongst older adults from 
households with lower household income, no health insurance and no post-
secondary education. This may be due to the kind of health care system i.e. paid for 
or free at the point of delivery. It is therefore reasonable to assume that in such 
countries; participants may rely more on HMPs or use them as alternatives to 
expensive medical consultations. 
 
There is increased awareness of interactions between conventional drugs and 
HMPs. However, the lack of agreement on how to identify HMPs or rigorous clinical 
evidence hinders researchers, clinicians and consumers in making informed 
decisions about safe combinations of conventional drugs and HMPs (Zhang, Chen, 
Zhu, & Zhou, 2017). Most of the evidence on herb-drug interactions is from case 
reports. Arguably the scarcity and poor quality of primary research, may mean that 
interactions of serious consequences  associated with concurrent use of HMPs are 
unknown and unrecognised (Posadzki, Watson, & Ernst, 2013). The evidence from 
this review would suggest that there is potential for harm.  
 
There is potentially high rate of unreported use of HMPs among older adults. Only 
28% of included studies asked participants if use of HMPs was disclosed to 
healthcare professionals. Our findings confirm previous research (Kennedy, Wang, & 
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Wu, 2008; Mehta, Gardiner, Phillips, & McCarthy, 2008; Robinson & McGrail, 2004) 
that only about one-third of HMP users disclose use to healthcare professionals. 
Disclosure of herbal medicine use is crucial to avoiding herb-drug interactions and 
non-adherence to prescription medications. Reasons for non-disclosure of HMP use 
as reported in this review and confirmed by other studies includes: perceived 
negative attitude of clinicians to complementary medicine use (Robinson & McGrail, 
2004; Samuels et al., 2012), clinicians do not ask (Howell et al., 2006; Robinson & 
McGrail, 2004; Vickers, Jolly, & Greenfield, 2006)  and the notion that HMPs are 
‘harmless’(Vickers et al., 2006) . 
4.7 Limitations of this Review 
The main limitation of this review is the heterogeneity or no definition of herbal 
medicinal product in available studies which prevented a meta-analysis. Secondly, 
we had to exclude many studies because either the use of HMPs was unclear or 
results reported were not age-specific to enable us extract data for ≥65 years. 
Finally, only four of the included studies were published in the last five years 
(Batanero-Hernán et al., 2017; Djuv et al., 2013; Peklar et al., 2014; Turkmenoglu et 
al., 2016), seventeen between 2000 and 2010, and one case report in 1999 (Lantz et 
al., 1999). The increasing use of HMPs worldwide could mean that the review 
underestimates the range and scale of the issues.  
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4.8  Conclusion 
The prevalence of concurrent use of prescription drugs and HMPs by older adults is 
generally substantial, although variations in the extent of use are reported. These 
variations can be explained by methodological factors including definition of HMPs, 
participant selection, sociodemographic factors and differences in health care 
systems. Concurrent use of prescription drugs and HMPs is associated with risks, 
some with potentially serious consequences. The most reported interactions in older 
adults were risk of bleeding due to use of Ginkgo biloba, garlic or ginseng in 
combination with aspirin and warfarin, or other antithrombotic drugs. Under reporting 
is substantial and adds to the problem, considering that in most countries there are 
no appropriate safeguards to minimise the potential harm. By identifying the most 
commonly used combinations, healthcare professionals including pharmacists can 
be informed on how to identify and manage patients at risks appropriately. It also 
highlights the need for targeted patient information provided by health care 
professionals and pharmacists as part of routine consultations. Further research is 
needed to explore why older people use HMPs alongside their prescribed medication 
and how their decisions about preferred treatments can be documented and 
discussed by prescribing clinicians, in order to identify and manage potential risk of 
herb-drug interactions. 
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4.9 Chapter Summary 
Chapter 4 presented the findings from a systematic literature review evaluating the 
prevalence, patterns, potential interactions and factors associated with the 
concurrent use of HMPs and prescription drugs among older adults. The chapter 
began with a rationale for exploring these issues, gave a summary of the methods 
used for the review before presenting the study findings. The findings have been 
presented as characteristics of the included studies and a description of the 
prevalence, patterns and potential interactions from the data synthesis.  A discussion 
of the findings is provided including the strength and limitations of the review. The 
implications of the findings to clinical practice were also considered. 
 
The next chapter will present the findings from the quantitative study which 
examined the prevalence and patterns of concurrent prescription drugs, herbal 
medicinal products and DS among UK community dwelling older adults. 
 
 
 
 
 
 
 
 
 114 
 
Chapter 5: Prevalence, Pattern and 
Potential Interactions among UK 
Community Dwelling Older Adults 
A paper based on the work presented in this chapter has been published as  
Agbabiaka, T. B., Spencer, N. H., Khanom, S., & Goodman, C. (2018). Prevalence of 
drug–herb and drug–supplement interactions in older adults: a cross-sectional 
survey. The British Journal of General Practice, 68(675), e711.-717 
 
5.1 Introduction to Chapter 
This chapter presents background and findings from the survey phase of the study. 
The aim of this phase was to build on the review findings (Chapter 4) and establish 
prevalence, patterns and potential interactions from the concurrent use of medicines 
among community dwelling older adults in the UK. Results from the cross-sectional 
study are presented. The demographic variations among the study population are 
identified and the prevalence of concurrent use is reported. Factors associated with 
concurrent use of prescription drugs, herbal medicinal products (HMPs) and  dietary 
supplements were explored and reported. Demographic variation between 
concurrent users and non-concurrent users were also explored and reported. A 
discussion of the survey findings, the strengths and limitations of the approach is 
presented. The implications of the study findings for practice and policy conclude the 
chapter. 
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5.2 Background 
The systematic review established that concurrent use is substantial among older 
adults, identified the range of HMPs and prescriptions frequently combined, for which 
conditions and potential herb-drug interactions from such combinations. The review 
also identified some limitations in current knowledge. Specifically, it identified that no 
recent UK study exists on the topic; the only UK study (Canter & Ernst, 2004) was 
over a decade old. Most importantly, while previous researches acknowledged 
potential interactions between herbal and conventional medicines due to concurrent 
use, much of this work was atheoretical or based on drug pharmacodynamics. Very 
little has been done to explore and explain the reasons for concurrent use and the 
experiences of concurrent users, to inform a theoretical understanding of why some 
groups are more likely to use HMPs alongside prescribed medications. These 
findings refine the study objectives and provided basis for survey of older people’s 
concurrent use of prescription drugs and HMPs.  
 
The working definition of herbal medicinal products for the survey (Commission of 
the European Communities, 2003) was “any medicinal product, exclusively 
containing as active ingredients one or more herbal substances or one or more 
herbal preparations, or one or more such herbal substances in combination with one 
or more such herbal preparations. 
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5.3 Study Objectives 
The objectives of the survey were to: 
i Establish the prevalence of concurrent prescription drugs and HMPs use 
among UK community dwelling older adults. 
ii Identify the pattern of concurrent use and the range of medicines combined. 
iii Examine potential herb-drug interactions from such combinations.  
 
5.4 Questionnaire Development and Pilot study  
Only 9 of the 15 older adults invited to participate in the pilot study responded; 6 from 
the two GP practices and 3 family and friends. One questionnaire was not completed 
because the individual misunderstood the purpose of the survey and did not 
understand that it should be completed even if not currently using herbal medicines. 
The patient information leaflets were changed to make this clear.  
 
The remaining 8 respondents completed all questions.  Areas where there was a 
need for clarification were around food and supplementary products. For example, 
garlic and ginger were regarded as food and not as medicines and some 
respondents could not differentiate HMPs from DS. This section of the survey was 
consequently reworded to capture all the HMPs used by participants. Some 
examples of common HMPs were also provided to demonstrate the possible breadth 
of responses (Appendix C). 
 
One participant listed five prescription medicines and then wrote etcetera, which 
suggested there were more medications but not listed. So, the question on 
prescription medicines included an option to attach a copy of repeat prescription if 
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participants did not want to list all their prescribed medications. Other minor 
amendments made to the questionnaire included; merging and re-phrasing a couple 
of questions that duplicated information on medicine use and this reduced the length 
of the questionnaire. The question on age was changed to appear as multiple 
choices for respondents to select age group. Question 3.2 was also modified to 
include what ‘does the HMPs looks like’, how often it is used and what it was used 
for. Overall feedback indicated that the questions were clear and easy to answer. 
The questionnaire took an average of twenty to thirty minutes to complete.  
 
5.5 Recruitment challenges  
Evidence suggests that non-participation in research increases with age 
(Christensen, Moye, Armson, & Kern, 1992; Grotzinger, Stuart, & Ahern, 1994). Non-
responders to research tend to be male (Christensen et al., 1992), from ethnic 
minorities (Hussain-Gambles, Atkin, & Leese, 2006; Redwood & Gill, 2013), less 
educated (Christensen et al., 1992), in poorer health than responders (Grotzinger et 
al., 1994) and in most cases community dwellers (Dibartolo & McCrone, 2003) as 
opposed to in-patients. It is known that recruiting and retaining older participants is 
difficult, especially for research undertaken in the community (Provencher, 
Mortenson, Tanguay-Garneau, Belanger, & Dagenais, 2014; Warren-Findlow, 
Prohaska, & Freedman, 2003).  
 
With this in mind, reported barriers to patient participation and retention (Bower et 
al., 2009; Herrera et al., 2010; NIHR, 2010) were mitigated by recruiting through 
general practice because older adults will participate in research, if recommended by 
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their doctors (Jenkins & Fallowfield, 2000) or by someone they know (Edelman, 
Yang, Guymon, & Olson, 2013).  
 
Practice Managers of the two GP practices were key in the research. They acted as 
gatekeepers, identified participants and signed letters inviting participants to the 
study. The letter introduced me as the researcher, outlined the study and sought 
their participation in the study (Forster et al., 2010) (Appendix I). 
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5.6 Results 
5.6.1 Response Rate 
Of the 400 questionnaires sent to participants, 155 were returned (response rate of  
39%). Six questionnaires were excluded from the final analysis for not providing 
information on medications. At the end of round 1 of mailing questionnaires, 69 
responses were received. Response from site SG was particularly low, only 15 
questionnaires were returned. Reminder letters sent to all 331 non –responders in 
round 2 (i.e. Week 4) generated only 28 more responses. The offer to win one of five 
£10 vouchers in the third round increased the number of responses. About one-third 
of the total responses (n=58) were received in the third round (Table 5.1). 
 
Table 5.1:  Weekly record of response to survey 
 
Weekly mailing No of responses  
Site NZ 
No of responses  
Site SG 
First mail out    
Week 1 10 7 
Week 2 27 6 
Week 3 17 2 
Week 4 (Reminder letters posted) 5 4 
Week 5 3 3 
Week 6 8 5 
Week 7 (New study pack posted with 
the offer of winning a voucher) 
2 2 
Week 8 11 22 
Week 9 19 2 
 
Total  
 
102 
 
53 
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5.6.2  Participants’ Characteristics 
Fifty-one percent (n= 76) of respondents were females and 47.7% (n= 71) males, 
two participants did not indicate gender. The majority (106; 71.1%) belonged to the 
youngest age group of 65-74years. No respondent was 95 years or older. About half 
of the participants (73; 49.6%) lived with a partner or spouse while 31.3% lived 
alone. Most respondents identified as White (126; 85.7%); about 10% were of Black 
or Black British origin and only 1% Asian or Asian British (Table 5.2).  
There was almost an even split in educational level between responders: 70 (46.9%) 
had some form of further education after secondary school. The majority had been to 
a technical college (42; 60%), university (18; 12.1%), distance learning or a 
correspondence course (2; 1.3%). Eight participants (5.4%) had other forms of 
further education i.e. professional qualifications in teaching, accountancy and 
nursing.  Two participants did not specify their level of education. The remaining 77 
respondents (51.2%) had no further education or training after secondary school.   
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Table 5.2: Demographics of all participants (n=149) 
 
Characteristics Total (%) 
 
Age group 65-74 
 
106 (71.1) 
75-84 
 
33 (22.1) 
85-94 
 
10 (10.0) 
>94 0 
Sex Male 
 
71 (47.6) 
Female 
 
76 (51.0) 
Not specified 2 (1.3) 
 
Ethnic background White 
 
126 (84.5) 
Asian or Asian British 1 (0.7) 
 
Black or Black British 15 (10.0) 
 
Mixed/Multiple background 3 (2.0) 
 
Other Ethnic Group 2 (1.3) 
 
Not specified 2 (1.3) 
 
Education  Tech College 42 (60.0) 
University 18 (12.1) 
Distance learning 
/Correspondence 
2 (1.3) 
Others 8 (5.4) 
No further education 77 (51.2) 
Not specified 2 (1.3) 
 
Living arrangement Alone 
 
46 (30.9) 
With partner/ 
spouse 
73 (49.0) 
With partner/ 
spouse and children 
15 (10.1) 
With children 
 
7 (4.7) 
Other 
 
5 (3.3) 
Not specified 3 (2.0) 
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5.7 Prevalence and Patterns of Concurrent Use among UK 
 Community Dwelling  Older Adults 
 
Six participants did not provide any information on medications used and were 
excluded from the final analysis. Of the 149 participants included in the study, fifty 
(33.6%) or about one in three respondents reported the use of other medicines aside 
those prescribed by a healthcare practitioner in the last 12 months.  
 
Females were more likely than males to be concurrent users (43.4% versus 22.5%, 
P= 0.009) (Table 5.3). There is little difference between groups that had or had no 
further education with each having about a third reporting concurrent use. Similarly, 
there were little differences between the categories of living arrangements. Those 
living with children reported somewhat lower levels of concurrent use, but this was 
not statistically significant. 
 
a. Concurrent Use 
Table 5.4 shows the number of non-prescribed medicines used by the participants, 
ranging from 1 to 8, with a mean value of 3 (standard deviation =1.65, median=1). 
Concurrent users (n=50) reported 55 herb-drug and supplement-drug combinations. 
Most concurrent users (39; 79.6%) used both HMPs and DS (including vitamins and 
minerals) with prescription drugs. 
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Table 5.3: Demographic of concurrent users and non-concurrent users (n =  
       149) 
Characteristics Concurrent 
users  
n = 50 (%) 
Non-
Concurrent 
users 
n = 99 (%) 
Total P valuea 
 
Age group 65-74 
 
37 (34.9) 69 (65.1) 106 (100) 
p = 0.729 
75-84 
 
11 (33.3) 22 (66.7) 33 (100) 
85-94 
 
2 (20.0) 8 (80.0) 10 (100) 
Sex Male 
 
16 (22.5) 55 (77.5) 71 (100) 
p = 0.009b 
Female 
 
33 (43.4) 43 (56.6) 76 (100) 
Not specified 1 (50.0) 1((50.0) 2 (100) 
 
Ethnic 
background 
White 
 
40 (31.7) 86 (68.3) 126 (100) 
p = 0.184 
Asian or Asian 
British 
1 (100.0) 0 (0.0) 1 (100) 
Black or Black 
British 
5 (33.3) 10 (66.7) 15 (100) 
Mixed/Multiple 
background 
1 (33.3) 2 (66.7) 3 (100) 
Other Ethnic 
Group 
2 (100.0) 0 (0.0) 2 (100) 
Not specified 1(50.0) 1(50.0) 2(100) 
 
Further 
education  
Yes 
 
24 (34.3) 46 (65.7) 70 (100) 
p = 0.862 
No 
 
25 (32.5) 52 (67.5) 77 (100) 
Not specified 1(50.0)  
 
2(100) 
 
Living 
arrangement 
Alone 
 
17 (37.0) 29 (63.0) 46 (100) 
p = 0.929 
With partner/ 
spouse 
26 (35.6) 47 (64.4) 73 (100) 
With partner/ 
spouse and 
children 
4 (26.7) 11 (73.3) 15 (100) 
With children 
 
2 (28.6) 5 (71.4) 7 (100) 
Otherc 
 
1 (20.0) 4 (80.0) 5 (100) 
Not specified 0 3 (100) 3(100) 
 
 
aFisher’s Exact test, bStatistically significant result (p < 0.05), cSuch as living with friends or 
relatives 
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b.  Prescription Drugs 
All the 149 participants were taking one or more prescription drugs regularly, ranging 
from 1 to 18 (Median =3) (Table 5.4). A total of 180 different types of prescription 
drugs were reported (mean = 3.96, standard deviation = 2.52). Table 5.5  shows the 
most reported drug classes as statins (69; 46.3% of respondents), beta blockers (26; 
17.4%), calcium channel blockers (23; 15.4%), non-steroidal anti-inflammatory drugs 
(NSAIDs) (19; 12.7%), biguanides (18; 12.1%), angiotensin-converting enzyme 
(ACE) inhibitors (18; 12.1%) and proton pump inhibitors (18; 12.1%). 
 
Table 5.4. Number and frequency of prescription medicines reported by participants 
 
No of prescription 
medications 
 
Frequency 
 
Percentage 
 
1 18 12.1 
2 28 18.8 
3 25 16.8 
4 20 13.4 
5 18 12.1 
6 11 7.4 
7 12 8.0 
8 3 2.0 
9 1 0.7 
10 3 2.0 
11 1 0.7 
18 1 0.7 
information not provided  8 5.4 
Total 149 100.0 
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Table 5.5 Range of prescription drugs reported by participants  
 
Drug class by BNF sections (Joint 
Formulary Committee, 2016) 
Prescription Drugs N % 
2.5 Hypertension & Heart Failure  
 
Renin-Angiotensin System Drugs 
 
 
Alpha-Adrenoceptor Blocking 
 
 
Ramipril 
Lisinopril 
 
Tamsulosin 
Doxazosin 
 
 
18 
11  
 
8 
11 
 
 
12.1 
7.4 
 
5.3 
7.4 
2.8 Anticoagulants and Protamine Warfarin 10  6.7 
2.4 Beta-Adrenoceptor Blocking Drugs  
 
Beta blocker  
 
 
Atenolol, Bisoprolol 
 
 
26  
 
 
17.4 
6.1 Drugs used in Diabetes 
 
Biguanides  
 
 
Metformin 
 
 
18 
 
 
12.1 
3.1 Bronchodilators  Salbutamol (Ventolin) 
inhaler 
11  7.4 
9.5 Minerals  
Calcium 
 
Adcal- D3 
 
5  
 
3.3 
2.6 Nitrates, Calcium Channel Blockers 
& Other Antianginal Drugs 
 
Calcium channel blockers 
 
 
 
Amlodipine 
 
 
 
23  
 
 
 
5.4 
2.2 Diuretics 
Loop Diuretic 
Thiazide diuretic 
 
Furosemide 
Bendroflumethiazide 
 
8  
9 
 
5.3 
6.0 
 
6.2 Thyroid and Antithyroid Drugs 
Thyroid hormones 
 
 
Levothyroxine 
 
 
13  
 
 
8.7 
4.7 Analgesics 
Opioid analgesics 
 
Aspirin 
Co-codamol 
 
19  
7 
 
12.7 
4.7 
1.3 Antisecretory Drugs and Mucosal 
Protectants 
Proton pump inhibitor  
 
 
Lansoprazole, 
Omeprazole, 
 
 
18  
 
 
12.1 
2.12 Lipid-Regulating Drugs 
Statins 
 
Simvastatin, Atorvastatin 
 
69  
 
46.3 
 
*only prescription drugs reported by 5 or more participants are listed on the table. 
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c. Herbal Medicinal Products (HMPs) 
Thirty-six different herbs (used either singly or as a combination product) were 
reported (Table 5.6). Figure 5.1 shows the most commonly used HMPs as evening 
primrose oil (Oenothera biennis)  used by 10.2 %,  a combination of hops (Humulus 
lupulus), valerian (Valeriana officinalis), gentian (Gentian) and passion flower 
(Passiflora) found in commercial products such as KALMS® and Nytol® used by 8.2 
%, garlic (Allium sativum , 6.1%), cinnamon (Cinnamomum zeylanicum, 4.1%), 
Lutein and Zeaxanthin (4.1%) which are naturally occurring carotenoids and 
Echinacea (Echinacea purpurea, 4.1%). Ten concurrent users (20%) used only 
HMPs with prescriptions. 
 
 
 
 
Figure 5.1: HMPs most frequently used concurrently with prescription drugs among 
UK older adults 
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Table 5.6 Range of herbal medicinal products reported by concurrent users (n= 49) 
 
Herbal medicinal  
product 
No of  
Users* 
 Herbal medicinal  
product 
No of  
Users* 
Arnica  1 Hawthorne 
 
1 
Arthrella 1 Herbal mixture remedy with 
local name 
 
2 
Artichoke 1  Lutein and Zeaxanthin 
(Retinex®, Visionace) 
 
2 
Bromelain 1 Mahanarayan oil 
 
1 
brown linseeds 1 mint green tea 
 
1 
Burdock 1 organic hemp oil  
 
1 
Cerassie (bitter melon) 1 Ortis cubes (Figs, Senna 
Leaves, lactose, tamarind 
pulp, natural orange extract) 
 
1 
Cinnamon 2 Peppermint 
 
1 
Combination of Hops, 
Valerian, Gentian, 
passionflower (KALMS®, 
herbal Nytol®) 
 
4 Rosehip  1 
cranberry tea 
 
1 Sage 1 
Echinacea  
 
2 Senna  1 
evening primrose oil 5 Stemflo (herbal supplement 
from extracts of Gotu kola, 
Indian gooseberry, Turmeric 
etc.) 
1 
flaxseed 1 St John’s wort 
 
2 
Garlic (garlic oil, Black garlic) 
 
3 Tamarind 1 
Gingko + Ginseng 
 (Sanatogen) 
 
1 Turmeric 1 
Green tea 1 Valerian  
 
4 
 
*Total number of users more than 49 as some individuals reported more than one HMPs 
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d.  Dietary Supplements 
Most concurrent users (n=39; 79.6%) were using DS, including vitamins and 
minerals (Table 5.7). Dietary supplements are concentrated source of a vitamin, 
mineral or other substance with a nutritional or physiological effect, alone, or in 
combination, sold in dose form.  
 
The most combined DS were cod liver oil, glucosamine, multivitamins and Vitamin D 
(Figure 5.2). Of the 50 concurrent users; 13 (26.5%) reported using both HMPs and 
DS concurrently with prescription drugs. 38.8% of concurrent users used three or 
more HMPs or DS concurrently with prescription drugs. 
 
 
 
Figure 5.2: Supplements most frequently used concurrently with prescription drugs 
among UK older adults 
 
*Percentages sum to more than 100% as individuals could report more than one HMP 
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Table 5.7 Range of DS combined with HMPs and prescription drugs 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* Total number of participants more than 49 as some individuals reported more than one 
dietary supplements 
 
 
 
 
 
Dietary supplements Number of 
participants taking 
named dietary 
supplement * 
As % of concurrent 
users (n= 49) 
Cod / Omega 3 Cod liver oils 23  
 
46.9 
Glucosamine (i.e. glucosamine 
Hcl, Glucosamine + Chondroitin, 
Glucosamine + Chondroitin + 
MSM, Glucosamine sulphate) 
 
15  30.6 
Multivitamins (i.e. Wellwoman®, 
Berocca®, centrum advance 
50+®) 
10  20.4 
Vitamin D 7  14.3 
Calcium  3  6.1 
Natural coenzyme Q10 3  6.1 
Zinc 3  6.1 
Magnesium 
 
2  4.1 
Omega 3 fish oils 2  4.1 
Vitamin C 2  4.1 
MSM (methylsufonylmethane) 
 
1  2.0 
B-complex  
 
1  2.0 
Epsom salts 
 
1  2.0 
Vitamin A  
 
1  2.0 
Vitamin E  1  2.0 
Iodine 
 
1 2.0 
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5.8 Associations between Demographic Factors  
 
Table 5.3 shows results of Fisher’s exact tests of the relationships between some 
demographic characteristics and the concurrent use of prescription drugs with 
HMPs. Most concurrent users were in the age group 65-74 years (n=37, 35%). 
However, no statistically significant association exist between age group and 
concurrent use of prescription drug and HMPs (p= 0.729). There was a statistically 
significant association between gender and concurrent use of prescription drugs and 
HMPs (p= 0.009). There were more female concurrent users compared to men 
(65.3% vs. 32.6%). And women were using more medications than men, 73.3% of 
those using 3 or more HMPs and DS were women (Table 5.3).  
 
There was limited response from people of BAME background and only five people 
who were Black or Black British (33.3%), and one participant each of Asian and 
mixed background reported concurrent drug use. Consistent with the overall sample, 
half of concurrent users had no further education after secondary school (n= 25, 
32.5%). The remaining concurrent users (24; 34.3%); 18 had further education from 
technical colleges and 6 were university graduates. There was no significant 
association between completing further education and concurrent use of prescription 
drugs and HMPs (p= 0.862). 
 
There was nothing distinctive to concurrent users when compared with non-
concurrent users with regards to living arrangements, although most concurrent 
users (26; 35.6%) lived with a partner or spouse. 
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5.9 Potential Interactions between HMPs/ Dietary Supplements 
 and Prescription Drugs 
 
Just over half of the 55 herb-drug and supplement –drug combinations (n=28, 
50.9%) were assessed as ‘no interaction’ or ‘no interaction of clinical significance’.  
Nevertheless, 21 combinations were interactions with ‘doubts about the outcome of 
concurrent use’, 3 combinations categorised as ’potentially hazardous outcome’ and 
another three of ‘significant hazard’ (Table 5.8).   
 
The herb-drug interaction assessments showed that 10 HMPs were involved in some 
risk of interaction.  The HMPs implicated in the potential risk for interaction include: 
 flaxseed 
 evening primrose oil 
 St John’s wort 
 peppermint,  
 Senna 
 Echinacea 
 Hawthorne 
 Ginkgo. 
 Green tea 
 
The five dietary supplements implicated in potential interaction are: 
 glucosamine 
 cod liver oil 
 omega 3 fish oil 
 calcium carbonate  
 a multivitamin.  
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The following 21 prescription drugs were involved with a risk of interaction; 
Levothyroxine, Ramipril, Gangfort, Lansoprazole, Metformin, Amlodipine, aspirin, 
Bisoprolol, Propranolol, Rivaroxaban, Lisinopril, Indapamide, Co-codamol, 
Paracetamol, Furosemide, Bendroflumethiazide, Simvastatin, Nifedipine, 
Trimipramine, Rabeprazole, Simvastatin. 
 
Most identified interactions involved potential alterations in the concentration or 
effect of the prescription medications, which included calcium channel blockers, 
HMG-CoA reductase inhibitors (statins) and aspirin.  
 
Of all the potential herb-drug and supplement –drug interactions, only seven were 
hazardous (Table 5.8). These relates to increase in blood-glucose concentrations, 
risk of bleeding and reduced efficacy or bioavailability of the prescription drug.  
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Table 5.8 Evaluation of HMPs/ Dietary Supplement - Prescription medicine Potential Interactions  
 
HMPs/ Dietary 
Supplement 
 
Prescription medicine 
[no of patients a] 
Possible interactions * 
HDI Interaction category:    significant hazard, Dosage adjustment or close monitoring is needed 
 
Bonecal Levothyroxine  
 
 
 
Case reports describe reduced levothyroxine effects in patients given 
antacids containing magnesium, aluminium, or a combination of both. 
Peppermint Lansoprazole 
 
Antacids may compromise the enteric coating of some commercially 
available peppermint oil capsules. H2-receptor antagonists and proton 
pump inhibitors may interact similarly. 
 
St John's wort Amlodipine St John's wort significantly reduces the bioavailability of nifedipine and 
verapamil. Other calcium-channel blockers would be expected to interact 
similarly. 
 
HDI Interaction category:  A potentially hazardous combination 
 
Glucosamine Metformin In a controlled study, glucosamine supplements with chondroitin had no 
effect on glycaemic control in patients taking oral antidiabetic drugs but 
increases in blood-glucose concentrations have occurred in patients with 
treated and untreated diabetes. 
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Omega 3 fish oil 
 
Bisoprolol [2] 
 
The hypotensive effect of propranolol might be enhanced by fish oils. 
Ginkgo Rabeprazole 
 
Ginkgo induces the metabolism of omeprazole. Most other proton pump 
inhibitors are likely to be similarly affected. 
 
HDI Interaction category:     Doubt about outcome of concurrent use b 
 
Omega 3 fish oil 
 
Aspirin [2] The concurrent use of aspirin and fish oils caused at least additive effects 
on bleeding time in healthy subjects, but clinical studies in patients taking 
aspirin alone and with clopidogrel have found no evidence of an increase in 
incidence of bleeding episodes. 
Cod liver oil Aspirin [2] The concurrent use of aspirin and fish oils caused at least additive effects 
on bleeding time in healthy subjects, but clinical studies in patients taking 
aspirin alone and with clopidogrel have found no evidence of an increase in 
incidence of bleeding episodes. 
Cod liver oil Bisoprolol 
Propranolol 
The hypotensive effect of propranolol might be enhanced by fish oils. 
 
Flaxseed Rivaroxaban Limited evidence suggests that flaxseed oil may have some antiplatelet 
effects, which could be additive with those of conventional antiplatelet drugs 
and increase the risk of bleeding with anticoagulants. 
Green tea Lisinopril 
 
Both black and green tea might cause a modest increase in blood pressure, 
which might be detrimental to the treatment of hypertension. Green tea 
reduced the effects of nadolol on blood pressure in healthy subjects. 
Senna pods Indapamide Theoretically, patients taking potassium-depleting diuretics could 
experience excessive potassium loss if they also regularly use, or abuse, 
anthraquinone-containing substances such as Senna. 
Glucosamine Co-codamol 
Paracetamol 
Limited evidence suggests that glucosamine might reduce the efficacy of 
paracetamol (acetaminophen). 
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Glucosamine Furosemide 
Bendroflumethiazide [2] 
 
Limited evidence from a large open study suggests that unnamed diuretics 
might slightly reduce the efficacy of glucosamine to some extent. 
Echinacea Midazolam 
 
Echinacea does not appear to alter the AUC and clearance of oral 
midazolam, although the bioavailability may be increased. Clearance of 
intravenous midazolam may be modestly increased in patients taking 
Echinacea. 
Hawthorne 
 
Nifedipine  
 
Limited evidence suggests that there may be additive blood pressure-
lowering effects if hawthorn is taken with conventional antihypertensives, 
but the effects are small. 
Visionace® (lutein, 
carotenoids, myrtillus, 
flavonoid compounds) 
Lansoprazole 
 
The desired effect of beta carotene supplementation may be reduced in 
those taking proton pump inhibitors. 
Evening primrose oil 
 
Aspirin Evening primrose oil can inhibit platelet aggregation and increase bleeding 
time. It has therefore been suggested that it may have additive effects with 
other antiplatelet drugs, but evidence of this is generally lacking. 
 
* Potential interaction reports from Stockley’s Herbal Medicine Interaction. 
a The number of patients exposed to the particular combination of HMPs /DS and prescription drug 
bGuidance about possible adverse effects, and/or some monitoring may be needed 
AUC- area under the plasma drug concentration-time curve 
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5.10 Benefits and Side Effects from the Concurrent Use of 
 Prescription Drugs and HMPs  
 
In response to the question on the perceived benefits from using herbs and HMPs, 
many concurrent users (n= 17, 34.7%) reported that it helps to maintain bone health. 
Participants also reported that HMPs treat arthritis and help mobility (35.9%), prevent 
health problems (30.6%), ease pain (22.4%), useful when feeling unwell (16.3%), 
improves digestions (8.2%) and gives strength (6.1%). Only one participant thinks 
HMPs help other medications work better. Interestingly, nineteen (38.7%) concurrent 
users reported that HMPs or DS were recommended to them by a healthcare 
professional. 
 
Forty-four of the 49 concurrent users answered the questions on side effects from 
taking HMPs. However, only two male participants had experienced a side effect. 
One participant reported stomach upset and frequent toilet visits after taking a liquid 
herbal remedy used for the treatment of haemorrhoids and impotency.  The name of 
the remedy was provided in local dialect by one participant and the other participant 
wrote ‘local remedy’ on the questionnaire. Another participant taking StemFlo® (a 
blend of antioxidants and enzymes that supports optimal blood circulation) and Stem 
Release3® (supports natural release of stem cells) once daily, reported high blood 
pressure as a side effect from taking these supplements. Both supplements were 
discontinued by the second participant on the advice of his GP. 
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5.11 Places of Purchase of HMPs and DS 
Herbal medicinal products and DS used by the participants were mainly purchased 
from health food shops (29%) and supermarkets (24.6%). Only 9.2% purchased 
HMPs from herbalists (Table 5.10). Other sources of HMPs and DS were over the 
internet (13.8%), through mail order and catalogues (9.2%). Most concurrent users 
bought commercially produced HMPs and DS over the counter in form of capsules, 
tablets and syrup. And only three participants (4.6%) had HMPs prepared by or 
purchased from herbalists. 
 
Table 5.9  Places of purchase of HMPs and DS 
 
Place of purchase Concurrent 
users with fewer 
than 3 HMPs 
Concurrent 
users with 3 or 
more HMPs 
Total 
(% of total) 
Pharmacy 
 
7 5 12 (18.5) 
Health food shop 
 
10 9 19 (29.2) 
Online 
 
5 4 9 (13.8) 
Supermarket 
 
7 9 16 (24.6) 
Herbalist 
 
1 2 3 (4.6) 
Others 
 
3 3 6 (9.2) 
Total 33 32 65 (100) 
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5.12 Discussion 
Almost one-third of older adults in this sample were currently using some form of 
HMPs or DS concurrently with prescription drugs. Among concurrent users, about 
33% were at risk for a potential interaction. The most commonly used HMPs were 
evening primrose oil (Oenothera biennis)  a combination of hops (Humulus lupulus), 
valerian (Valeriana officinalis), gentian (Gentian) and passion flower (Passiflora) 
found in commercial products such as KALMS® and Nytol® garlic (Allium sativum ), 
cinnamon (Cinnamomum zeylanicum), Lutein and Zeaxanthin and Echinacea 
(Echinacea purpurea ). The most combined DS were cod liver oil, glucosamine, 
multivitamins and Vitamin D. And simvastatin, atorvastatin, amlodipine, aspirin, 
bisoprolol and metformin were the most frequently used prescription medications. 
And the most commonly combined prescription drugs by older adults were statins, 
antihypertensive drugs, beta blockers, diuretics, antihyperlipidemic agents, 
anticoagulants, analgesics, antihistamines, antidiabetics and antidepressants. These 
are similar to the range of prescription medications reported by older adults in 
previous studies (Qato et al., 2016). The number of prescription drugs each 
participant took ranged from 1 to 18, and 35 % were taking 5 or more prescription 
medications. This figure is consistent with a recent study of the US population which 
reported more than 1 in 3 older adults use 5 or more prescription medications 
concurrently (Kantor, Rehm, Haas, Chan, & Giovannucci, 2015). The number of 
HMPs and DS used by concurrent user ranged from 1 to 8, with almost half of 
concurrent users using three or more HMPs and DS with prescription drugs. 
 
Previous studies reported prevalence of concurrent prescription drugs, herbal 
medicines and DS use among older adults varying widely from 9% to 88.3% 
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(Batanero-Hernán et al., 2017; Blalock et al., 2009; Dergal et al., 2002; Elmer et al., 
2007; Loya et al., 2009; Ly et al., 2002; Nahin et al., 2009; Peklar et al., 2014; Peng 
et al., 2004; Yoon & Horne, 2001; Yoon & Schaffer, 2006).  The prevalence of 
concurrent use in this study (33% ) is similar to that from a descriptive questionnaire-
based study among community dwelling older adults on the US- Mexico border, 
34.6% of participants reported use of at least one herbal product (Loya et al., 2009). 
It is also in the range of another US study with 38% prevalence rate, conducted 
among primary care older adults (Peng et al., 2004). However, two studies from the 
United States reported lower prevalence rates of 15% (Elmer et al., 2007) and  
22.8% (Ly et al., 2002). The study by Elmer and colleagues was secondary analysis 
of data from a large sample of 5,052 older adults. While the study by Ly and 
colleagues had a smaller sample size of 285 primary care patients aged 65 years 
and older.  
 
The reported prevalence of concurrent prescription drug and HMPs use among older 
adults vary widely. This is often due to the different definitions adopted for HMPs, the 
types of HMPs assessed and demographic characteristics of participants. There are 
inconsistencies on what may or may not be included as HMPs. Some studies 
exclude vitamins and minerals (Blalock et al., 2009; Elmer et al., 2007), other studies 
included DS, vitamins and minerals (Dergal et al., 2002; Kaufman et al., 2002; Nahin 
et al., 2009; Peklar et al., 2014; Singh & Levine, 2007). A current systematic review 
concluded that although the prevalence of concurrent prescription and HMPs use 
among older adults varies widely between different countries, it is however 
substantial (Agbabiaka et al., 2017). 
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Certain demographic and clinical characteristics are associated with concurrent 
medicine use. Women (Canter & Ernst, 2004; Qato et al., 2008), oldest age groups 
(Kaufman et al., 2002), people with chronic conditions such as diabetes and high 
blood pressure (Peklar et al., 2014; Singh & Levine, 2007), those with less than a 
high school education (Delgoda et al., 2010; Peklar et al., 2014) and those on low 
income (Delgoda et al., 2010) were more likely to be concurrent users. The majority 
of concurrent users in the current study were women (n=33; 66.7%), confirming 
previous findings that women tend to use more herbals and DS than men (Canter & 
Ernst, 2004; Farina et al., 2014; Qato et al., 2008). In fact, up to 60% of women in 
the oldest age groups use prescription medications in combination with herbal DS 
(Qato et al., 2008). Increased odds for a co-user to be female (34% vs 18%, p= 
0.001) has also been confirmed (Djuv et al., 2013). Higher herbal medicine use 
among women is likely to be for many reasons. Generally, women tend to live longer 
than men, they are main carers for children and older people; also responsible for 
buying medicines and remedies for the home and tend to use weight loss products 
than men. Although concurrent use was highest in the age group 65-74 years 
(24.1%) but declined among those 75 years and older. A similar trend was reported 
in the use of herbal medicines  by Arcury and colleagues (2007). 
 
The varying prevalence of concurrent prescription drugs and HMPs use among older 
adults from different countries suggests that the use of herbal medicines differs 
between countries and ethnic groups (Arcury, Suerken, et al., 2006; Cherniack & 
Pan, 2004; Raji et al., 2005). The 2007 USA National Health Interview Survey 
reported nearly 20% herbal use in the general population (Barnes, Bloom, & Nahin, 
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2008) . While the Czech (Schoen et al., 2007) and Saudi-Arabian (Elolemy & 
Albedah, 2012) population studies reported higher herbal use (50-57%) compared to 
the USA population. As ethnic groups favour certain herbal medicines over others 
(Cherniack et al., 2008), differences were observed in the HMPs and DS used by the 
different ethnic groups reported by Elmer and colleagues(Elmer et al., 2007). African 
Americans used significantly more garlic (p =.003) and cod liver oil/fish oil (p < .001) 
and less glucosamine and lecithin (p ≤ .001 for both). However, no significant 
differences were found in the use of ginseng, gingko, or CoQ10 between African- 
Americans and White participants. Due to low response of non- white participants in 
this study, it was not possible to assess differences in the use of HMPs among 
ethnic groups. 
 
A total of 20 potential interactions affecting 7 older adults were identified, 
predominantly classified as doubts about the outcome of concurrent use, and three 
combinations potentially hazardous and another three as significant hazard. This 
suggests that 1 in 7 of all concurrent users were at risk of a potential interaction. 
While the potential for herb-drug interactions and supplement –drug interaction has 
been reported in studies from the USA (Elmer et al., 2007; Loya et al., 2009; Ly et 
al., 2002; Peng et al., 2004; Sultan, Viqar, Ali, Tajik, & Jahangir, 2015) , no previous 
study has reported the prevalence and severity of these interactions among UK older 
adults. 
 
In this study, concurrent use of prescription drugs and HMPs was similar across 
educational levels. The number of concurrent users with further education was like 
those without further education. Although available evidence suggests that 
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concurrent herb-drug use was greater amongst individuals with education no higher 
than secondary level (Delgoda et al., 2010; Peklar et al., 2014).  And higher 
education was associated with a lower probability of potential interaction and those 
with less than a high school education 70% more likely to exhibit at least one 
potential interaction (Singh & Levine, 2007).  
 
Supermarkets and health food stores were the most common places to purchase 
HMPs and DS in this study. Previous studies have reported sources of information 
on HMPs as recommendation by friends and family, internet, magazine, physician, 
CAM practitioner (Molassiotis et al., 2005; Vickers et al., 2006). However, very little 
is available in the literature regarding where HMP is purchased or sourced.  
 
 
5.13 Strengths and Limitations of the Survey 
This study has investigated concurrent prescription and HMPs use among older 
adults, whereas previous studies have looked at any conventional medicines, 
including over-the-counter medicines. This study is unique in that participants were 
community dwelling older adults recruited from general practices, whereas previous 
studies have researched patients with specific conditions. Also, this is the only UK 
study on concurrent herbal and prescriptions medicines use among older adults in 
over ten years. 
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The survey provided important information about participant’s demographics, the 
types of herbal and prescription medicines, how they are combined and potential 
interactions. It also allowed for demographic characteristics such as age group 
gender and education between concurrent user and non-concurrent users to be 
examined and explored.  
 
Response rate to postal questionnaires are often poor, and could be as low as 20% 
(Kelley et al., 2003). Low response rates increase the potential for bias and threaten 
study validity (Cook, Dickinson, & Eccles, 2009). For these reasons, a larger sample 
size is required to ensure respondents reflect demographic profile of the survey 
population and there is enough data for reliable analyses. The response rate of 39% 
for this study was substantial and enough to provide credible findings. Post hoc 
power calculations showed that the 155 responses achieved rather than the intended 
minimum of 171 still provides almost as much power as the 171 would have done. 
Every effort was made to increase responses; contact was made with participants 
three times even though some authors suggested two contacts (Bryman, 2012; 
Edwards et al., 2002; Edwards et al., 2009). Although there is limited evidence for 
health care research on how to improve response to postal questionnaires in patient 
populations (Nakash, Hutton, Jørstad-Stein, Gates, & Lamb, 2006), follow-up 
strategies such as reminder letters, postcards, repeat mailing or telephone contact 
are good ways to increase responses (Edwards et al., 2009; Salim Silva, Smith, & 
Bammer, 2002). However, the ethics of repeated patient contact and whether this is 
acceptable and would not cause distress to patients must be properly considered. 
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The survey also confirmed findings from the literature review that there was no 
consensus regarding the terms used for herbal medicines or herbal medicinal 
products. And although every effort was made to explain what was meant by HMPs 
and examples were provided. It was clear that some participants did not consider 
products such as garlic or ginger as HMPs and did not report them in the 
questionnaire. Therefore, the use of these HMPs also commonly used as foods may 
not have been well reported. It was also clear from responses that participants did 
not differentiate HMPs from dietary supplement, so non-herbal DS were reported. 
Therefore, it was decided to analyse and report non-herbal DS as well, even though 
the focus of the study was HMPs including herbal DS. 
 
Questionnaire surveys are not without limitations. Although efforts were made to 
include participants from all ethnic backgrounds, respondents were largely from 
white background. And so, the sample may not be representative of the UK mixed 
population. Also, using postal questionnaires was an expensive approach to data 
collection. Online or telephone survey would probably have been less expensive, but 
the study population was 65 years and older, and are more likely to respond to 
postal questionnaires, so this was the preferred option.  
 
Although the survey provided an overview of the HMPs and supplements used by 
older adults alongside prescribed drugs and the potential interactions. However, it 
did not provide an understanding of the reasons why older adults concurrently use 
medications, their views and experiences. Also, it provided limited data about 
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whether HMPs were regarded as preventive, curative or palliative (i.e. for symptom 
management). This was explored in the next phase of the study using semi-
structured interviews. The survey data informed how participants were identified for 
in-depth interviews as it ensured that those recruited were willing to participate, were 
taking HMPs alongside prescribed medication and were typical of this population. 
Findings from the survey also informed areas to further explore within the qualitative 
interviews and informed development of the interview guide (Appendix F). 
Specifically, it was necessary to explore during the interviews if participants are 
aware of possible interactions from combining HMPs with prescription medicines, 
and if they discuss using HMPs with healthcare professionals. 
 
5.14 Chapter Summary 
This chapter presented results from the cross-sectional survey, providing 
demographic characteristics of the participants, the prevalence of concurrent use of 
HMPs, DS and prescriptions drugs among a sample of UK community dwelling older 
adults. The names and the types of HMPs, DS and prescription drugs combined 
were provided. An assessment of potential interactions between the medicines 
reported revealed some potential risks of adverse herb-drug interactions. 
 
The results from this quantitative study provide an insight into the prevalence and 
pattern of concurrent prescription drugs and herbal medicinal products (HMPs) use 
among community dwelling older adults in the UK. The findings demonstrate that 
certain combinations of prescription drugs and HMPs can have serious 
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consequences and contributes to the growing literature supporting evidence that 
concurrent drugs use among older adults is substantial.  
 
Findings from a qualitative study to understand why older adlts concurrently use 
HMPs, Ds and prescription drugs will now be explored in Chapter 6. The Chapter will 
provide detailed accounts of the main themes from the interview data. This relates to 
the decisions and motivations to concurrently use HMPs and DS with prescribed 
medicines. 
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Chapter 6: Understanding Concurrent 
use of HMPs and Dietary Supplements 
with Prescription Drugs among Older 
Adults 
 
6.1 Introduction to Chapter 
The previous two chapters (systematic review and questionnaire survey) focused on 
answering questions on prevalence of concurrent use, what medications older adults 
combined with prescription drugs and possible interactions from such combinations. 
The systematic literature review (Agbabiaka et al., 2017) and cross-sectional survey 
(Agbabiaka et al., 2018) confirmed that concurrent use of herbal medicinal products 
(HMPs) and dietary supplements (DS) with prescription drugs is substantial among 
older adults. However, there is limited information about the reasons for concurrent 
use. Therefore, it is necessary to explore why older adults concurrently use HMPs or 
dietary supplements alongside prescribed medicines and understand the 
experiences of concurrent users.  
 
The aims of the qualitative study reported in this chapter were: 
 To explore reasons why older adults concurrently use HMPs and DS with 
prescription drugs 
 To understand their experiences of concurrently using HMPs and DS with 
prescription drugs. 
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This qualitative phase of the study builds on the quantitative findings described in 
Chapter 5 to explore what drives concurrent HMPs, DS and prescription medicine 
use among older adults.   
 
The chapter begins with an overview of the interview participants; including their 
characteristics and the HMPs and DS they were taking. The chapter provides an 
overview of the main themes and sub-themes in relation to what contributes to the 
decision by older adults to concurrently use HMPs and DS with prescription drugs.  
 
6.2 Description of Interview Participants 
Of the 149 survey participants 19 indicated in their response that they were happy to 
be interviewed for Phase 2 of the study. By the time of the interviews, two 
participants had moved away from the area. Four people subsequently changed their 
mind and declined to be interviewed; two declined due to ill health. A total of 13 older 
adults, were interviewed between 30 November 2015 and 16 August 2016. Most of 
the participants belonged to the age group 65-74 years; eight women and five men. 
They have been identified with a code, made up of the study centre (NZ= Practice A; 
SG= Practice B) and a number. For example, SG 070 denotes Participant number 70 
from Practice B. Table 6.1 provides an overview of interview participants. 
 
 All the 13 participants have been using HMPs and/or DS for a period ranging 
between 5 and 20 years. Consistent with the overall survey sample, most interview 
participants (i.e. 8 out of 13) were in the age group 65-74 years. Ten were White 
British, two self-identified as Black, first generation immigrants (one African and the 
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other Caribbean) and one from mixed/multiple background (i.e. white and black 
African). The majority lived with their spouse or partner (n=8). Only two participants 
were university graduates, but all had pursued other forms of training after 
secondary school. All the interviews but one was conducted individually, a couple 
(NZ 068 and NZ 069) was interviewed together at their request. Interviews lasted 
between 25 and 45 minutes and were conducted in English.  
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Table 6.1: Characteristics of interview participants including participant’s demographics, names and number of medicines reported. 
 
Code Sex  Age 
group 
Ethnicity Education Living 
arrangement 
Prescription drugs 
(total) 
HMPs/dietary 
supplements (total) 
SG 003 
 
M 65-74 Black Further 
education/ 
Tech college 
Living 
alone 
Metformin (1) combination of herbs  
SG 070 
 
M 75-84 Black Further 
education/ 
Tech college 
With partner/ 
spouse 
Insulin (1) Garlic, golden seal, Red 
clover, Dandelion roots, 
oleander (5) 
SG 072 
 
M 65-74 White University Living 
alone 
Methamphetamine (1) cod liver oil (1) 
SG 181 
 
F 65-74 Mixed Further 
education/ 
Tech college 
With partner/ 
Spouse/ 
children 
Amlodipine,  
Atorvastatin (2) 
multivitamins & minerals,  
Vitamin D3, Iodine 
calcium magnesium with 
Vitamin D3,  
Joint care (Glucosamine, 
chondroitin &MSM,  
Omega 3,  
Mahanarayan oil,  
Arthrella (8) 
 
NZ 001 
 
F 85-94 White Other forms of 
further 
education 
Living 
alone 
Atenolol, 
Bendroflumethiazide, 
Macushield, Adcal-D3 (4) 
herbal tincture containing 
celery seed, Bog bean, 
Artichoke, Black cohosh 
etc.  for arthritis 
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Code Sex  Age 
group 
Ethnicity Education Living 
arrangement 
Prescription drugs 
(total) 
HMPs/dietary 
supplements (total) 
NZ 045 
 
M 75-84 White Further 
education/ 
Tech college 
With partner/ 
Spouse/ 
children 
Metformin, Tamsulosin, 
Lamotrigine, 
Omeprazole, Allopurinol, 
Losartan,  
Aspirin (7) 
Vitamin D3 (1) 
NZ 068 
 
M 65-74 White Further 
education/ 
Tech college 
With partner/ 
spouse 
Ramipril, 
Bendroflumethiazide, 
Doxazosin, Tamsulosin 
(4) 
Glucosamine sulphate 
(1) 
NZ 069 
 
F 65-74 White Further 
education/ 
Tech college 
With partner/ 
spouse 
Bendroflumethiazide, 
Lisinopril, Lansoprazole,  
Ventolin inhaler,  
Clenil modulite inhaler 
(5) 
Glucosamine,  
Visionace Plus (2) 
   
NZ 070 
 
F 75-84 White No further 
education 
Living 
alone 
Alendronic acid, 
Calcichew D3 Forte, 
Aspirin, Bisoprolol, 
Losartan, 
iron magnesium  
hydroxy carbonate  
Lansoprazole (7) 
cod liver oil, Vitamin A, 
Vitamin D,  
KALMS (Hops, Valerian, 
Gentian) (4) 
NZ 084 
 
F 65-74 White Further 
education/ 
Tech college 
With partner/ 
spouse 
Ramipril, 
Amlodipine,  
Levothyroxine, Calcium 
(4) 
Cod liver oil,  
evening primrose oil 
  
2 
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Code Sex  Age 
group 
Ethnicity Education Living 
arrangement 
Prescription drugs 
(total) 
HMPs/dietary 
supplements (total) 
NZ 142 
 
F 75-84 White No further 
education 
Living 
Alone 
Cetirizine, Estradiol 
patches (3) 
Opti-omega3,  
Glucosamine + 
Chondroitin,  
Cod liver oil,  
St John’s wort (4) 
 
NZ 146 
 
F 65-74 White University With partner/ 
Spouse 
Simvastatin,  
Lisinopril,  
Lansoprazole (3) 
Glucosamine + 
Chondroitin + MSM,  
Green lipped muscle,   
CoEnzymeQ10 (5) 
 
NZ 199 
 
F 65-74 White No further 
education 
With partner/ 
Spouse 
Tramadol, 
Amlodipine, 
Paracetamol (3) 
Turmeric, 
Cinnamon, 
KALMS (Hops, Valerian, 
Gentian) (3) 
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6.3 Why Older Adults Concurrently Use HMPs and DS with 
 Prescription Drugs 
 
How the participants engaged with the interview was revealing about how they 
understood the use and place of HMPs as an adjunct to their medication. All thirteen 
participants were happy to talk to me. Some of the participants had assumed that I 
was a doctor and were puzzled as to why a doctor was so interested in their use of 
herbal medicines. They were interested in knowing more about the study; particularly 
why I thought it was an important issue to research. This was explained as being 
because their previous experiences with GPs and some other healthcare 
practitioners have been that of little or no interest with regards to herbal medicines, 
abrupt or judgemental discussions. When they realised that I was neither a GP nor a 
healthcare practitioner, this changed the dynamic of the interview and participants 
appeared more open about their medication use. For example, NZ146 offered me a 
drink, became more expansive in her answers and voluntarily showed me containers 
of her HMPs and supplements. It may also have been an early indicator, 
subsequently demonstrated (see below), that participants did not perceive there was 
a connection between HMPs and prescribed medication. 
 
Many of the participants stated that they did not consider HMPs or DS to be 
medicines. Rather, they were regarded as remedies or the ‘help yourself’ products to 
be used as and when required. They did not see that decisions about taking HMPs 
needed discussion with anyone. The suggestion that combining their prescriptions 
with HMPs and DS could be unsafe had not been considered. In fact, only two 
participants demonstrated an awareness of potential interactions and described how 
they considered the implications of concurrently using HMPs or supplements with 
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their prescribed medicines. One was a retired nurse, who suffers from arthritis, and 
will only consult and buy her remedies from a registered herbal medical practitioner. 
The other participant was a retired schoolteacher who also suffers from arthritis; she 
described how she checked online for information on HMPs and supplements and 
participates in online forums of complementary medicine users. 
 
I belong to a sort of blog site online for arthritis and so all these people, you know, 
they come up with these different things that you’ve probably never heard of. 
And they’ve tried it, they swear by it and all the rest of it, and it was like the MSM 
(Methylsulfonylmethane) which I started using about two years ago. I suddenly read 
this and there was a little string of information, I don’t know, from people that had 
used it or were using it and I thought “do you know what? I’ll give that a try. Where 
on earth do, I get it from?” Anyway, I sourced it from Holland & Barrett, they actually 
do it in a capsule with the Chondroitin and the other things, and I started taking it… 
                   (NZ199, Female, 75-84 years, White) 
 
There were recurring and overlapping themes that explained why the participants 
choose to concurrently use HMPs and DS with prescription drugs (Figure 6.1). The 
cross-cutting narrative however was one that participants perceived HMPs as 
helpful, easing and improving health problems but low impact and not essential and 
by association safe and harmless. There was no expectation that HMPs were 
curative. 
 
Six themes that captured the recurring patterns in the interview data explained the 
range of experiences and underlying reasoning as summarised in Table 6.2, with full 
codes (nodes) listed in Appendix H.  The six main themes are: values and beliefs, 
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decision to use HMPs and DS, sources of information and advice, self-management 
and taking control, disclosure and non-disclosure, potential herb-drug interactions. 
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Table 6.2 Codes and categories from the analytic framework 
 
Themes 
 
Values and 
Beliefs 
Decision to use 
HMPs or DS 
Sources of 
information and 
advice  
 
Self- management 
and taking control 
Disclosure and 
Non-disclosure 
 
Potential  
herb-drug 
interactions 
 
Codes 
 
Length of 
use 
 
They work 
but don’t 
know how 
they work 
 
herbal 
medicines 
are natural 
and safe 
 
 
Convenience and 
access to 
conventional 
medicine 
 
Previous negative 
experience of 
using conventional 
medicines 
 
 
 
 
 
 
 
Family and 
friends 
 
Online sources 
 
Healthcare 
professionals 
 
Herbalists and 
other CAM 
practitioners 
 
 
HMPs and 
supplements for less 
serious conditions  
 
Maintaining and 
improving health and 
day to day ailments 
Trial and error 
 
 
 
Disclosure and 
Non-disclosure 
 
 
Knowledge of 
herb-drug 
interactions 
 
Experience of 
herb-drug 
interactions 
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6.4 Values and Beliefs 
There was an underlying assumption at the start of the study that traditional beliefs, 
custom and practice within families and ethnicities play an important part in the 
decision to use herbal medicine, and the HMPs that they decide to use. However, 
most participants in this study were of White British background. There was very little 
in the data to suggest that using herbal medicine was due to family traditions, ethnic 
or cultural beliefs, but there was evidence of family members influencing decisions to 
try HMPs or not. For many, the conviction to use HMPs arose from personal 
experience of using them over many years, testimonies from friends, wanting to 
avoid problems that others had experienced and from internet searches. For some 
participants, the use of HMPs and supplements could be linked to key events or 
people in their lives. As the quote below demonstrates, HMPs were taken on the 
recommendation of a family member or online discussions with peers. These were 
seen as having a positive effect, but participants were cautious in claiming it had 
cured the condition. The assumption was they were not doing any harm, NZ 199’s 
daughter-in-law told her about turmeric tablets and bought her the first pack when 
her arthritis became problematic. 
 
Every morning I take two Tramadol and one blood pressure pill and, yeah, turmeric. I 
reckon they’re good. My daughter-in-law, well, one of them anyway, got me onto 
these (turmeric tablets). I think they’re really good, really good. I’m gonna say that. I 
mean, at the moment my arthritis is terrible, but my hair has got thicker, I don’t know 
if it’s anything to do with them. 
       (NZ199, Female, 75-84 years, White) 
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NZ 070’s account was different. For her, it was something her mother had done and 
now she was continuing its use, hoping it slows down the progression of her arthritis, 
even though she did not know if it was effective. 
 
Well because I understood it was good for joints and my mother had arthritis quite 
badly and I had a hip replacement now, but prior to that it had been troublesome for 
years really, gradually getting worse. And my thumbs [laughs] very ugly now, but I 
don’t know if that [cod-liver oil] helps or not because I take it and I have taken it 
probably for 20 years. I sort of like to think that I’d be worse if I didn’t take it, but I 
don’t exactly know too much about the action of it on the body. 
      (NZ 070, Female, 75-84 years, White) 
 
For another participant, the decision to use HMPs was influenced by the information 
and experiences of other people that she read on blogs and online chat groups. 
 
I belong to a sort of blog site on there for arthritis and so all these people, you know, 
they come up with these different things that you’ve probably never heard of that 
they have tried. And they’ve tried it, they swear by it and all the rest of it, and it was 
like the MSM which I started using about two years ago, I suddenly read this and 
there was a little string of information, I don’t know, from people that had used it or 
was using it and I thought “do you know what, I’ll give that a try…                                                                          
       (NZ146, Female, 65-74 years, White) 
 
The two participants that identified with a family history or cultural background of 
using herbal medicines were African and Afro-Caribbean.  As the quote below 
demonstrates, the use of HMPs was rooted in having limited access to formal health 
care, possibly due to cost as well as a community knowledge of which HMPs could 
be used for different conditions. 
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... I am Jamaican, well we believe in…., we don’t call it herbal. But as far as we are 
concerned that is what we know about, what is available to use. It’s our natural and 
traditional. Traditional… that is our belief. That is our system, we don’t see a doctor. 
Well, you see my mother had 12 kids, we never see a doctor. So, you grew up with 
this knowledge of what is available. What to do and what to take and that’s why … 
     (SG 070, Male, 75-84 years, Black- Caribbean) 
 
The African participant has a similar narrative although with emphasis on the belief 
and understanding that herbal medicine works. 
 
… In Africa it’s common, because most of the time you can't even afford to go to the 
hospital. You know yourself [referring to me], so most of them rely on the… you 
know herbal medicine, which is effective, most of them are very good. Because, well, 
I mean, I know a lot of them (herbs). You see, when we were young, our parents, 
they used to heal us with those (herbs). There was a tree in the farm, they’d go for 
the bark of it, put it in a pot, put pepper and everything, boil it. Every morning you 
have to drink it before you go to school. You see, and it kept us very, very strong. 
So, I think, to me, [laughs] I prefer that.  
      (SG 003, Male, 65-74 years, Black-African) 
 
a.  Length of use 
The systematic review and survey findings were unclear about how people used 
HMPs and DS or if there were different patterns of use. For example, if they were 
used when there was an exacerbation of ill health, or if HMPs were seen more as 
prophylactics.   
 
All those interviewed were long term users, with length of use ranging from 5 years 
to over 20 years. It was difficult for some participants to recount or explain why they 
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started using HMPs, but after using them for such a long time, they see no reason to 
stop. They believe it had helped in treating their symptoms or promoted good health 
and some had evidence of what happened when they stopped taking the HMP. 
 
Yeah. I did stop taking 'em [glucosamine) last Christmas I think it was, and I thought 
perhaps I don't need 'em, but after about three months my knees and my hip ached 
and I started taking 'em again, and it gradually got better, so I, it's quite good at them 
now...      (NZ 069, Female, 65-74 years, White) 
 
And for NZ 199: 
I don’t take it all the time that actually. I take it, um, I mean I think, there are certain 
things that I take all the time because if I stop taking them my arthritis gets worse 
again within sort of two or three weeks of stopping taking them. So, I tend to take 
them all the time. But I stay on the lowest doses possible that they recommend. 
      (NZ199, Female, 65-74 years, White) 
 
 
b. ‘They work but don’t know how they work’ 
Participants were often unsure of how the HMPs or DS worked for their conditions 
but continued to buy and use them. Interestingly, some of them also talked about 
their prescription medications in a similar manner. For example, NZ 070 was told by 
a friend that KALMS Lavender© tablets helps with anxiety. She (NZ 070) bought 
some over the counter to relieve her anxiety during a long journey with another older 
driver to Blackpool. She was calmer during the journey but uncertain if it was due to 
the tablets or not.  
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Whether they worked or not, I don’t really know, but I made the journey without 
having a heart attack [laughs]… And I took some again; I had a journey at the 
weekend which was an even longer one to Blackpool with an elderly driver aged 94  
      (NZ 070, Female, 75-84 years, White) 
 
In the case of NZ 068, she wanted to avoid or delay the need for what she saw 
would be the unpleasant procedures associated with managing the macular 
degeneration in her eyes. So, she sought less invasive and less painful alternative. A 
supplement was suggested by her doctor. Although she could not say that it was 
certainly due to the supplement, she attributed the stabilising of her condition to the 
HMP.  
 
It could be coincidence, we don't know, but I will take them (supplement) 'cos I don't 
have to have an injection in my eye, 'cos they inject right into the eye. And I said to 
them (Doctor), 'is there any supplement I can take' and they said 'anything with 
Lutein in' which this has [referring to the supplement], and I haven't had the injection 
now for about eighteen months.  
       (NZ 068, Male, 65-74 years, White) 
 
And NZ 084 said although Evening Primrose oil helped her through menopause, but 
she has no idea how. 
 
... When I was going through the menopause, I decided to take Evening Primrose Oil 
and I mean, I just sailed through the menopause. Yes, like hot flushes and those 
sorts of things and I just found that I just felt better because I was taking it, whether 
it’s a psychological thing, I don’t know but I always take it … 
      (NZ084, Female, 65-74 years, White) 
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c. Herbal medicines are natural and safe  
The intrinsic safety of HMPs was a recurring theme. The overarching narrative was 
one that saw HMPs and supplements as helpful, easing and improving chronic 
conditions, but low impact and natural. This was integral to discussions about other 
issues such as non-disclosure to GPs, because HMPs were not perceived to be 
worth talking about. They were being used to supplement, or possibly augment the 
main action of the prescribed medication. 
 
The perception of products as natural and are therefore safer than conventional 
medicines was linked to their perceived provenance. Herbal medicines were 
described as from plants; organic and thus synonymous with being natural and 
therefore free from the side effects or adverse reactions associated with 
conventional medicines.  
 
According to NZ 069, 
You don't know if they're doing any good but they're definitely doing no harm, so… 
                  (NZ 069, Female, 65-74 years, White) 
 
 
This extended to how they were made as well as the ingredients used, not only were 
they safe, they were not as strong or potent. For example, one participant compared 
the safety and effectiveness of HMPs with prescription medications; 
 
Um, they’re produced more naturally [i.e. herbal medicines] whereas prescription 
medication things are added, it’s from plants alright but things are added to them to 
be effective or maybe even more effective. But when you get something like the 
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Arthrella, it’s produced naturally too but the extra things added to make them more 
effective are not there so it’s safe…  
   (SG181, Female, 75-84 years, mixed/multiple background) 
 
This contrasted with the perceived danger of some prescription medicines, where 
HMPs were represented as safer alternatives. NZ146 was wary of taking more 
prescription medicines and the side effects associated with them. 
 
Interviewer: Before you tried these supplements and herbal medicine did you try 
any prescription medicine for these aches and pains? 
NZ146: Well they just said take Ibuprofen. Really? I mean they said, “if it gets much 
worse, we can put you on these”, I don’t know what they were called to be honest 
with you but they’re really strong drugs with quite a side-effect. I don’t know whether 
they’re steroids or something, I’m not really sure what they are. But I really didn’t 
fancy taking them, I’ve got to be honest with you. And so, I was quite seriously 
looking round for some sort of herbal thing that I could use that wasn’t going to have 
those awful side-effects from the sort of manufactured drugs. Because I do, I do feel 
that the drugs that we get are actually only there for us because they’re there to 
make the drug companies a lot of money and they’re not necessarily the best things 
for you. 
      (NZ146, Female, 65-74 years, White) 
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6.5 Decision to use HMPs or dietary supplements 
In addition to the participant’s values and beliefs regarding HMPs and DS (Section 
6.4) the interviews explored how other factors influencing the decision to use HMPs 
and DS with prescription drugs. The responses focused on two main areas: 
convenience and access to conventional medicine and their previous negative 
experiences with conventional medicine. 
 
a. Convenience and access to conventional medicine 
Primary care is usually the patient’s first route to diagnosis and treatment. In the UK, 
the GP and their teams are the most commonly used access point to the NHS. 
Participants explained the popularity of HMPs and DS particularly among older 
adults as being partly due to the inconveniences they experienced in accessing the 
GPs. This led to their taking control of their situations and seeking alternative more 
readily available options like HMPs and supplements to treat their symptoms. The 
problems with access to a GP was a recurring theme in the interviews and 
participants spoke about difficulties in booking appointments with the GP, insufficient 
time to discuss their symptoms, compounded by waiting times of up to two weeks or 
more. This woman described the encounter with GPs as impersonal, 
 
Yeah, they don’t have time, 10 minutes is ridiculous, isn’t it? Before when you go to 
the doctors, they go, “How’s your mum? How’s that?” But nowadays you’re just in 
and out. They know my husband; they know because we’ve been going ever since 
we lived here. But no, they don’t go, “How’s your husband?”  The girls on the 
reception do, they know us really well but once you go into the doctors, no, they 
 165 
 
don’t. I find that they’re very impersonal… as you’re talking to her; she’s writing you a 
prescription. That’s not family doctors, well, they’re not… 
      (NZ 199, Female, 65-74 years, White) 
 
For some, avoiding the effort of getting to the GP outweighed the cost of using an 
HMP. 
I suppose, to be honest, because I don’t like going to the doctor very often. I haven’t 
got a fear of the doctor or anything but I just, I suppose, can’t be bothered and as 
you say, it is, these things, over the counter medicine, is expensive but hmm… 
 
       (NZ 070 Female, 75-84 years, White) 
 
All participants were 65 years or older and eligible for free prescriptions. They were 
however willing to spend between £5 and £50 monthly on HMPs or DS. The cost of 
complementary medicines was discounted against the perceived benefits especially 
if the prescribed medication was not alleviating symptoms or problems e.g. Pure Cod 
Liver Oil with Evening primrose for healthy bones and muscles. 
 
Because I don’t feel I could get these on prescription and I just feel that they are 
beneficial to me because I’ve been taking them for many years and I just feel, you 
know, it’s not about the cost now but the benefit you get from it.  
No, that’s right. The cost is not important, no. I mean I would shop around and get 
them cheaper, but I did get those, it was buy three for two or something. 
 
               (NZ 084, Female, 65-74 years, White) 
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Participants described a range of routes to sourcing HMPs and supplements. These 
were supermarkets, health shops, mail order catalogues and the internet. The 
majority (n=8) of these purchases were impersonal and did not involve advice 
seeking or discussion about options. 
 
Well I mostly source it on the Internet first and if I think Holland & Barrett do it then I 
will get it from there probably. Like the MSM and the Chondroitin and that sort of 
thing, they do that, so I’ve just stuck with them. Although I think there are other 
places on the Internet that I can, where I can get it. I think Health Nature or 
something, they do it and, but I just find it easier to get to the Holland & Barrett, 
mainly because they’re just around more. And they have their penny sales so it’s 
always a little bit more… 
      (NZ146, Female, 65-74 years, White) 
 
 
A few participants bought from popular health shops, with regular discounts and buy 
one get one free offers attracting them to buy more. 
 
Yes, I always buy it from Holland & Barrett, you get three for two. And I pay, I think, I 
just bought some actually; I think it’s £27 for three. 
      (NZ 069, Female, 65-74 years, White) 
 
Three participants (NZ 001, SG 181 and SG 003) had consulted herbal medicine 
practitioners and purchase their supplies from them. SG 070 is himself a natural 
medicine practitioner. 
 
And it was while I was on the south coast; the manufacturers of Vegitex gave up, 
sold up. And so, it was then, that I thought have to go to an herbalist, which of 
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course is a lot more money. And it was the herbalist that picked up my erratic blood 
pressure… 
      (NZ 001, Female, 85-94 years, White) 
 
 
b. Previous negative experience of using conventional medicines 
 
The side effects or adverse reactions from conventional medicines and procedures 
are why some participants turned to HMPs and DS. Some of them described their 
experiences as unpleasant, uncomfortable or very painful.  
 
I was getting quite a lot of discomfort here [she points to the side of her face] and I 
didn’t want an eardrum washout. You know what they are? Is where they flush it and 
the gook comes out, but it doesn’t cure it. All it does is that it flushes out your 
sinuses, but it flares up again. So, I have garlic ever since and it controls that [the 
sinuses] I would have had sinus trouble. So yes, I have proved medically it helped. 
 
      (NZ 001, Female, 85-94 years, White) 
 
 
So, they would rather actively seek and take alternative medicines which they 
believe treat their symptoms and have minimal side effects. 
 
Some years back, because a medicine like Co-codamol, I took it and it nearly killed 
me. So, from then, I say these tablets, no more. My stomach, I had a stomach upset, 
I tried to vomit, I couldn't, and I became sort of, you know, I was, I was very 
uncomfortable, so I have [laughs], I have sworn not to take Co-codamol again. 
 
      (SG 003, Male, 65-74 years, Black-African) 
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There is awareness that as they are getting older, they were being prescribed more 
medications, and with that came additional risk which informed why some 
participants used HMPs. Paradoxically, it was an awareness of the problems and 
interactions associated with polypharmacy that could trigger considering HMPs as an 
alternative for the increasing number of health problems experienced. 
 
Yeah. As you get older, you’re sort of looking for things, aren’t you? Because you do 
develop things and you just think “oh do I have to put up with this? Can I go on this 
medicine or that medicine and what are the consequences of that? And I’m sure 
there are things that help arthritis a lot but unless I have to take them, I’m not going 
to, if you see what I mean? I mean I will go along while I can use just the herbal 
medicines because I don’t like the look of the drugs that they’re using. And I’m pretty 
sure that the drug, the drugs that are available, all, for everything virtually are only 
available there because somebody’s making a lot of money and we all know who 
that is. [Laughs]  
       (NZ146, Female, 65-74 years, White) 
 
 
 
6.6 Sources of information and advice  
a. Family and friends 
The interviews demonstrated that participants drew on a wide range of information 
and advice. These included family, relatives and friends, online sources, health care 
professionals and herbalists. Of these the most favoured were family and friends. 
For a few, family members were the main source of information and recommended 
HMPs or DS. 
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…Well, my daughter-in-law told me that it’s good for arthritis. I don’t know, that’s 
what she told me, and to take it. … yeah, I take them for arthritis … 
 
      (NZ 199, Female, 65-74 years, White) 
 
 
b. Online sources 
Online sources were not extensively used.  Of those interviewed, two described 
actively searching online for guidance and as this quote shows it was not a 
systematic process.  
 
I had problem with my knees as well, they were very painful, so I was sort of 
hobbling around really and my lower back is quite painful as well. So, I was in a bit of 
a state really and I didn’t really know whether to, what to do about it really. And in the 
end, I went onto the Internet and looked to see for these various things, and I found 
these blog sites and things. And they just come up with these things and I tried them 
and that was the thing (Green Lipped Mussel) that really worked for me. I mean I 
suddenly felt that the pain had gone, I didn’t get that aching at night, nothing was 
waking me up, and my knees got much better and it was just such a relief. 
 
       (NZ146, Female, 65-74 years, White) 
c. Healthcare professionals 
 
For two participants, and as counter to accounts that they were using HMPs to 
compensate for deficiencies in conventional medicine, it was the doctor, nurse or 
pharmacist who recommended HMPs or DS to them. These participants appeared to 
trust the recommendations of healthcare professionals over family and friends. So, 
when the recommendation to use HMPs or DS is from a healthcare practitioner, it is 
more likely to be taken more seriously. 
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... It was recommended by... I think he was just a pharmacist… the Cod Liver Oil. I 
just feel is good for helping bones, you know, osteoporosis, all those sorts of things 
that people get as they age. I’m okay, at the moment. 
 
              (NZ084, Female, 65-74 years, White) 
 
For another participant it was a doctor who suggested trying supplements and this 
validated the use of an HMP. The participant expected that the doctor would know, if 
there were potential interactions with the patient’s prescribed medication, or would 
have checked there is none before making the suggestion. 
 
I think it was the doctor there that suggested taking them (cod liver oil). He said, 
“Have you ever taken, other than prescription medicine?” and I said, “No.” So he 
said, “Well I advise you to take that.” And my husband did as well, so I’ve just kept 
on with them. You know, my doctor knew that I was taking them so I thought well, if 
he thought that I shouldn’t be taking them, they would say so, you know, but… 
 
      (NZ 142, Female, 75-84 years, White) 
 
 
d.  Herbalist and other CAM practitioners 
 
Four of the thirteen participants had consulted a professional medical herbalist for 
their conditions. In the case of NZ 001; a retired nurse, she was seeking relief from 
arthritic pains and did not want to be dependent on conventional pain reliefs because 
of the side effects. Her clinical and nursing background may be why she sought help 
from a qualified practitioner and not from the internet or other sources. 
 
In 2008, I consulted a medical herbalist who has a BSc in this subject. Before then, I 
discovered through trial and error a selection of mixed herbal combinations, sold as 
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tablets in the health store. I discovered one that worked. Before I was woken up with 
pain where I had former fractures as a result of two car crashes, I was not the driver. 
This type of arthritis, in my experience, responds to herbal treatment and I was 
reluctant to seek Ibuprofen, Voltarol etc. I found it was the right mixture when I slept 
through the night and didn’t need to take de-acidified aspirin. When the manufacturer 
(Lane’s) stopped manufacture, I then consulted the medical herbalist in Brighton. 
She is a young mother with school age children and as I need more of her mixture 
(in an alcohol base), so she posts them 2 litres at a time, which helps me a lot. 
      (NZ001, Female, 85-95 years, White) 
 
Interestingly, SG 003 (Black African male) also consulted an herbalist while he was 
on holidays back home in Africa. According to him, herbalists are still very relevant in 
modern day healthcare in Africa. He too recognised their qualifications as educated 
practitioners combining traditional approaches with modern techniques and 
equipment for diagnosis and treatment.  
 
6.7 Self-management and Taking Control 
Medication taking is a complex behaviour that involves multiple steps and decisions 
on the part of the patient. What was apparent from the older adults’ narratives were 
the desire to be in control and care for their health based on what worked for them 
and the differentiation between serious health problems that needed prescribed 
medication and minor conditions that could benefit from HMPs, Figure 6.1. 
 
The use of HMPs was expressed in terms of how they managed troubling symptoms, 
maintained existing health or dealt with problems where conventional medicine had 
 172 
 
failed.  This was seen as different to the activity of taking prescribed medication for 
specific health problems. 
 
a. HMPs and supplements used for less serious conditions 
Approaches to self-care included supplementing their prescribed medications with 
HMPs and/or DS, varying the dose of the prescribed medications to reduce the side 
effects, or using HMPs as supplement for what were perceived as less serious 
problems. A recurring narrative within this theme was the value of using HMPs in 
relieving symptoms as opposed to treating the underlying cause. These herbal 
medicines include evening primrose oil for menopausal symptoms, valerian for 
insomnia, Echinacea for colds and DS such as cod-liver oil and glucosamine for 
arthritis.  
 
Participants said they disliked conventional medicines and would not use them 
unless necessary, but this did not apply to those that were seen as curative and 
lifesaving. For example, conditions such as cancer, asthma and heart problems. The 
participants’ expectations of what HMPs could achieve for them were lower than for 
their prescribed medication. 
 
One participant reaffirmed her reliance on herbal medicines and supplements but 
said she would seek help from conventional doctors and rely entirely on prescription 
drugs, if she were to be diagnosed with cancer. In fact, she has maintained her 
yearly appointments with the heart specialist for the heart murmurs she was 
diagnosed with as a little girl. As this quote demonstrates the woman placed herbal 
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remedies as only to be used for minor symptoms and health problems, not ones that 
were life threatening. 
 
…you know, you might as well just persist with it until it stops working. If at some 
point it doesn’t work or if, I mean if I was to get something really serious like, you 
know, cancer or something like that, I wouldn’t be looking at the herbal side of things. 
I mean obviously I’d go straight to the medical profession and anything that was 
serious wrong with me obviously then I would do that. But I think if you’re looking at 
things where you’ve just got to live along with those conditions. 
      (NZ146, Female, 65-74 years, White) 
 
 
Another participant puts it differently; she relied on HMPs and DS for managing 
stress and anxiety but would seek help from the doctors if she were to get seriously 
ill or debilitated from any of these conditions. 
 
Well I wouldn’t go to the doctor and ask for something to calm me down unless I very 
seriously felt that I was ill, and I don’t feel I’m ill. When I am taking something 
because I’m a little bit stressed or because I’m going for a drive. So, I wouldn’t ask 
the doctor for treatment then. Possibly the same with cod liver oil because they’d 
probably say, well, you know, “You don’t really need it” [Laughs]. 
       (NZ 070 Female, 75-84 years, White) 
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b. Maintaining and improving health and day to day ailments 
Many participants used DS mainly to maintain or improve their health. This desire to 
keep the body strong, to continue leisure activities and daily chores was strongly 
expressed by many participants. Therefore, HMPs and supplements are used as a 
boost to keep on top of day to day living and coping with ageing.  
 
Two participants reported using HMPs and DS to improve their appetite and 
digestion. Participant SG 003 was convinced that the improvement he experienced 
with his appetite was due to a mixture of herbs he got from an herbalist while he was 
on holidays in Ghana. 
 
It helped me in eating well [referring to the herbal mixture], you know, because there 
are some foods that I like a lot, but when I eat it, it gave me some problems. But not 
when I had this medicine… 
       (SG 003, male, 65-74 years, Black) 
 
 
The majority reported more general benefits, in order to maintain health and keep 
well. 
 
Um, well, um, I shall be 77 next month and I just, I’m on the go the whole day, I very 
rarely sit down. Yes, I do get tired and I nod off perhaps when I’ve got the television 
on in the evening, but I feel fit. Cos I’m very active and, I don’t know if I told you on 
the phone, but I’m caring at the moment for a neighbour, so my energy levels have 
got to be..., I’ve got to keep going [laughs]. 
      (NZ 142, Female, 75-84 years, White) 
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No, no, no, no. Just to keep me as I am, hopefully [laughs] for a few years anyway. 
But yes, I know some people are real pill pushers, aren’t they, sort of thing? They 
just go on and go on and they can read something and think oh yes, I’ll try that, 
irrespective of whether it is doing them any good…  
      (NZ 142, Female, 75-84 years, White) 
 
c. Trial and error 
The data had shown that there were a wide range of influences and information 
sources used by participants. How often and how much they used HMPs and 
supplements appeared to be driven by trial and error, and how long they were 
prepared to persevere 
 
.…is it worth carrying on with this and just seeing, you know, a little bit longer?” And 
over the next week the symptoms, the gastric symptoms all went and then over the 
next two or three weeks I slowly upped the dose to two teaspoons. They recommend 
three flat teaspoons a day and I take two and that’s what I’ve stuck with because it 
does work for me. 
      (NZ146, Female, 65-74 years, White 
  
      
And for NZ 001: 
In 2008, I consulted a medical herbalist who has a BSc in this subject. Before then, I 
discovered through trial and error a selection of mixed herbal combinations, sold as 
tablets in the health store. I discovered one that worked. 
      (NZ  001, Female, 85-94 years, White) 
 
 
For many of the participants, nothing from the interviews suggests that they stopped 
taking their prescription medications altogether. Rather, the HMPs or DS were used 
concurrently or alongside the prescribed medicines. Therefore, suggesting that for 
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participants, the issue was not symptomatic of non-adherence or seeking 
alternatives to prescribed medications. 
 
 
In many of the accounts, the use of HMPs was for conditions or complaints were 
different from those that they were using prescribed medicines for. The condition or 
symptoms for which they were using HMPs or DS were not diagnosed by a doctor. 
One female participant spoke of the pain she was experiencing and her assumption 
that nothing could be done with conventional medicine. 
 
 
… I’ve got to be honest with you I’ve never really gone to the doctors to have my 
arthritis confirmed but I’ve had it for years now and it’s progressively got slightly 
worse… I would say over the last sort of seven or eight years. And I just think it is 
osteoarthritis. It’s just wear and tear and I don’t honestly think if I went to the doctors 
about it, they could really do anything much. I mean if I was so crippled that I couldn’t 
walk then I would but what I do seems to make a lot of difference to me and so I’m 
happy to stick with that because I can lead an active and much more normal life just 
using those herbal supplements… 
       (NZ146, Female, 65-74 years, White) 
 
 
 
Medication sharing is one form of self-medication often seen among older adults. 
And often it involves lending and borrowing of prescription medications between 
family members, friends and acquaintances. The interviews showed that not only 
were prescription medications shared, but so were HMPs and DS. Three participants 
told me that they share or swap with family and friend’s herbal product or 
supplement that has resolved a condition or symptom for them, to try them out 
before deciding to buy. Or in some cases, it was simply because they ran out of 
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supply and would borrow a few tablets until they can get to the shops to buy or 
before their online or mail orders were delivered 
 
Yes, that’s in a different box because the gentleman that I’m caring for, he’s had, he 
has cod liver oil and Chon, Chon, Chondroitin. I don’t know whether it’s the same as 
that, but he has them from this firm and he’s had them for years and he ran out and I 
gave him one of my packs. Of course, when he got his next lot, he gave me a pack 
back but that’s why it’s a different manufacturer… 
     (NZ142, Female, 75-84 years, White) 
 
6.8 Disclosure and Non-disclosure 
Most of the participants in this study did not consult their doctors, pharmacists or 
other healthcare practitioners before starting HMPs or DS. Eight of the 13 
participants were using HMPs and supplements without the knowledge of their 
doctors or other healthcare practitioners. The participants did not think there was 
need to inform the doctor since they did not ask. Some of the participants may have 
provided this information if they were asked by the GPs or other healthcare 
practitioners. 
 
No. No, they haven’t, no. I mean, they never ask me what I’m on. They just look and 
see what I’m taking from them. 
       (NZ146, Female, 65-74 years, White) 
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In some cases, the participants too did not think it was important to let them know of 
the other medicines they were taking 
 
Um, probably because they didn’t ask. It didn’t occur to me that it would be 
important, no. They’ve never asked me, in fact, you saying about they could have a 
counter-effect, yeah, I’m not aware of that.   
      (NZ 084, Female, 65-74 years, White) 
 
Participant NZ 199 thinks that the GPs are non-empathic to her condition. Therefore, 
she did not see reason to share her use of HMPs with them. In this case, she found 
Turmeric tablets helpful in relieving her arthritic pains, but the GP was dismissive. 
So, she never talked about her use of HMPs with healthcare practitioners. She was 
reluctant to talk to me about her non-disclosure of HMPs to healthcare practitioners 
and changed the subject when asked. 
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6.9 Potential Herb-Drug Interactions  
a.  Awareness of herb-drug interactions 
The awareness of possible herb-drug interactions from the co-use of prescriptions 
with HMPs or DS varied among the older adults. For many participants, HMPs and 
DS were believed to be safe.  
 
A few participants have considerable knowledge of potential risks from combining 
prescription drugs with herbal medicines and supplements. And these participants 
either sought advice from a healthcare practitioner or searched the internet for 
information about the HMPs or DS and any potential side effects before using them. 
Those participants with an awareness of herb-drug interactions had a clinical 
background, went to University or technical college.  
 
Not without asking the pharmacist because, because if, if I didn’t take anything, I 
might, you know, if I was 50 and on no medication, I probably would try it without 
discussing it with the pharmacist. But as I’m on all this medication I wouldn’t take 
anything without discussing it. 
      (NZ 070, Female, 75-84 years, White) 
 
 
For SG 181, she was aware and concerned about side effects from conventional 
medicines. Although the conventional medicine may be working to treat her 
condition, it may have unwanted side effects or cause long term harm. So, the need 
to either not use it all the time or use a lower dose and look up to HMPs to act as 
important supplements. Like many older adults in this study, she had not considered 
that the HMPs could interact with her prescription drugs and cause side effects, 
which may be serious. 
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Um, the prescription medication is something like Panadol, from which I will get the 
relief. But what I’m saying is that the daily use of it is not what I feel is not right… 
 
   (SG 181, Female, 65-74 years, mixed/multiple background) 
 
 
 
b.  Experience of herb-drug interactions 
One participant reported experiencing side effects from a DS. According to her, she 
was visiting the toilet frequently and unable to leave the house. However, she did not 
stop taking the supplement until the reaction stopped because it helped with the 
pains in her hips and knees and therefore it was worth it. 
 
… Anyway I sourced it from Holland & Barrett, they actually do it in a capsule with 
the Chondroitin and the other thing, and I started taking it because there are all these 
warnings about, you know, it might give you gastric upsets and all the rest of it . And 
I thought “well I’ll try it”. And I tried it and I did have a few problems for the first sort of 
week or so but, although I only took a very small dose, but then at the end of the 
week I thought “oh do you know what, I don’t know if I can take this” because I 
couldn’t really go out anywhere, you know, I had to keep going to the loo basically. I 
had to keep going to the loo basically. And [laughs], and then I thought “but just a 
minute, your hip doesn’t ache anymore in bed and your knees are not hurting and 
your fingers are fine”! 
       (NZ146, Female, 65-74 years, White) 
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Regardless, it could not be assumed that people will not seek help from the GP if 
there were adverse events. Two male participants also experienced some side 
effects. One of them reported stomach upset and frequent toilet visits after taking a 
liquid herbal remedy used for the treatment of haemorrhoids and impotency. The 
name of remedy was provided in local dialect by the participant who wrote ‘local 
remedy’ on the questionnaire. Another participant taking StemFlo® (a blend of 
antioxidants and enzymes that supports optimal blood circulation) and Stem 
Release3® (supports natural release of stem cells) once daily, reported high blood 
pressure as a side effect from taking these supplements. Both supplements were 
discontinued by the second participant on the advice of his GP. 
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Figure 6. 1: Concurrent use of HMPs and dietary supplement with prescriptions drugs among older adults 
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6.10 Strengths and Limitations of the In-depth Study 
A major strength of this qualitative study is that it explored in-depth the reasons why 
older adults concurrently use HMPs, dietary supplements and prescription medicines 
and explained the factors that may influence this behaviour. I was reflexive 
throughout the study with regards to how my own social, academic and personal 
backgrounds may potentially compromise the way in which I interpreted participant’s 
narratives 
 
This study is limited by the fact that the sample of participants were self-selecting 
older adults (n=13), all of whom had been taking HMPs for a sustained period of 
time. The interviews did not capture older people who had tried HMPs and then 
discontinued using them. Moreover, most participants were White and primarily 
British. Therefore, the findings are not necessarily inclusive of the views of older 
adults from other cultures and ethnic backgrounds. The findings from the two 
participants with BAME background did suggest that they drew on traditional 
remedies and beliefs. Nevertheless, participants revealed a wide range of reasons 
for taking HMPs concurrently with prescribed medications, sources of information 
used and recurring issues around ease of access, wanting to delay the effects of 
ageing, and differentiating between minor and serious problems. All of which 
suggests that a range of experience of using HMPs concurrently with prescribed 
medication was captured. 
 
In addition, only participants who were long term users of HMPs and DS are 
represented in this study, those who had tried HMPs or DS and then stopped were 
not captured. Therefore, further research is needed to understand these different 
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groups i.e. those who are regular users, those who try and give up and those who try 
it every now and again. 
 
6.11  Conclusion 
This qualitative element of the study explored further the review and survey findings 
to provide in-depth understanding of the reasons why older adults concurrently use 
HMPs and dietary supplement with prescription drugs. The interviews demonstrate 
the wide range of motivations and sources of information that older adults draw on in 
making the decision to concurrently use HMPs or dietary supplements with 
prescription drugs.  
 
Older adults were pragmatic in the use of HMPs and dietary supplements in the 
hope that they work and would continue to use them unless proven otherwise. The 
possibility of interactions by combining them with their prescribed medications was 
not recognised and participants were willing to experiment and sample a range of 
products until they found one that suited them. Many did not think of them as 
medicines per se and might partly explain why they did not see them as harmful, and 
worth trying. For many participants, the purpose was to delay the effects of ageing, 
keep well and deal with minor complaints. Disclosure of HMPs and supplement use 
to GPs were infrequent. The only examples being when there was an adverse event, 
there were low expectations that the GPs would be interested. 
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6.12 Chapter Summary 
This chapter presented an overview of the main themes arising from the semi – 
structured interviews with 13 participants in relation to why older adults concurrently 
use HMPs and dietary supplements with prescription drugs. The motivations and 
decision to concurrently use prescribed medications with HMPs and DS is captured 
through the accounts of community dwelling older adults. It goes on to explain what 
influences these decisions and how it manifests into some self-management 
behaviours or strategies.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 186 
 
Chapter 7: Discussion of Findings 
7.1 Introduction to Chapter 
This chapter draws together findings from the three phases of the study to answer 
the study objectives and research questions regarding the concurrent use of 
prescription drugs and herbal medicinal products (HMPs) among UK older adults.  
To demonstrate how this work contributes to new knowledge concerning the 
concurrent use of prescriptions drugs and HMPs among older adults, the discussion 
addresses the key findings from all phases of the work in relation to the research 
questions and the existing evidence. In this Chapter, particular attention will be given 
to how little empirical work has previously been completed in this area, the 
methodological challenges in this study and whether the findings about perceptions 
of safety and the challenges of accessing health care are specific to the experience 
of older people.  
 
The aim of the mixed method explanatory study is to understand the concurrent use 
of prescription drugs and herbal medicinal products (HMPs) among older adults. 
Specific objectives and research questions for the individual phases were: 
Phase 1: Systematic literature review 
 What is known about the concurrent use of prescription drugs and herbal 
medicinal products (HMPs) among older adults? 
 What patient and clinical characteristics are associated with concurrent use of 
prescription drugs and HMPs? 
 What are the risks of concurrent prescription drug and HMPs use in older 
adults? 
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Phase 2: Questionnaire survey 
 What is the prevalence and patterns of concurrent prescription drugs and 
HMPs use among UK community dwelling older adults? 
 What types of HMPs and prescription drugs are concurrently used? 
 What is the potential herb-drug interactions from the HMPs, and 
prescription drugs reported? 
 What patient and clinical characteristics are associated with concurrent 
HMPs and prescription drugs use? 
 
Phase 3: In depth exploration of older adults’ experiences of using HMPs with 
      prescribed medications 
 Why do older adults concurrently use prescription drugs, HMPs and dietary 
supplements (DS)? 
 What is the experience of concurrent users? 
 
7.2 What is known about the concurrent use of prescription 
 drugs and herbal medicinal products (HMPs) among older 
 adults? 
 
a. Literature Evidence 
The review and survey addressed this question and demonstrated that concurrent 
prescription drugs and HMPs use among older adults is widespread, with potentially 
serious herb-drug interactions from certain combinations. Whilst Previous studies 
have examined the use of herbal medicines among older adults (Bruno & Ellis, 2005; 
de Souza Silva et al., 2014; Gonzalez-Stuart, 2011) and potential interactions with 
conventional medicines (Dergal et al., 2002; Loya et al., 2009). The new learning is 
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about concurrent use of HMPs and DS with prescription drugs among older adults. 
Specifically, there has been no research on this issue conducted in the UK on older 
adults for over a decade. The findings demonstrated the existence of an elastic 
understanding of what is meant by old age and very little systematic work around the 
use of HMPs for conditions and medications common in old age.  
 
b. Prevalence and Patterns of Concurrent Prescription Drugs and HMPs 
 Use 
Among 15 of the studies included in the review, the prevalence of concurrent 
prescription and HMP use varied widely between 5.3% and 88.3%, while this study 
estimated it to be 33.5%. An accurate estimate of the prevalence of concurrent 
HMPs use with prescription medicine is difficult, because of the array of definitions 
adopted for HMPs, what is considered an HMP or not, non-disclosure, as well as the 
way information about concurrent use was collected. Therefore, it is reasonable to 
assume that the review and survey have identified an important and under-
researched issue. However, the true prevalence of concurrent prescription drug and 
HMPs among older adults is likely to be higher. Effort was made in this study to 
explain what was meant by HMPs with examples provided, because some 
participants may not consider products containing garlic and ginger as HMPs. Future 
studies may need to consider the most common phrases and terms to describe 
HMPs and always include these in questions and study materials. Providing some 
examples of the products being researched could also help participants in providing 
relevant responses.  
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The introduction of this thesis noted the previous attempts at definition and 
regulation. The findings from this study would suggest that this is important; not 
having a shared understanding of what HMPs are is a barrier to public 
understanding, professional guidance and future research. 
 
c. Most Frequently Combined Prescription Drugs  
According to review evidence, the prescription drugs most commonly combined with 
HMPs  are beta blockers, diuretics, antihyperlipidemic agents, anticoagulants, 
analgesics, antihistamines, antidiabetics, antihypertensive drugs, antidepressants, 
non-steroidal anti-inflammatory drugs (NSAIDs) and statins  (Batanero-Hernán et al., 
2017; Djuv et al., 2013; Nahin et al., 2009). Unsurprisingly the same classes of drugs 
were reported by participants in the Phase 2 survey of this research, confirming the 
findings of previous studies. This suggests that the participants were typical for their 
age group. 
 
The study findings demonstrate the importance of focusing on this population as 
being potentially more at risk of adverse drug reactions secondary to use of HMPs 
with prescribed medication. Medication use increases with ageing (Gao et al., 2017; 
Health and Social Care Information Centre, 2015; Qato et al., 2016) and the average 
person over 65 years will be on five or more prescription drugs (Franchi et al., 2014; 
Guthrie et al., 2015). Participants in this study however described the difficulties of 
access and a belief that their health issues were not of interest to clinicians. Whilst it 
is not possible to prove that HMP use was a response to lack of access and 
increasing difficulty in managing health problems. There were multiple examples of 
where this was a preferable option to seeing a GP. Other studies have highlighted 
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the difficulties older people experience in continually accessing health care services 
(Allin, Masseria, & Mossialos, 2011; Mohan, Nolan, & Lyons, 2019; Reeves et al., 
2018).  Social exclusion and isolation can compound this experience (Ford, Wong, 
Jones, & Steel, 2016). The findings of this study are an expression of what is known 
about the difficulties this population face in accessing the advice and support they 
need and how proximity to a GP will affect access to services. 
 
d. Most Frequently Combined HMPs  
The survey further confirmed what was already reported in the literature regarding 
the most frequently combined HMPs with prescribed medicines. Evening primrose oil 
(Peklar et al., 2014), Ginkgo biloba (Elmer et al., 2007; Ly et al., 2002), garlic (Dergal 
et al., 2002; Loya et al., 2009) and Echinacea (Nahin et al., 2009) were the most 
used HMPs by survey participants.  Other HMPs reported in the literature include 
ginseng, St John’s wort (Yoon & Schaffer, 2006), Saw palmetto (Peng et al., 2004), 
and ginger (Delgoda et al., 2010).  
 
Survey participants in this study also reported Valerian, Nytol herbal© (a commercial 
combination of hops, valerian, gentian and passionflower), and cinnamon. These 
HMPs were not frequently cited in the literature. The differences in the types of 
HMPs used by older adults in this study and those reported in previous ones may 
indicate a changing and expanding herbal medicines market. Europe is the second 
largest market for natural therapies and remedies due to large disposable income 
(Grand View Research, 2019). Another explanation for this difference is increased 
awareness of healthy lifestyle, which is  raising demands for food supplements for 
healthy aging (CBI, 2018). More people are experimenting and trying out new or 
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foreign health foods, natural cosmetics and natural hygiene products (Nirmal SA, 
2013).  
 
The range of HMPs taken by older adults are used to manage degenerative or age-
related conditions (Williamson et al., 2013) such as insomnia and other sleep related 
problems (Espiritu, 2008; Tel, 2013). Valerian is a common component of herbal 
sleeping pills and relaxation products (Alsanad et al., 2016; Bent, Padula, Moore, 
Patterson, & Mehling, 2006), Ginger and turmeric may be effective for the treatment 
of symptoms associated with osteoarthritis, especially pain (Ernst, Soeken, & Long, 
2001). Garlic and Echinacea are used to treat upper respiratory infections such as 
cold, flu, and chronic bronchitis, nasal and throat catarrh (Kaufman et al., 2002; Kelly 
et al., 2005). Women use evening primrose oil to manage menopausal symptoms 
(Farzaneh, Fatehi, Sohrabi, & Alizadeh, 2013), while saw palmetto is mainly used by 
men to treat symptoms of benign prostatic hyperplasia (Marks et al., 2000). 
 
While aging by itself is not a disease, many conditions worsen with age and the 
medicalisation of aging may lead to more harm than benefit for older adults (Birrer & 
Tokuda, 2017). Many older adults who participated in this study integrate non-
prescribed medicines such as HMPs or DS into their self-management of daily 
symptoms. The focus on HMPs and DS provides some insight about health beliefs, 
and this links to the interview findings on safety and the perception that the use of 
HMPs was of little or no interest to GPs. Moreover, what we do not know is whether 
HMPs and prescribed drugs are equally valued or one is preferred over another 
(Arcury et al., 2012). Although the findings from the interviews suggested that older 
people differentiated between the curative function of prescribed medications, and 
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the augmentation or supplementary function of HMPs. A perception that prescribed 
drugs were no longer working or a possible dissatisfaction with the medical 
profession as a source of expertise for some conditions encourages the growing 
consensus among patients towards a more eclectic view of health, resulting in herbal 
and dietary supplement medicalisation. 
 
e.  Dietary Supplements also combined with Prescription Drugs 
The review found that in addition to herbal remedies, dietary supplements (Loya et 
al., 2009; Shane-McWhorter & Geil, 2002) as well as vitamins and minerals 
(Kaufman et al., 2002; Peng et al., 2004) were also concurrently used with 
prescription drugs. The dietary supplements most combined with prescription drugs 
were cod liver oil, glucosamine, multivitamins and Vitamin D. Although cod liver oil 
and glucosamine are technically dietary supplements, they are advertised as ‘cures’ 
for various conditions including joint pain and arthritis, hence the blurring with HMPs. 
The lack of a common understanding or operational definitions of what is and what is 
not an HMP highlights the clinical and methodological challenges of tracking HMP 
use in the older population.  
 
The use of dietary supplements among older adults continues to be high; 70% of US 
adults reported using ≥1 dietary supplements regularly (Gahche, Bailey, Potischman, 
& Dwyer, 2017) and about 79% of participants in this study. The findings from all 
three phases of the study provides further evidence that despite an increasing 
market in HMPs and dietary supplements, their use with prescribed medications is 
not seriously considered with regards to potential herb-drug interactions. The 
majority of concurrent use is not discussed or disclosed to healthcare practitioners 
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(Foley, Steel, Cramer, Wardle, & Adams, 2019; Jou & Johnson, 2016; Kennedy et 
al., 2008), some of which could have serious implications. Therefore, non-disclosure 
and not asking patients for information, poses a major concern from a safety-risk 
perspective. There is a dissonance between the level of use of HMPs and 
supplements and clinicians asking or documenting (Ben-Arye, Halabi, Attias, 
Goldstein, & Schiff, 2014; Pinto et al., 2012).  
 
An up-to date national representative data on HMPs and dietary supplement use 
among UK older adult is long overdue, to provide reference data and information for 
public health policies including nutrition and health monitoring, and prevention 
initiatives. There is a vital role for healthcare practitioners in facilitating disclosure of 
CAM use by enquiring from patients. However, it appears that discussions about 
CAM use are more commonly patient rather than provider initiated (Roberts et al., 
2006; Roter et al., 2016).  
 
Healthcare practitioners initiating such discussions may be an avenue for improving 
disclosure and this may be achieved by including a use CAM inquiry as standard in 
case-taking. Including specific questions related to dietary supplements in case-
taking doubled the rate of supplement use disclosure among patients (Ben-Arye et 
al., 2014). Encouraging shared responsibility for the communication and subsequent 
discussion of CAM use is also argued to be key to achieving optimum disclosure 
(Ben-Arye et al., 2014). This may be facilitated through person-centred approaches 
to clinical care, which encompass patient involvement in shared decision-making, 
face to face interactions, provider empathy and recognition of patients’ values (Bunn 
et al., 2018; Pinto et al., 2012). However, the findings from this study suggest that 
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this would require structural changes to how clinical appointments are organised 
both in terms of access, how consultations are structured and length of time for 
discussing what is important to the older person.  As the study also found that some 
older people were using online resources, there may be scope for investment in 
advice and interactive guidance that can be accessed online (Washington, 
Meadows, Elliott, & Koopman, 2011; Yardley, Morrison, Bradbury, & Muller, 2015). 
Although evidence to date suggests there are significant barriers to overcome (Yusif, 
Soar, & Hafeez-Baig, 2016; Ziebland & Wyke, 2012). 
 
7.3 Factors Associated with the Concurrent Use of Prescription 
Drugs and HMPs 
  
It is known that demographic and clinical characteristics are associated with the use 
of herbal medicines, and this was explored as part of the study objectives. Being 
female, older than 70 years, using prescription medicines, having higher than high 
school education and a chronic condition, are some of the documented factors 
associated with herbal medicine use (Peklar et al., 2014; Rashrash et al., 2017).   
 
Whilst, as in previous studies (Canter & Ernst, 2004; Farina et al., 2014; Qato et al., 
2008) females more than males were likely to be concurrent users (43.4% versus 
22.5%). The analysis of concurrent users in this study did not show consistent 
patterns for these characteristics known for HMPs and DS use. They were not easy 
to group into likely and unlikely users of HMPs, challenging narratives that a health 
condition, cultural beliefs or being an identifiable population or group will predispose 
people to use certain HMPs with prescription drugs. It is possible that this group are 
very different to those who are choosing herbal products as a conscious and 
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deliberate rejection of conventional medicine. This was not explored in the evidence 
reviewed; also the survey and interviews did not suggest that participants were 
suspicious of their medications. They supplemented or augmented prescription 
drugs with HMPs or DS which were self-prescribed, recommended by friends and 
relatives, or purchased from supermarkets, health shops or over the internet. There 
was no evidence of older adult adults substituting their prescribed medicines with 
HMPs or DS. 
 
Previous work has found that older age groups are not significantly associated with 
concurrent use (Peklar et al., 2014; Yoon & Horne, 2001). When looking at within 
group characteristics, the survey found little or no differences in the education and 
living arrangements of concurrent and non-concurrent users. A third of participants 
with and without further education had reported concurrent use. The findings 
underline the importance of individualised care. There was little to suggest from the 
review, survey or interviews that there would be a particular “at risk” group, what was 
more striking was the cross generational assumption that this was a safe option.  
 
7.4 Potential Risks from the Concurrent Use of Prescription 
Drugs and HMPs  
 
This study identified specific risks associated with herb- drug interactions. Medication 
prescribing for older adults is complex, treating for more than one chronic illness 
increases drug burden and the risk of ADRs (Hajjar, Cafiero, & Hanlon, 2007; Nisly, 
Gryzlak, Zimmerman, & Wallace, 2010). Polypharmacy is a recognised patient safety 
risk and consistently associated with interactions and ADE (Guthrie et al., 2015). An 
average older adult is on 5 or more prescribed medications (Kim & Parish, 2017). 
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Considering that about one in four use prescribed medicines concomitantly with 
HMPs or supplements (Gardiner et al., 2006), the potential risk for drug interactions 
may be further increased.  
 
The risk of bleeding due to concurrent use of Ginkgo biloba, garlic or ginseng with 
aspirin and warfarin are the most frequently reported potential herb-drug interactions 
amongst older adults (Elmer et al., 2007; Peklar et al., 2014; Shane-McWhorter & 
Geil, 2002). The potential interactions identified in many studies were either minor, of 
unknown clinical significance or of uncertain risk for an adverse interaction. A similar 
trend was recorded in phase 2 survey for this study. Over half of the herb-drug and 
supplement–drug combinations were assessed as ‘no interaction’ or ‘no interaction 
of clinical significance’. However, seven of the 55 combinations were assessed as 
potentially serious. These relates to increased blood-glucose concentrations, risk of 
bleeding and reduced efficacy or bioavailability of the prescription drug. 
 
Despite this cumulative evidence, assessing the safety of HMPs remains 
complicated for many reasons, including poor and minimal data on herb-drug 
interactions (Izzo et al., 2016; Williamson, 2003) and no clear definition of what 
HMPs are. In fact, most of the available evidence on herb-drug interactions is from 
pre-clinical studies, uncontrolled clinical trials and case reports which are limited by 
the quality and quantity of information available on the herbal products and the 
adverse reaction, making them inconclusive and inconsistent. For example, the 
survey found that the 149 participants were prescribed 180 different types of drugs 
including a range of statins and beta blockers. Although herbal medicines are plant-
derived, they are chemically complex mixtures of pharmacologically active 
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phytochemicals, with multiple potential targets and mechanisms (Jordan, 
Cunningham, & Marles, 2010; Pelkonen, Xu, & Fan, 2014). This complexity 
increases the risk of clinical drug interactions. However, most studies focus on single 
HMP and or their interactions with a drug (Barone, Gurley, Ketel, Lightfoot, & Abul-
Ezz, 2000; Blonk, Colbers, Poirters, Schouwenberg, & Burger, 2012; Bressler, 
2005). Therefore, the findings from this study suggest that evaluating the interactions 
of two products is over-simplistic and reductionist. It will only ever achieve a partial 
account because in real life situations, several prescribed drugs, HMPs and DS are 
used simultaneously. 
 
The evidence on herb-drug interactions continues to grow and it is compelling 
(Alsanad, Williamson, & Howard, 2014; Awortwe, Bruckmueller, & Cascorbi, 2019; 
Henderson, Yue, Bergquist, Gerden, & Arlett, 2002; Izzo & Ernst, 2009; Kennedy & 
Seely, 2010; Posadzki, Watson, & Ernst, 2013; Ulbricht et al., 2008), even when 
many of the studies are limited by poor methodological quality and risk of bias. This 
would suggest that there is a growing awareness of the issues but is yet to affect 
public and lay perceptions of risk. In the survey and interviews, participants did not 
think there was a risk of harm or that it was worth mentioning to clinicians what other 
medicines they were taking. This must be considered against the survey findings that 
the majority of herb-drug combinations were unlikely to cause clinically significant 
interactions and appropriate herb-drug combination could benefit patients. To guide 
the practical application of this combined therapy in a manner that benefits 
consumers while minimising the risk of interactions, high-quality studies are required 
to evaluate the impact of specific herb-drug and supplement-drug combinations 
among different cohorts, in multiple settings and with larger sample sizes,   
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This study’s findings would suggest that a general look at the use of HMPs is too 
broad. Therefore, there is a need to build on this and focus on specific HMPs and 
prescribed medicines that are known to have high risk of interactions and adverse 
outcomes. The consistent findings about certain prescription drugs that are most 
commonly combined with HMPs and supplements as provided by this study is a 
basis for more focused work, particularly among older adults.   
 
7.5 Understanding Why Older Adults Concurrently Use 
 Prescriptions Drugs with HMPs and DS 
 
One of the objectives of this research was to explore in depth older adults’ reasons 
and decision making regarding the concurrent use of prescription drugs with HMPs 
and dietary supplements. Chapter 6 identified recurring themes from the interview 
data about why and how they used HMPs alongside their medications. Studies 
(Dergal et al., 2002; Elmer et al., 2007; Peng et al., 2004) have reported the potential 
but untested interactions between some of the prescription medicines and HMPs that 
older adults often combine. What this study adds is an in-depth exploration of why 
older adults combine HMPs with prescribed medicines. Although there are theories 
of how health beliefs affect interactions and discussions with medical services 
(Leventhal & Cameron, 1987; Munro, Lewin, Swart, & Volmink, 2007), understanding 
how health beliefs about HMPs are reconciled with using prescribed medication has 
received less attention. For younger populations, there is a divide between what is 
seen as medical need and activities and HMPs that support personal health. This 
was partly supported by some of the participants’ accounts of what they did to keep 
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well. There were however multiple reasons why individuals choose to combine 
prescription medicines with herbal products.  
 
The wide range of motivations and sources of information identified from a relatively 
small sample that older adults draw on in making their decisions about using HMP 
with prescribed medicines were striking. These motivations as discussed in Chapter 
6 ranges from dissatisfaction with conventional medicine, perceptions that HMPs are 
safe and convenient, to the desire to take control over their own health and minimise 
the inconvenience and difficulty of accessing conventional medical support. These 
resonate with the findings from previous research on why people use CAM and 
herbal medicine (Bishop & Lewith, 2010; Cheung, Geisler, & Sunneberg, 2014; 
Welz, Emberger-Klein, & Menrad, 2018). It is an important finding that the reasons 
were so diverse and not always influenced by the experience of deteriorating health 
associated with ageing. 
 
It could not be assumed from the survey findings that the people who are 
concurrently using prescription drugs with HMPs conform to any easy categorisation 
about who they are and why they are using HMPs. This is now discussed in more 
depth in relation to the themes and sub-themes from the interview findings.   
 
 
7.5.1 Tried and Tested or Learnt from Personal and Others’  
 Experience   
 
a. Herbal Medicines are Natural and Safe  
Many participants did not consider HMPs or dietary supplements to be medicines. 
They were represented as remedies or ‘help yourself’ products to be used when 
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required. This affected how they made judgements about whether to mention it to the 
GP or not. There is an interesting paradox that whilst participants did not think HMPs 
were harmful, they had plenty of examples of where they thought prescribed 
medication and treatment were life threatening or likely to trigger additional health 
problems. The possibility of interactions from combining HMPs and DS with 
prescription medications was not considered and the interviews revealed a 
willingness to sample a range of products until they find one that suited them. These 
findings raise questions about the health literacy of the population studied (Mayor, 
2012) and how clinicians manage and support people to make informed choices 
about their health.  
 
Health literacy is considered to be the degree to which individuals have the capacity 
to obtain, process, and understand basic health information and services needed to 
make appropriate health decisions (Ratzan, Parker, Selden, & Zorn, 2000). Health 
literacy is therefore relevant here in this context.  What emerges from this study is 
that we do not know if people knew what their prescribed medications did, or if they 
were clear what the HMPs achieved or not. Although the study highlighted beliefs 
about their purpose and how this was different from prescribed medication. Limited 
health literacy is associated with poor use of preventive health services (Kobayashi, 
Wardle, & von Wagner, 2014), lower ability to self-manage health conditions,  poorer 
health outcomes (Berkman, Sheridan, Donahue, Halpern, & Crotty, 2011) and 
mortality (Bostock & Steptoe, 2012). Difficulties with reading and understanding 
medical information, making and keeping appointments and following medication 
instructions (Sørensen et al., 2012), as well as social stigma creates barrier to 
gaining social support and advice (Easton, Entwistle, & Williams, 2013; Parikh, 
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Parker, Nurss, Baker, & Williams, 1996). Although this study did not identify 
resistance or inability to read instructions in the findings, it reinforces a lack of 
understanding about the importance of sharing information and the significance of 
exploring different decisions. Participants did not really understand how HMPs or 
prescribed medications work. This possibly explained why and how they sourced 
their information, which came from such a wide range of informants including family, 
friends and the internet.  
 
b. ‘They Work But Don’t Know How They Work’ 
Some participants were sceptical of how the HMPs or DS worked for their conditions 
but continued to buy and use them. Interestingly, some of them also talked about 
their prescription medications in a similar manner.  A possible explanation for this 
might be that older adults are practising self-care maintenance, which are 
behaviours performed to improve well-being, maintain physical and emotional 
stability (Riegel, Jaarsma, & Strömberg, 2012). For people living with chronic illness, 
self-care behaviours often mirror recommendations from healthcare providers. For 
example, they proactively take non-prescribed medications to control persistent or 
minor symptoms that the prescription medicines did not resolve. Consequently, 
higher use of herbal medicines and nutritional supplements is reported among older 
adults with chronic diseases compared to the general population (Gonzalez-Stuart, 
2011; Rashrash et al., 2017; Tulunay, Aypak, Yikilkan, & Gorpelioglu, 2015).  
 
7.5.2  Decision to Use HMPs or Dietary Supplements 
This study looked at a specific group of older people who took both prescribed 
medication and HMPs. There was overlap in the findings from studies that consider 
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older people’s use of CAM that report they are pragmatic and eclectic (Heller, Lee-
Treweek, Katz, Stone, & Spurr, 2005; Sharma, 1992; Sharp et al., 2018), often 
interested in whether a therapy might work for them rather than the theory behind the 
practice. As reported in this study, older adults will try any treatment that seems to 
work or has worked for people they know. Reports (Bishop, Yardley, & Lewith, 2008; 
Family, Jordan, Blaxall, & Sengupta, 2018) show that consultations with CAM 
practitioners are reported as providing more satisfactory meanings and 
interpretations of their symptoms than orthodox practitioners. In this study however, 
CAM practitioners were rarely consulted and were not seen as preferable or more 
knowledgeable, the two world views of how medicine works were held in tension. 
 
Evidence suggests that ethnicity and culture are important determinants in how a 
person implements health self-management (Greenhalgh, Helman, & Chowdhury, 
1998; Shaw, Armin, Torres, Orzech, & Vivian, 2012), particularly how 
complementary and alternative health care such as herbs are incorporated into a 
self-management regimen (Arcury et al., 2007). Self–management is discussed 
further in Section 7.5.4.  For many older adults in this study, the belief in or the 
conviction to use HMPs arose from using them over many years, testimonies from 
friends, desire to avoid problems that others had experienced and information from 
internet searches. The findings demonstrated these different influences on 
participants’ decision making but none emerged as particularly dominant.  
 
The modest data available about BAME from this study, would seem to suggest that 
it is learnt efficacy either from personal experience or peer recommendations that 
shapes decisions to use HMPs rather than cultural. The self-regulatory model (SRM) 
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framework (Cameron & Leventhal, 2012) argues that shared beliefs (culture) about 
what is right or possible to do for health, often dictates health behaviours. Members 
of an ethnic group share beliefs and common experiences that affect their 
willingness to use different forms of health care. Often, the use of herbs for the 
prevention and treatment of ill health has its roots in the traditional and contemporary 
cultures, including European, Asian, African, Latino, and Native American heritage 
(Arcury, Suerken, et al., 2006; Barnes et al., 2004; Raji et al., 2005). However, this 
study had limited evidence that the use of herbal medicine was due to family history, 
ethnic or cultural beliefs passed onto them by their parents or grandparents. Cost 
and access to health care were dominant reasons for herbal medicine use, and a 
pragmatic response to the difficulties of accessing mainstream care. The difficulties 
experienced by people from BAME backgrounds were likely to reflect deeper and 
more pervasive inequalities in lack of income and education.  
 
a. Convenience and Access to Healthcare  
Older people increasingly find life challenging and appreciate options that make their 
life less complicated and with “less hassle”. It is a recurring finding in the research 
literature that the impact of living with a long term condition and the endless visits to 
health care practitioners over time are exhausting (Goodwin, Curry, Naylor, Ross, & 
Duldig, 2010; Hill, Sutton, & Cox, 2009). For some participants, avoiding the effort of 
getting to the GP outweighed the cost of HMPs. It is also worth reflecting whether the 
findings were indicative of older people maintaining choice and retaining control, as 
more and more decision making about how and where they live is shaped by their 
functional ability and those who support them. There were several examples of older 
people resenting that they had to fit in with the systems of health care, specifically 
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experiencing a lack of choice about when and for how long they see clinicians. 
Decisions to use HMPs were an expression of patient choice only in as much there 
was a decision not to “battle” a system. It was not a positive action. The decisions 
were pragmatic responses to the difficulties they encounter in discussing and 
debating options for care (Bunn et al., 2018). The study by Hansen and colleagues 
(2014) found that where there was evidence of continuity of care, patients were less 
likely to seek out complementary and alternative medical practitioners. They 
suggested this may be due to mutual trust in the GP-patient relationship, quality of 
care they receive, good communication, mutual knowledge and understanding.  
 
b. Previous Negative Experience of Using Conventional Medications 
There is an interesting paradox that whilst participants did not think HMPs were 
harmful they had plenty of examples of where they were disappointed or frustrated 
with prescribed or conventional medication and treatment. They thought prescribed 
medicine was not working, too many side effects or were likely to trigger additional 
health problems. So, they would rather actively seek and take alternative medicines, 
which they believe treat their symptoms and were thought to have minimal side 
effects. Research on medication concordance and compliance in older populations 
highlights that many either do not take the medication or reject the medication 
because of limited opportunities to discuss its impact or unpleasant side effects 
(Holt, Rung, Leon, Firestein, & Krousel-Wood, 2014; Salter, 2010; Yap, 
Thirumoorthy, & Kwan, 2016). Communication with healthcare providers as a 
positive factor to medication concordance is a recurring theme in these studies. 
There were few examples from the interviews that identified positive encounters with 
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health care professionals although there was one example of a GP recommending 
an HMP and the advice seen as trustworthy because of their role.   
 
The dissatisfaction and negative experience of prescribed medicine or treatments 
(‘push’ factor) and the positive beliefs or experiences of herbal medicine (‘pull’ 
factors) (Bishop, Yardley, & Lewith, 2010; Sirois, 2008; Welz et al., 2018) are 
thought to be closely associated with the decision to use HMPs and the motivation to 
continue using them and eventually using them with prescribed medications. This 
raises questions about whether future interventions to reduce the risk of adverse 
reactions should consider how much time and opportunity clinical consultations offer 
for discussion, review and continuity of care. 
 
c. Disclosure and Non-disclosure of HMP Use to Healthcare Practitioners 
The findings from this research reinforced the literature about non-disclosure of 
HMPs to healthcare professional (Foley et al., 2019; Robinson & McGrail, 2004). It 
identified that many older adults do not disclose HMPs or supplement use either 
because healthcare practitioners do not ask, they believe that herbal products are 
‘natural’ and therefore ‘safe’, they fear being judged, as well as practitioners lacking 
time or knowledge of HMPs. 
 
There was evidence from the interviews that some older people would welcome the 
opportunity to discuss their medications but had low expectations that healthcare 
practitioners would be interested. They were interested in knowing more about the 
study; particularly why I thought it was an important issue to research. Given this 
knowledge, it is important that future research explores targeted questioning of 
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patients about the use of alternative medicines or supplements to initiate wider 
conversation about HMPs and possible interactions.  
 
As widely shown in the literature (Brennan et al., 2012; Milosavljevic, Aspden, & 
Harrison, 2018; Van Wijk, Klungel, Heerdink, & de Boer, 2005), public conversations 
and debates can be used to enforce and improve medication adherence. Healthcare 
practitioners, particularly the community pharmacists could educate patients by 
explaining the potential risks of taking HMPs with their prescribed medicines and 
discussing with patients their beliefs and knowledge about their health and 
associated treatments. Good patient and doctor rapport, an understanding of the 
illness in the patient’s terms and reaching a shared understanding and agreement 
about proposed treatment and alternative choices is likely to enhance concordance 
(Ng et al., 2018; Wahl et al., 2005). 
 
This research becomes more relevant as cannabis is increasingly used medically 
(Hamilton, Brands, Ialomiteanu, & Mann, 2017; Park & Wu, 2017), particularly 
among the elderly (Abuhasira, Schleider, Mechoulam, & Novack, 2018; van den 
Elsen et al., 2014). This is an example of how an HMP, although mainly used for 
recreational purposes is becoming mainstream. The interaction between cannabis 
and other drugs is largely unknown but the metabolism of the cannabinoids may be 
altered when used concurrently with drugs which influence the cytochrome P450 
(CYP) enzymes. For example, concomitant administration of cannabidiol (CBD) 
significantly changed serum levels of topiramate, clobazam, and zonisamide (Gaston 
et al., 2017), while rifampin reduced CBD levels by 50% to 60% (Jiang, Yamaori, 
Takeda, Yamamoto, & Watanabe, 2011). Although none of the participants in this 
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study acknowledged using cannabis not least because they are HMPs, but it is okay 
to declare some and not others. 
 
 
7.5.3  Sources of Information and Advice 
Older adults are the fastest growing population of online users (Choudrie, 
Pheeraphuttharangkoon, Zamani, & Giaglis, 2014; Olson, O’Brien, Rogers, & 
Charness, 2011). The interview findings demonstrated that the internet is a major 
source of information on HMPs and dietary supplements among older adults. 
Ordering of HMPs and supplements from around the world has also become a much 
easier process. For some participants, the decision to use HMPs was influenced by 
information and experiences of other people gathered from blogs and online chat 
groups. This represents a different source of peer to peer learning for different 
groups which may promote products but may not have standard information about 
adverse effects. None of the participants in the study mentioned receiving advice or 
warnings about side effects or potential interactions from family and friends or online 
chat groups where they had originally received information or the suggestions to try 
HMPs. 
 
Users of health services are also more likely to use the internet for health information 
(Choi, 2011). On the other hand, many economically disadvantaged or under- 
represented groups still lack access to basic digital resources and the skills to use 
them effectively (Robinson et al., 2015). Hence, the lower rates of use recorded 
among the poor, disabled, home-bound or those  from BAME backgrounds (Choi & 
Dinitto, 2013). 
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In this study and many others, advice on HMPs was rarely sought from doctors and 
pharmacists, although some studies reported other healthcare practitioners, 
especially pharmacists as major sources of information on HMPs (Anonymous, 
2010; Cheung et al., 2014; Knotek, Verner, Chaloupkova, & Kokoska, 2012). This 
may be due to the way health care systems are organised or limited access to the 
literature and the internet. In the UK, there is a general lack of knowledge about 
herbal medicine among doctors and pharmacists (Anonymous, 2010; Cramer, Shaw, 
Wye, & Weiss, 2010); in particular many do not have standard sources or references 
for information about HMPs. Therefore, they may feel less confident and competent 
to discuss the use of HMPs or provide evidence-based advice regarding potential 
interactions (Williamson et al., 2013). 
 
7.5.4  Self-management and Taking Control 
The use of herbal medicines is a self- management activity (Arcury, Bell, et al., 2006) 
and a key argument of health self-management is that adults are actively involved in 
monitoring and making decisions about their health (Arcury, Bell, et al., 2006; Corbin 
& Strauss, 1985; Schulman‐Green et al., 2012). What many of the participants in this 
study described were different behaviours or strategies to supplement their 
prescribed medications with HMPs or DS. This included using prescribed medicines 
for only serious conditions while relying on HMPs or supplements for less serious 
ones, using HMPs to prevent the onset of new disease, to treat symptoms of chronic 
conditions and not disclosing use to healthcare practitioners. All these behaviours 
represent self-management strategies in relation to the use of medicines, to exercise 
control over their health and maintain their quality of life. This resonates with existing 
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literature on the common-sense model (CSM) of illness behaviour (Diefenbach & 
Leventhal, 1996) and self-management (Arcury et al., 2012; Bandura, 1997; 
Bodenheimer, Lorig, Holman, & Grumbach, 2002; Cameron & Leventhal, 2012; 
Corbin & Strauss, 1988). 
 
The Leventhal’s self-regulatory model provides a theoretical framework for 
understanding specific health self-management behaviours that older adult exhibit 
(Cameron & Leventhal, 2012; Leventhal, Halm, Horowitz, Leventhal, & Ozakinci, 
2004) and argues that individuals will select a self-management behaviour based on: 
 their beliefs of a symptom or illness 
 their perceptions and understanding of their health 
  their knowledge of treatments, personal resources and structural factors that 
affect access to a therapy. 
 
This theory also considers individual characteristics since it may differentiate their 
health seeking behaviours, hence the use of herbal medicines. For example, women 
tend to have more health knowledge and are better at seeking healthcare than men 
(Smith, Braunack-Mayer, & Wittert, 2006; Thompson et al., 2016). Moreover, women 
tend to use more HMPs than men (Farina et al., 2014; Qato et al., 2008) and the use 
of HMPs and dietary supplements also increases with age (Arcury, Bell, et al., 2006; 
Zeilmann et al., 2003) and among certain ethnic groups (Graham et al., 2005; 
Upchurch & Wexler Rainisch, 2012). It is beyond the scope of the survey and 
interview findings to know if this applies to the participants. However, the findings did 
suggest that the reasons were more nuanced than the difference between the sexes 
that this research highlights.   
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Medical pluralism is another manifestation of self-management and occurs when 
patients use more than one medical system or use both conventional and 
complementary and alternative medicine (CAM) for health and illness (Baer, 2004; 
Wade, Chao, Kronenberg, Cushman, & Kalmuss, 2008). This affects how clinicians 
engage with patients and vice versa. Kleinman (Kleinman, 1980) argued that all 
health care systems are composed of three overlapping parts i.e. the popular (lay, 
non-professional, non-specialist), the professional and the folk sector 
(complementary and alternative medicines). Patient make choices between these 
three sectors and make judgement about the advices they are given, and what they 
believe makes sense to follow. The evidence suggests that actively involving 
patients in their own care, treatment and support can improve outcomes and 
experience for patients, and potentially yield efficiency savings for the NHS and 
support people to stay well and manage their own conditions better (Lorig et al., 
1999; Vassilev et al., 2015; Zwerink et al., 2016) .  
 
Despite the availability of a range of treatment options including the NHS 111 
telephone helplines and policy changes (NHS England, 2010) advocating greater 
use of self-treatment, patients are uncomfortable discussing their use of self-
treatments (Stevenson, Britten, Barry, Bradley, & Barber, 2003) and the findings 
from this research also supports this (Section 6.8). Only a few GPs in the study by 
Stevenson and colleagues (2003) initiated conversations about self-treatment but 
some patients did not disclose this to avoid conflict during the GP consultations.  The 
evidence from the interviews in this study however suggested that it was not 
avoidance of conflict that was the reason for non-disclosure but an assumption the 
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GP would not be interested. Opportunities should be created for older people to 
engage with clinicians in discussing what would be best for long term conditions and 
this could possibly influence their decision to use or not to use HMPs. 
 
7.5.5  Awareness and Experiences of Herb-Drug Interactions 
The review, survey and interviews all demonstrated that the potential risks of herb-
drug interaction among older adults were underreported and not widely recognised. 
The notion that herbal medicines are natural therefore safe encourages self-
prescription (Lynch & Berry, 2007; Walji et al., 2011) and non-disclosure of usage to 
health care professionals. Moreover, in most cases health professionals do not 
routinely ask about herbal medicine use (Lisk, 2012). Only three participants (NZ 
001, SG181 and SG003) had consulted herbal medicine practitioners and purchased 
their supplies from them. For NZ 001, this suggests a lack of safeguards with 
regards to the monitoring and use of HMPs. 
 
Concurrent use, medication sharing, lending and borrowing of prescription 
medication are well recognised behaviours among older adults (Beyene, Sheridan, & 
Aspden, 2014; Markotic, Vrdoljak, Puljiz, & Puljak, 2017). However, there is not a 
great deal of awareness regarding the potential risks from concurrent medication 
use.  
 
As people get older and are prescribed more medications, there are additional risks 
which they may try to mitigate by using HMPs for conditions they consider as less 
serious while relying on prescribed medications for more serious ones. However, 
they do not equate using HMPs with prescription drugs as carrying similar risks and 
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negative outcomes as polypharmacy. This is a further evidence of the dissonance 
between how using conventional medicine with HMPs is understood, and the illusion 
that they are separate and do not interact. Older adults did not recognise the 
possibility of HMPs interacting with prescribed medicines or see them as unsafe. 
The survey findings suggest that the perception of risk by older adults was not a 
misplaced view but there were key interactions that were of concern. For example, 
HMPs like kava, valerian and St John’s wort have been found to interfere with 
anaesthetic agents and many other drugs administered at the pre-operative periods 
(Ang-Lee, Moss, & Yuan, 2001; Bajwa & Panda, 2012; Borrelli & Izzo, 2009; Wong & 
Townley, 2010). Therefore, a different approach is needed to highlight specific drugs 
that are most likely implicated and how this should be routinely reported rather than 
just talk about the concurrent use of HMPs with prescriptions. 
 
7.6 Strengths and Limitations of the Study 
The key strength of this study is that it has demonstrated what is known about how 
many older people use HMPs concurrently with prescribed medication and explored 
some of the underlying reasons. The use of a mixed method approach allowed a 
progressive focusing on what is known, how extensive the practice of using HMPs 
with prescribed medication is and what influences people’s decisions provided a 
comprehensive account of an under researched topic. 
 
By recruiting older people through GP practices serving different populations, it 
showed that it was possible to identify older people systematically. Previous studies 
have relied on self-selected samples and people with a known interest in HMP use. 
The response rate of 39% for the survey and 13 participants for the qualitative phase 
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is small, but enough to provide credible findings. Moreover, the richness of the data 
demonstrated the multiple influences and reasons for older community dwelling 
people taking HMPs.  
 
Methodologically, there is also learning about which approaches work best for this 
population. In the early stages of developing this research, I tried recruiting some 
older adults into pilot focus groups to inform and develop questions for the survey, 
but many of them declined to participate. Further interrogation revealed that many 
were not comfortable talking about their use of ‘other’ medicines in a group. This 
level of disclosure about personal health issues and being open to possible censure 
were significant barriers to participation. In individual interviews, participants in this 
study spoke freely about other medicines they were taking and what they use them 
for, when they realised that I was neither a GP nor a healthcare practitioner. On 
reflection, it is possible that some of the older adults surveyed did not disclose or 
underreported their use of HMPs and dietary supplements. Therefore, the true 
prevalence of concurrent use of HMPs and supplement with prescription drugs may 
be higher than shown by the survey.  
 
7.7 Reflections on Chosen Methodology and Methods 
a. Resources 
Mixed method studies are challenging to plan and conduct. Careful planning and 
considerations were required for all aspects of each phase of this research. With the 
sample sizes for both the quantitative and qualitative phases carefully estimated, 
taking into consideration what was already known about the population. The 
quantitative phase had to be analysed very quickly after the survey ended, to identify 
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respondents that were eligible and willing to be interviewed for the next qualitative 
phase. It was also important to contact participants immediately to schedule 
interviews, since they may forget about the study after some time or change their 
mind about participating.  
 
Good qualitative and quantitative research skills are essential to undertaking a mixed 
method study, often involving on a multi-disciplinary team of researchers. My 
background is within qualitative methods and this positivist sense of the world has 
been the driving force in this PhD research. My initial idea was to conduct a purely 
quantitative study, to assess the concurrent use of HMPs and prescription medicines 
among UK older adults, and the potential interactions from such combinations.  
Although previous studies have also used quantitative approaches to study this 
issue, but there were no recent studies from the UK. The systematic review identified 
an important knowledge gap in this area; the lack of evidence as to why older adults 
concurrently use medicines. It became increasingly clear that using purely 
quantitative approaches would limit not only the understanding but would also not 
answer the question ‘why do UK older adults concurrently use prescription medicine 
and HMPs?’ Therefore, a mixed method approach provided a pragmatic way of 
addressing both the ‘what’ and ‘why’ elements of the research question. 
 
Mixed method studies are labour intensive and often require additional resources 
than single method study.  Using postal questionnaires was an expensive approach 
to data collection. Online or telephone survey would probably have been less 
expensive. However, because the study population is ≥65 years, and more likely to 
respond to postal questionnaires, this was the preferred option. 
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b. Approaches 
Focus groups were planned for initial phase of this research, to test assumptions of 
the research objectives and inform focus for subsequent phases of the study. 
However, recruiting for the focus groups proved difficult. As argued by some authors 
(Erzberger & Kelle, 2003), the outcomes of multi-strategy research is unpredictable. 
There may be the need to combine strategy either because of unexpected results or 
non-realisation of potentials after data collection, even though advanced decisions 
about design were made pre-data generation. With this in mind, I was open to a 
change in the study design that may arise due to unexpected results. Therefore, 
Individual interview was adopted to inform the survey phase in place of focus groups, 
as enough participants could not be recruited.  
 
Similar surveys that used interviewers achieved better response rate. For example, 
Of the 399 eligible persons invited to participate in a survey by Delgoda et al (2010), 
365 agreed, yielding a 91.5% response rate. 
 
c. Low Response Rate 
Although the response rate of 39% achieve is relatively low, but it is consistent with 
other studies on this topic and provides credible findings.  Non-response is a known 
problem for questionnaire surveys. A lot of efforts were made to increase the 
response to this study by contacting participants three times, even though two 
contacts are suggested (Bryman, 2012; Edwards et al., 2002). In addition, an 
incentive of £10 voucher was offered during the third contact, and this might explain 
the increased responses of 58 for this round.    
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7.8 Chapter summary 
 
This Chapter has presented an overview of the main findings from the research and 
this was discussed in relation to the research questions asked in each phase. It has 
discussed how the findings have reinforced and added to existing literature around 
the concurrent use of HMPs and dietary supplements with prescribed drugs. Older 
adults did not recognise the possibility of HMPs interacting with prescribed 
medicines or see them as unsafe. 
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8  Conclusions 
8.1  Introduction to Chapter 
This thesis has addressed the concurrent use of prescription drugs and herbal 
medicinal products (HMPs) among older adults. It has provided a rationale for 
answering the research questions using a sequential mixed method design. It 
included a systematic literature review which suggests that the concurrent use of 
prescription drugs and HMPs among older adults is substantial. The quantitative 
phase examined the prevalence of concurrent prescription drugs and HMPs among 
UK community dwelling older adults and one-third of participants reported concurrent 
use in the last 12 months. Most concurrent users used dietary supplements with 
prescription drugs. Most commonly reported dietary supplements were cod liver oil, 
glucosamine, multivitamins and Vitamin D. HMPS most concurrently used with 
prescriptions were evening primrose oil, valerian and Nytol Herbal®.  
 
The qualitative phase explored the reasons for concurrent use of prescriptions drugs, 
HMPs and DS. These interviews uncovered the influences their decisions to 
concurrently use HMPs and supplements with prescriptions and how this manifest 
into some self-management behaviours or strategies. 
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8.2 Contributions to Knowledge 
There is a growing problem of polypharmacy with conventional medicines among 
older adults. The concurrent use of HMPs and DS increases the risks of drug 
interactions. Findings from this study have established the range of prescribed 
drugs, HMPs and DS that older adults most commonly combine. It also 
demonstrated the reasoning and system challenges that inform the decision to use 
HMPs in this way.   
 
The study has provided the first estimate of the prevalence of concurrent HMPs and 
prescription drug use among UK older adults. It has also highlighted potential 
interactions from certain combinations of prescription drugs, HMPs and dietary 
supplements which healthcare practitioners could routinely ask older adults about. 
 
The qualitative phase of this study addressed why older adults concurrently use their 
prescriptions drugs with HMPs and DS. Findings from this study provide a platform 
for health care professionals to review their own practice and knowledge. Also, it has 
demonstrated the need to systematically identify older people who may be at risk of 
potential herb-drug interactions. 
 
The range of reasons for concurrently using HMPs and/or dietary supplements with 
prescriptions drugs provided by this study provides an added perspective to the 
literature on polypharmacy and interventions to support medicine management for 
older adults living at home with multiple health needs.  
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8.3 Implications for Practice and Recommendations 
This is the first study exploring why community dwelling older adults concurrently use 
prescription drugs with HMPs and dietary supplements and there is scope for further 
work. Evidence from the systematic review indicates that many older adults 
concurrently use prescription drugs with HMPs and DS. It also showed the 
combinations of prescription drugs and HMPs concurrently used and the potential 
interactions from these combinations. In addition, the survey provided an overview of 
the HMPs and DS used by UK community dwelling older adults alongside prescribed 
medications and the possible interactions from such combinations. Therefore, this 
study provides healthcare practitioners with a ‘snapshot’ of some combinations 
commonly used by older adults to look out for during drug reviews and consultations. 
 
Considering that the prevalence of concurrent use among UK older adults is 
substantial and the associated risks, healthcare professionals should regularly ask 
their patients questions regarding use of other medications. Moreover, a good 
understanding of the extent and the manner which older adults combine prescription 
drugs, DS and HMPs in their health regimens is important knowledge for healthcare 
practitioners. Based on the findings from this study, there is a need to revisit how 
responsibilities and conversations are negotiated with all the different people 
involved- from manufacturers to clinicians and regulators. With regards to regulation 
and sale of HMPs, accurate and key information regarding precautions for those with 
pre-existing conditions, interactions with other products and possible adverse effects 
should be provided.  This will enable consumers make informed choices about the 
safe use of HMPs.  
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The evidence in this study suggested that quite a large number of older adults use 
HMPs and DS with their prescribed medicines. The implications of this for regulation 
and monitoring how these products are marketed include: 
 Public education as the next step to inform and encourage patients to tell 
healthcare providers about their use of HMPs and DS.  
 Healthcare practitioners routinely initiating discussions about HMPs and DS 
during consultations and treatment. 
 Government, regulators and manufacturers to increase publicity for patient 
reporting by targeting advertising campaigns at the public.  
 Regulators (e.g. MHRA) making reporting of suspected side effects or 
adverse reactions from HMPs and DS much more easier for patients and 
healthcare professionals, particularly  through the Yellow Card Scheme 
(Medicines and Healthcare products Regulatory Agency, 2013). The Yellow 
Card Scheme helps the MHRA monitor the safety of all healthcare products in 
the UK and is available online at 
https://yellowcard.mhra.gov.uk/yellowcards/tobaccoreportmediator/ 
 This study highlighted that the responsibility for finding out and alerting people 
to possible interactions and adverse events is unclear.  Therefore, the public 
should be helped and encouraged to check the quality of herbal products and 
where to find accurate information. 
 Proactive efforts by healthcare practitioners particularly in community 
pharmacy and general practice could publicise and promote patient reporting 
of adverse interactions. 
 Patients could be educated about the THR logo on the label of HMPs and 
encouraged to have raised expectations about the quality of HMPs (See 
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Section 2.3). The THR certification mark shows that the herbal medicine has 
been registered with the MHRA and meets standards of quality, safety, and 
patient information (Medicines and Healthcare products Regulatory Agency, 
2012).  A list of registered HMPs is available online and updated regularly at: 
https://www.gov.uk/government/publications/herbal-medicines-granted-a-
traditional-herbal-registration-thr/herbal-medicines-granted-a-traditional-
herbal-registration. 
 Key drugs should routinely highlight potential interactions with HMPs and DS. 
For example, St. John’s wort and cyclosporine, Coumadin, digoxin, and 
benzodiazepines, among others, and this should be linked to community 
pharmacist guidance. 
 
8.4 Implications for Pharmacy- led Research 
Clinical pharmacists increasingly work as part of general practice teams, to carry out 
structured medication reviews for patients with ongoing health problems. They 
support patients to get the most from their medicines and attend to some of the 
many self-limiting minor ailment consultations.  Patients are also more likely to 
disclose use of HMPs and DS to pharmacists. Therefore, Pharmacists could  
 Enquire and document the use of HMPs and DS as part of medication 
reviews, to capture the range of medicines used concurrently and provide 
advice where necessary.  
 Commissioners could explore the opportunities for consultations and 
education of this group as health care professionals who have recurring 
contact with older people. 
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8.5 Implications for future research  
These findings have implications for further research and implementation of risk 
reduction policies and strategies. They demonstrate the complexity behind the 
‘simple’ decision to use HMPs concurrently with prescribed medications. Based on 
the conclusions from this study, future research on this issue should consider: 
 Only participants who were long term users of HMPs and DS are represented 
in this study and not those who tried HMPs and DS then stopped.  
 Future research should consider a larger study involving people with a wide 
range of experiences of using HMPs and DS with prescription drugs. 
 Although health care professionals’ knowledge of HMPs and DS was not 
explored in this study, the literature suggests it is underdeveloped. There is 
limited knowledge on and lack of access to information on herbal medicines 
(Kemper et al., 2003; Robinson & Lorenc, 2011; Shorofi & Arbon, 2017). This 
stops healthcare practitioners initiating discussions about herbal medicine use 
with patients. Pharmacists, especially community pharmacists are well 
positioned within the NHS to provide medicines advice and support. 
Educational opportunities for healthcare practitioners should be enhanced to 
provide them with up-to-date knowledge of complementary and alternative 
medicines, particularly HMPs and potential interactions. This will in turn 
empower them to assist patients in making informed decisions regarding 
alternative medicines. Future studies should explore the knowledge, attitude 
and experiences of healthcare practitioners to HMPs and DS, particularly GPs 
and pharmacists. 
 The internet is a major source for information and advice and for the purchase 
of HMPs and dietary supplements. This study found that older adults were 
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using the internet for health information. Further research should explore the 
influence of online information on older adult’s choices and health seeking 
behaviours.  
 The volume and quality of patient reports to the Yellow card scheme is very 
poor. Providing links and advice on reporting adverse reactions to the Yellow 
Card Scheme will also improve pharmacovigilance of HMPs and DS. Future 
research should investigate the barriers and facilitators to patient reporting 
herb-drug, supplement-drug reactions. 
 There is value in future research focussing on specific health conditions such 
cancer, diabetes, arthritis etc. for which prescribed medications and HMPs are 
most concurrently used. This has been done with cancer patients (Alsanad et 
al., 2016; Berretta et al., 2017; Farooqui et al., 2016; Yates et al., 2005) but 
further work is needed to address the long term conditions identified in this 
study such as diabetes and arthritis.  
 
8.6 Impact and Dissemination of Research Findings 
Findings from research will only affect policy and improvement if they are effectively 
disseminated and to the right audience. There is a huge literature on dissemination 
and implementation science (Brownson, Colditz, & Proctor, 2018; Sandström, 
Borglin, Nilsson, & Willman, 2011; Wandersman et al., 2008) which shows that just 
communicating research findings may bring about little or no changes. I have made 
use of available opportunities throughout the PhD to network with other researchers, 
GPs and patients to discuss my research methodology, and present the findings as 
they emerged.  
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There is a high level of interest in HMPs and dietary supplement. Therefore, findings 
from this research will appeal to the public, media, the NHS, as well as regulatory 
authorities such as the MHRA. The systematic review and survey were published in 
reputable Open Access journals to make them accessible to all. The survey findings 
were shared widely in national newspapers and Radio stations, stimulated 
discussions and actions from the National Institute of Medical Herbalists (NIMH) and 
a leading herbal pharmaceutical company, Dr Willmar Schwabe Germany (Appendix 
K). 
 
8.7 Chapter Summary  
This chapter concludes the thesis and presented the strengths and limitations of the 
study, significance of the research and implications of the findings to evidence, 
research and healthcare professionals. 
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Appendix E: Literature Review Search Strategy 
 
1 herb*.ti,ab. 
2 (plant* adj3 (caplet* or capsule* or compound* or cream* or decoction* or drug* or essence* or extract* or 
formul* or heal* or herb* or Infus* or juice* or medic* or mixture* or powder* or prepar* or prescri* or 
product or products or remed* or supplement* or tablet* or tea or teas or therap* or tincture* or tisane* or 
treatment*)).ti,ab. 
3 (phytodrug* or phytomed* or phytopharmac* or phytother* or phytochemical*).ti,ab. 
4 ((natural* or naturo*) adj3 (caplet* or capsule* or compound* or cream* or decoction* or drug* or essence* 
or extract* or formul* or herb* or Infus* or juice* or medic* or mixture* or powder* or prepar* or prescri* or 
product or products or remed* or supplement* or tablet* or tea or teas or therap* or tincture* or tisane* or 
treatment*)).ti,ab. 
5 (botanical* adj3 (caplet* or capsule* or compound* or cream* or decoction* or drug* or essence* or 
extract* or formul* or heal* or herb* or Infus* or juice* or medic* or mixture* or powder* or prepar* or 
prescri* or product or products or remed* or supplement* or tablet* or tea or teas or therap* or tincture* or 
tisane* or treatment*)).ti,ab. 
6 (Ethnobotan* or pharmacogno* or Ethnopharmaco* or ethnomedic*).ti,ab. 
7 ("diet* supplement*" or "nutri* supplement*" or "food supplement*").ti,ab. 
8 Pharmacognos*.ti,ab. 
9 (traditional adj3 (caplet* or capsule* or compound* or cream* or decoction* or drug* or essence* or 
extract* or formul* or herb* or Infus* or juice* or medic* or mixture* or powder* or prepar* or prescri* or 
product or products or remed* or supplement* or tablet* or tea or teas or tincture* or tisane*)).ti,ab. 
10 (folk adj3 (caplet* or capsule* or compound* or cream* or decoction* or drug* or essence* or extract* or 
formul* or herb* or Infus* or juice* or medic* or mixture* or powder* or prepar* or prescri* or product or 
products or remed* or supplement* or tablet* or tea or teas or tincture* or tisane*)).ti,ab. 
11 (Aloe or aloes*).ti,ab. 
12 ("black cohosh" or "actaea racemosa" or "Cimicifuga racemosa").ti,ab. 
13 (Echinacea or "Coneflower").ti,ab. 
14 ("Evening primrose" or "oenothera biennis").ti,ab. 
15 (feverfew or "tanacetum parthenium" or "Chrysanthemum parthenium" or "Pyrethrum parthenium").ti,ab. 
16 (garlic or "Allium sativum").ti,ab. 
17 (ginger or "zingiber officinale").ti,ab. 
18 (ginkgo or "fossil tree" or "maidenhair tree" or "Japanese silver apricot" or baiguo or "bai guo ye" or "kew 
tree" or yinhsing or "yin-hsing").ti,ab. 
19 (ginseng or "Panax quinquefolius" or "Eleutherococcus senticosus").ti,ab. 
20 (Grapefruit or "Citrus adj2 paradisi").ti,ab. 
21 (Hawthorn* or Crataegus).ti,ab. 
22 ("John's wort" or "Johns wort" or hypericum or "Klamath weed" or "goat weed").ti,ab. 
23 (licorice or liquorice or glycyrrhzin or "Glycyrrhiza glabra" or "sweet root" or "gan zao").ti,ab. 
24 ("saw palmetto" or serenoa).ti,ab. 
25 (Soursop or "Annona muricata" or "durian blanda").ti,ab. 
26 (valerian or "valeriana officinalis" or Valerianaceae).ti,ab. 
27 (Mint or Mentha or peppermint or menthe or Spearmint).ti,ab. 
28 exp Plants, Medicinal/ 
29 exp ethnobotany/ or exp pharmacognosy/ 
30 plant preparations/ or exp plant extracts/ 
31 exp Ethnopharmacology/ 
32 exp Dietary Supplements/ 
33 Medicine, Traditional/ 
34 exp Herb-Drug Interactions/ 
35 exp Plant Exudates/ 
36 materia medica/ or plant extracts/ 
37 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 
21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 
38 prescri*.ti,ab,kw. 
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39 ((conventional or synthetic) adj2 (drug* or medicin* or pharmaceut* or medicat*)).ti,ab,kw. 
40 "drug therap*".ti,ab,kw. 
41 ("over-the-counter" or "over the counter" or otc).ti,ab. 
42 (("non-prescri*" or nonprescri*) adj2 (drug* or medicin* or pharmaceut* or medicat*)).ti,ab,kw. 
43 ("behind-the-counter" or "behind the counter" or btc).ti,ab,kw. 
44 exp Prescriptions/ 
45 exp Drug Therapy/ 
46 exp Prescription Drugs/ 
47 exp Nonprescription Drugs/ 
48 38 or 39 or 40 or 41 or 42 or 43 or 44 or 45 or 46 or 47 
49 (elder* or old* or aged or geriatr* or Gerontol*).ti,ab,kw. 
50 exp Aged/ 
51 exp Geriatrics/ 
52 49 or 50 or 51 
53 37 and 48 and 52 
54 Animals/ 
55 Humans/ 
56 54 not (54 and 55) 
57 53 not 56 
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Appendix G: Interview Consent Form 
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Appendix H: Snapshot of Analytical Framework from NVivo 
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Appendix I: Invitation Letter to Study Participants 
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Appendix J: School of Health & Social Care Poster Award 
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Appendix J: Impact, Presentations and Papers related to the PhD  
 
a. Oral and Poster Presentations 
 Poster presentations at the School of Health and Social Care (HSK) 
Research Conference in July 2015, my systematic review protocol was 
awarded Best Poster prize (Appendix J). 
 Oral presentation of survey findings at the University of Hertfordshire 
School of Health and Social Care Postgraduate Research Conference in 
July 2017. 
 Poster presentation of systematic review findings at the International 
Society for Pharmacovigilance Conference at Liverpool in October 2017. 
 Poster presentation of survey findings at the Safer Primary Care 
Conference at Manchester in March 2017. 
 Two Poster entries at the University of Hertfordshire Postgraduate 
Research Poster Competition in Oct 2017. 
 
b.  Journal articles   
 Protocol for the Phase 1 systematic review has been published (Agbabiaka 
et al., 2016).  
 Findings from the review is published in the journal Drugs and Aging 
(Agbabiaka et al., 2017). This paper has been very well received; currently 
over three thousand downloads and has been cited by 13 other papers. 
This systematic review was one of the five most downloaded articles on the 
publisher (Springer Link) platform from January to December 2018. 
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 The phase 2 questionnaire survey has been published in published British 
Journal of General Practice (Agbabiaka et al., 2018) 
 
c. Networking with Professional Bodies and Manufacturers 
 The survey paper had stimulated much discussion amongst members of 
the National Institute of Medical Herbalists (NIMH). A response to the paper 
from the Institute was published on the BJGP website(Deakin, 2018 ) . 
 The Institute’s Director of Professional and Inter-professional Development 
also contacted me by email to acknowledge the issues raised by the paper 
and what the Institute and members are doing to avoid potential herb-drug 
interactions and improve patient outcomes. My response to his letter was 
published in the Institute’s newsletter.  
 A leading herbal pharmaceutical company, Dr Willmar Schwabe Germany, 
contacted me for additional information on the potential interactions 
reported in the survey. 
 
d. Media 
 The survey paper published on the 24th of September 2018 generated 
huge media and public interest. It was featured by several media outlets 
including Daily Telegraph, Daily Mail, Daily Express, ITV, BBC and CNN.  
 I also had the opportunities to talk about the study on BBC Counties Radio, 
BBC Radio 5 and Bob FM. Additional coverage appeared on news 
websites Yahoo.com and AOL (Appendix K) 
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Appendix K: Some of the Media Coverage for the Study 
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